Print

[Julian]

In diesem Thread

Eine Klagewelle der Anthroposophen?
http://www.allaxys.com/~kanzlerzwo/index.php?topic=12730.0

wurde neues Beweismaterial gesichert. Es geht um eine Klagewelle der Anthroposophen. Hierzu muß man wissen, daß die Anthroposophen anscheinend schon vor einigen Jahren in der Carl-und-Veronica-Carstens-Stiftung an die Macht gekommen sind, einer Stiftung, die eigentlich für HOMÖOPATHIE-Föerderung gedacht war. Aber - nur als Beispiel - der berüchtige Berliner Stiftungsprofessor Michalsen sagt, daß Homöopathie nichts bringt. Aber darüber mehr an anderer Stelle.


Das Thema ist jetzt der große Pfusch (das ist noch milde ausgedrückt!) der Carl-und-Veronica-Carstens-Stiftung und ihrer Macher und Hintermänner.

In diesem Thread wurde dazu bereits Beweismaterial vorgelegt:

Lüdtke und die Pfuscher
http://www.allaxys.com/~kanzlerzwo/index.php?topic=12144.0

Aber wir haben inzwischen noch mehr.


Bei der GWUP heißt es in einem Kommentar (siehe

Eine Klagewelle der Anthroposophen?
http://www.allaxys.com/~kanzlerzwo/index.php?topic=12730.0 )

[*quote*]
Wie es die Schwurbler mit der WHO als vorgebliche Referenz halten, dass offenbart z.B. eine frühere Auflage des „Homöopathie-Quickfinders“ des seit gefühlt 200 Jahren omnipräsenten Herrn Wiesenauer, wo er scheibt:

„Das Fazit einer Bestandsaufnahme mit dem Titel „Forschung zur Homöopathie“, die von der Karl-und-Veronica-Castens-Stiftung (Bindestriche wie im Original) im Auftrag der Weltgesundheitsorganisation (WHO) erstellt wurde, lautet …“

Wie sie lautet, ersparen wir uns, denn so eine Arbeit „im Auftrag der Weltgesundheitsorganisation“ gab es nicht. Deshalb steht davon in Folgeauflagen auch nichts mehr.
[*/quote*]


Der Kommentator pfuscht, wie das so typisch ist bei Psiram und GWUP und Konsorten, und gibt die Quellen nicht sauber an.


Deswegen muß man das mit Vorsicht und Bedacht auseinander nehmen. Es geht nämlich um ZWEI Quellen, einmal das Buch von Wiesenauer und einmal um dessen Quelle!

Wiesenauer zitiert das nicht mehr so wie früher? Interessant! Dem sollte man nachgehen. Wiesenauers Quelle ist nämlich anscheinend dieser Absatz aus dem folgenden Text, und der stammt nachweisbar von der Karl-und-Veronica-Carstens-Stiftung:

[*quote*]
3 Publikationslage und –möglichkeiten

Eine von der CARSTENS-STIFTUNG im Auftrag der World Health Organsiation (WHO)
und des European Committee of Homeopathy (ECH) erstellte Übersicht identi-
fizierte über 300 klinische Studien zur Wirksamkeit der Homöopathie, von denen
weniger als ein Drittel in Zeitschriften mit einem Gutachtersystem publiziert
wurden.
[*/quote*]


DAZU muß noch die Verbindungen von Wiesenauer prüfen, denn der spielte bei der Karl-und-Veronica-Carstens-Stiftung eine entscheidende Rolle. Wo hatte er die Finger drin? Wofür war und ist er verantwortlich?


Der Volltext:

https://de.readkong.com/page/homoopathie-zum-stand-der-klinischen-forschung-eine-5124077

[*quote*]
Homöopathie - Zum Stand der klinischen Forschung - Eine Stellungnahme der Karl und Veronica Carstens-Stiftung

Eine Stellungnahme
der Karl und Veronica Carstens-Stiftung
Stand: März 2006
Herausgeber:        Der Vorstand der KARL UND VERONICA CARSTENS-STIFTUNG
                    Am Deimelsberg 36
                    45276 Essen
                    Tel.: (0201) 56305 – 0
                    Fax: (0201) 56305 – 0
                    www.carstens-stiftung.de
Redaktion: Dipl.-Stat. Rainer Lüdtke

                  © KARL UND VERONICA CARSTENS-STIFTUNG, Essen 2006

Alle Rechte, insbesondere die Übersetzung in andere Sprachen vorbehalten. Kein
Teil dieses Manuskripts darf ohne schriftliche Genehmigung der Stiftung in
irgendeiner Form – durch Photokopie, Mikroverfilmung oder irgendein anderes
Verfahren – reproduziert oder in eine von Maschinen, insbesondere
Datenverarbeitungsmaschinen, verwendbare Sprache übertragen oder übersetzt
werden.

                                 Seite 2 von 20                   © KARL UND VERONICA CARSTENS-STIFTUNG
Kurzfassung

Warum dieser Bericht?
Schon seit über 200 Jahren wird der wissenschaftliche Streit, ob die
Homöopathie eine wirksame Therapie ist, die Patienten helfen und heilen kann,
erbittert und zum Teil unversöhnlich geführt. Gerade in letzter Zeit flammt dieser
Streit erneut auf.
Dieser Bericht soll die bisherige klinische Forschung, die zur Frage der
Wirksamkeit der Homöopathie betrieben wurde, aus der Sicht der KARL UND
VERONICA CARSTENS-STIFTUNG, dem deutschlandweit größten Forschungsförderer
zur Homöopathie, zusammenfassen und bewerten.

Homöopathie und Forschung – das Problem!
Die Homöopathie ist – entgegen der landläufigen Meinung – ein durchaus
heterogenes    Therapiesystem:   Herstellungsweise  und    Anwendung     der
Arzneimittel variieren ebenso wie die Vorgehensweise, die richtige Arznei zu
finden. Innerhalb der Homöopathie gibt es eine Vielzahl von Schulen und
Richtungen mit einer starken Regionalisierung. Dieser Umstand spiegelt sich
auch in der Forschung wider: Klinische Studien und Experimente der
Grundlagenforschung entstammen sehr verschiedenen Vorgehensweisen bzw.
Richtungen.

Die Homöopathie im praxisrelevanten Kontext
In der Forschung gelten randomisierte placebokontrollierte Doppelblindstudien
als goldener Standard zur Bewertung therapeutischer Interventionen. Komplexe
Interventionen, wie z.B. die Homöopathie, werden dabei oft in verschiedene
Einzelbestandteile zerlegt, deren Wirksamkeit isoliert voneinander geprüft wird.
Neben dieser Studienform haben sich in der klinischen Forschung auch
sogenannte Outcome-Studien etabliert, deren Ziel die Erfassung gesundheitlicher
Veränderungen unter einer homöopathischen Behandlung ist. Outcome-Studien
haben den Vorteil, das therapeutische Vorgehen in der Homöopathie als Ganzes
bewerten zu können.
In diesen Studien berichten jeweils weit über 50% aller homöopathisch
behandelten      Patienten    von     relevanten    Verbesserungen     ihres
Gesundheitszustands [1-5]. In der bisher größten Studie dieser Art an 4.000
Patienten aus den Praxen von 100 homöopathischen Ärzten wurde gezeigt, dass
es bei schweren chronischen Krankheiten unter homöopathischer Behandlung zu
einer deutlichen Abnahme der Beschwerden kommt; die Lebensqualität der
Patienten nimmt zu und der Verbrauch an schulmedizinischen Medikamenten
ebenso    deutlich    ab.  Die    Besserung    hält  über   den    gesamten
Beobachtungszeitraum von zwei Jahren an [5].

Wirken die homöopathischen Arzneimittel?
Zur Frage, ob das homöopathische Arzneimittel isoliert betrachtet wirksam ist
(also unabhängig vom Gesamtzusammenhang, in dem die Arzneimittelgabe
stattfindet), können ungefähr 150 placebokontrollierte Studien identifiziert
werden. Davon zeigen etwa zwei Drittel ein für die Homöopathie positives

                                   Seite 3 von 20                    © KARL UND VERONICA CARSTENS-STIFTUNG
Ergebnis. Verschiedene systematische Übersichtsarbeiten kommen daher zu der
Schlussfolgerung, dass die Effekte der homöopathischen Arzneimittel nicht auf
reine Placeboeffekte zurückzuführen seien [6-9]. Dabei muss aber berücksichtigt
werden, dass ein Großteil der dort bewerteten Studien, wie in allen anderen
Bereichen der Medizin auch, den heutigen methodischen Ansprüchen nicht mehr
genügt, so dass das Gesamtbild für die Homöopathie zu positiv gezeichnet sein
könnte [10]. Die neuesten Analysen sprechen daher davon, dass die Wirksamkeit
der Homöopathie nicht mehr generell angenommen werden kann [11].

Bei welchen Erkrankungen der Wirksamkeitsnachweis gelang!
Nach dem derzeitigen Stand kann die Wirksamkeit homöopathischer Arzneimittel
unterstellt werden bei Heuschnupfen [12, 13], lebensbedrohlichem Durchfall bei
Kindern [14], Weichteilrheuma [15-17], Darmlähmung nach Operation [18] und
Atemwegsinfektionen [19].
Dagegen muss angenommen werden, dass bei der Behandlung von Muskelkater
[20], Warzen [21-23] und Spannungskopfschmerzen oder Migräne [24] der
Arzneimitteleffekt nicht über einen Placeboeffekt hinausgeht.
Für die allermeisten Erkrankungen ist der heutige Wissensstand aus
wissenschaftlicher Sicht nicht ausreichend, um eine Beurteilung abgeben zu
können.

Fazit
Insgesamt steht die Erforschung der Homöopathie sicher erst am Anfang. Sie
befindet sich in einem Stadium der Machbarkeitsprüfung, da zum Teil erst noch
die geeigneten Methoden gefunden bzw. entwickelt werden müssen. Was die
Zukunft der klinischen Forschung angeht, erscheinen Studien, in denen die
homöopathische mit der konventionellen Therapie verglichen wird, besonders
sinnvoll und Erfolg versprechender als randomisierte Doppelblindstudien zum
isolierten Arzneieffekt.
Für eine systematische Erforschung der Homöopathie fehlen allerdings bis heute
die wichtigsten Voraussetzungen: die Bereitschaft der Universitäten, die
Homöopathie in ihre Forschung einzubeziehen, die Bereitschaft der
homöopathischen Ärzte, an harter Forschung mitzuwirken, und nicht zuletzt:
ausreichend finanzielle Mittel [25].

                                  Seite 4 von 20                   © KARL UND VERONICA CARSTENS-STIFTUNG
1 Einleitung
Dieser Bericht bewertet den Stand der klinischen Forschung in der Homöopathie
aus der Sicht der KARL UND VERONICA CARSTENS-STIFTUNG. Zweck der CARSTENS-
STIFTUNG    ist   die   Förderung   der     wissenschaftlichen  Durchdringung
unkonventioneller Methoden in der Medizin. Sie ist der deutschlandweit größte
Förderer zur Erforschung der Homöopathie.
Dieser Beitrag beschränkt sich auf die klinische Forschung, also die Forschung
am Patienten, mit dem Ziel, die Wirksamkeit der Homöopathie zu beweisen. Die
Grundlagenforschung, deren Ziel es ist, die grundlegenden Wirkmechanismen
aufzuklären, wird Gegenstand eines weiteren Berichts sein; ebenso die
Bewertung der klinischen Wirksamkeit der Homöopathie am Tier.

2 Wirksamkeitsforschung in der Homöopathie
Von Seiten der universitären Medizin werden die Effekte, die unter homöo-
pathischer Behandlung auftreten, meist als Placeboeffekte eingestuft. Dies liegt
in der Tatsache begründet, dass in der Homöopathie oft speziell hergestellte
Arzneimittel verwendet werden (die sog. Potenzierung), die aus konventioneller
Sicht hochverdünnt erscheinen. Ihre Wirkung kann daher nicht auf dem von der
universitären Medizin entwickelten Modell basieren, das im Wesentlichen von
einer chemisch vermittelten Informationsübertragung zwischen Arznei und
Organismus ausgeht.
Die Potenzierung der homöopathischen Arzneien ist seit Begründung der
Homöopathie der wesentliche Streitpunkt zwischen Homöopathen und
Schulmedizinern. Auch die moderne klinische Forschung konzentriert sich nahezu
ausschließlich auf Wirksamkeit der homöopathischen Arzneimittel, wobei z.B. die
Rolle der Anamnese oder die Art und Weise, wie das homöopathisch sinnvollste
Arzneimittel gefunden wird, meist ausgeblendet wird. In einem reduktionisti-
schen Ansatz wird das „Gesamtpaket“ der homöopathischen Behandlung in
Einzelteile zerlegt, deren Effekte losgelöst von den anderen Teilen bewertet
werden.
Die klinische Forschung zur Homöopathie ist in der Regel eine Rechtfertigungs-
forschung, d.h. eine Forschung, die der kritischen wissenschaftlichen Fachwelt
die Wirksamkeit homöopathischer Verdünnungen beweisen soll. Sie dient
beinahe nie dazu, die Homöopathie selbst weiter zu entwickeln oder unwirksame
Elemente zu eliminieren. Um den Wirksamkeitsnachweis zu erbringen, bedient
sich die klinische Forschung zur Homöopathie der seit Jahrzehnten in der
Schulmedizin etablierten Verfahren, also in der Regel der randomisierten1
Doppelblindstudie2.
Erst in den letzten Jahren ist ein Trend zu erkennen, der versucht, die alltägliche
Praxis der homöopathischen Therapie als Ganzes abzubilden. Das Ziel dieser
Studien ist eine umfassende Bewertung von Gesundheitsänderungen bei
Patienten, ohne streng kausale Bezüge zur homöopathischen Therapie nach-
weisen zu wollen bzw. zu können (sogenannte „Outcome Forschung“). Dabei
werden sehr heterogene Patientengruppen zugelassen, z.B. multimorbide oder
schulmedizinisch begleitbehandelte Patienten. Zudem werden Selektions-
mechanismen, wie unterschiedliche Patientenpräferenzen, abgebildet.

1   eine Studie nennt man randomisiert, wenn die Patienten nach dem Zufallsprinzip der homöopathischen
    Behandlung oder einer Kontrollbehandlung zugeteilt werden (z.B. Placebo)
2   eine Studie wird als doppelblind bezeichnet, wenn weder der Patient noch der behandelnde Arzt wissen,
    welche der zur prüfenden Behandlungen der Patient tatsächlich bekommt.

                                              Seite 5 von 20                             © KARL UND VERONICA CARSTENS-STIFTUNG
Im Zentrum der Forschung, und vor allem der wissenschaftlichen Wahrnehmung,
steht aber weiterhin die placebokontrollierte3 randomisierte Doppelblindstudie.
Diese ist im Falle der sog. klassischen Homöopathie mit besonders hohem
logistischen Aufwand verbunden, da für jeden Patienten ein eigenes Verum bzw.
Placebo hergestellt werden muss [26]. Aus diesem Grund haben sich zwei
weitere Modelle klinischer Studien etabliert, die die homöopathische
Einzelmitteltherapie leichter beforschbar machen.
Allgemein akzeptiert ist das Modell der doppelten Selektion, in dem die Ein- und
Ausschlusskriterien der Studie nicht nur, wie in klinischen Prüfungen üblich, nach
der schulmedizinischen Diagnose und Indikation definiert werden, sondern
zusätzlich auch über die homöopathisch relevanten Symptome, die ein Patient
aufweist. Eingeschlossen werden dann nur solche Patienten, deren Symptomen-
bild auf die für die Studie vorgesehenen und verfügbaren Arzneien passt.
Umstrittener ist das Modell der klinischen Homöopathie. Analog zum standardi-
sierten Vorgehen in der konventionellen Medizin wird eine standardisierte
homöopathische Arznei definiert, mit der alle Studienpatienten behandelt
werden. Nach gängiger Lehrmeinung in Deutschland ist dieses Modell allerdings
kaum geeignet, die homöopathische Behandlung adäquat abzubilden (z.B. [27]).
Andere abgeleitete Formen der Homöopathie, die Isopathie (d.h. die Therapie mit
Potenzierungen des krankheitsauslösenden Stoffes) oder die Verwendung
homöopathischer Komplexmittel (d.h. die Mischung verschiedener ähnlicher
homöopathischer Arzneien), werden ebenfalls beforscht. Da Komplexmittel
patentierbar sind, sind die entsprechenden Studien in der Regel von homöo-
pathischen pharmazeutischen Unternehmen initiiert oder gesponsort, während
insbesondere die Studien zur klassischen Homöopathie primär wissenschafts-
getrieben sind und mit öffentlichen oder Stiftungsgeldern gefördert werden.

3 Publikationslage und –möglichkeiten
Eine von der CARSTENS-STIFTUNG im Auftrag der World Health Organsiation (WHO)
und des European Committee of Homeopathy (ECH) erstellte Übersicht identi-
fizierte über 300 klinische Studien zur Wirksamkeit der Homöopathie, von denen
weniger als ein Drittel in Zeitschriften mit einem Gutachtersystem publiziert
wurden. Von diesen wurde nur der kleinere Anteil in konventionellen Zeitschriften
veröffentlicht, der größere erschien in Journalen, die auf komplementär-
medizinische Themen spezialisiert sind.
Dieser erste Anschein lässt vermuten, dass die Qualität der Forschung in der
Homöopathie zu schlecht ist, um konventionellen Ansprüchen zu genügen. Dass
dieses nur ein Teil der Wahrheit ist, hat Resch gezeigt [28]. Er wies bei
Gutachtern konventioneller Zeitschriften zum Teil erhebliche Vorbehalte
gegenüber komplementärmedizinischen Methoden (insbesondere der Homöo-
pathie) nach, so dass entsprechende Manuskripte häufiger abgelehnt werden als
solche gleicher Qualität, die schulmedizinische Methoden untersuchen.
Die Gründe für die oft mangelnde Qualität der klinischen homöopathischen
Forschung sind vor allem strukturell bedingt. Hierzu zählen eine fehlende metho-
dische Ausbildung innerhalb der homöopathischen Fachgesellschaften, fehlende
Fördergelder, eine fehlende bzw. schlecht ausgebaute Infrastruktur, mangelndes
Interesse bei konventionellen Forschern mit fundierter methodischer Ausbildung
und die pauschale Ablehnung üblicher Studienformen mit der Begründung, diese
seien auf die speziellen Bedürfnisse der Homöopathie nicht anwendbar [25].

3   ein Placebo ist ein Scheinmedikament, das genauso aussieht wie das zu prüfende Medikament, aber stofflich
    unwirksam ist.

                                               Seite 6 von 20                               © KARL UND VERONICA CARSTENS-STIFTUNG
4 Die Wirksamkeit der homöopathischen
  Arzneien allgemein
Der Stellenwert der Homöopathieforschung als Rechtfertigungsforschung führt
nicht nur dazu, dass die Ergebnisse innerhalb der Homöopathie selten
wahrgenommen und homöopathisch diskutiert werden, er hat auch zur Folge,
dass die Diskussion zwischen Homöopathie und Schulmedizin beinahe
ausschließlich um die allgemeine Frage kreist, ob Homöopathie ein Placebo ist
(allgemeine    Placeboannahme).     Differenzierungen   der   Art,  ob   das
homöopathische Medikament A bei der Indikation B wirksam ist (spezifische
Placeboannahmen), werden nicht gemacht. Demzufolge stehen im Zentrum der
wissenschaftlichen Auseinandersetzungen systematische Übersichtsarbeiten
(Reviews), in der placebokontrollierte Studien analysiert werden, unabhängig
davon, welche homöopathische Herangehensweise gewählt wurde, welches
homöopathische Medikament verwendet wurde und welche Erkrankung bzw.
Gesundheitsstörung behandelt wurde.
Die erste systematische Übersicht über kontrollierte klinische Studien zur
allgemeinen Placeboannahme wurde 1991 veröffentlicht. 81 der 105
identifizierten Studien (77%) berichteten positive Ergebnisse zugunsten der
Homöopathie [6]. Auch unter den 22 Studien, denen eine hohe methodische
Qualität (Randomisation, Doppelblindheit, hohe Fallzahlen, angemessene
statistische Analyse und andere Kriterien) zuerkannt wurde, waren 68% positiv.
Die Autoren folgerten: „Der Anteil positiver Belege sogar unter den methodisch
besten Studien war für uns sehr überraschend. Auf der Basis dieser Studien
würden wir durchaus akzeptieren, dass Homöopathie wirksam sein kann, wenn
nur die Wirkmechanismen plausibler wären“.
1997 erregte eine Meta-Analyse4 zur Homöopathie Aufsehen, die in einem
hochrenommierten wissenschaftlichen Journal erschien [7]. K. Linde bewertete
89 placebokontrollierte Studien und kam zu dem Ergebnis, dass die Chancen
eines Patienten, von der homöopathischen Therapie zu profitieren, um den
Faktor 2,45 höher sind als unter einer Placebotherapie. Ein nahezu identisches
Ergebnis konnte für die 31 Studien erzielt werden, in denen homöopathische
Hochpotenzen getestet wurden: Hier lag der Faktor bei 2,66.
Mit zunehmender Studienqualität nahm dieser Faktor zwar ab, blieb jedoch auch
für die 26 qualitativ höchstwertigen Studien statistisch signifikant5 [29]. Weitere
Analysen zeigten, dass die Ergebnisse für die klassische Homöopathie, klinische
Homöopathie und Komplexmittel etwa gleich gut waren, die für die Isopathie
aber deutlich besser (vgl. Abb. 1; siehe auch Kap. 5.8).
Die Schlussfolgerung der Arbeit liest sich entsprechend positiv: „Unsere
Ergebnisse sind nicht mit der Hypothese vereinbar, dass die Effekte der
Homöopathie vollständig auf Placeboeffekte zurückzuführen sind. Zu der Frage,
ob die Homöopathie in irgendeiner einzelnen Indikation eindeutig wirksam ist, lag
nicht genug Erkenntnismaterial vor.“
Lindes Meta-Analyse ist in den Folgejahren intensiv diskutiert worden. Von Seiten
der Kritiker wurden zwei Punkte besonders herausgestellt. Zum einen sei die
Qualität der einzelnen, der Meta-Analyse zugrunde liegenden Studien so
schlecht, dass starke Verfälschungen des Gesamtergebnisses zu erwarten seien
[30]. Zum anderen wurde auf die Möglichkeit verwiesen, dass eine Reihe

4   Eine Meta-Analyse ist eine Übersichtsarbeit, in der die einzelnen Studien systematisch gesammelt und
    bewertet werden. Die Ergebnisse werden dann in einer einfachen Maßzahl zusammengefasst.
5   signifikant ist ein statistischer Fachbegriff, der andeutet, dass es unwahrscheinlich ist, dass die beiden
    verglichenen Therapien (in diesem Fall Homöopathie und Placebo) gleich wirksam sind

                                                Seite 7 von 20                               © KARL UND VERONICA CARSTENS-STIFTUNG
negativer Studien nicht wissenschaftlich veröffentlicht seien und die positiven
Studien daher überrepräsentiert seien (Publication Bias). J. Sterne kam nach
einer Reanalyse der Linde-Daten zu dem Ergebnis, dass verschiedene Effekte
(inklusive Publication Bias) zu einer deutlichen Überschätzung der Therapie-
effekte führten und ein signifikanter Vorteil der Homöopathie nicht nachzuweisen
sei [10].

                       5

                       4
              Faktor

                       3

                       2

                       1
                                                          Hochpotenzen

                                                                                                      Isopathie
                                                                         Homöopathie

                                                                                       Indikationen
                                          hohe Qualität
                           alle Studien

                                                                                                                  Komplexmittel
                                                                            klass.

                                                                                           bew.
                                                              nur

Abbildung 1: Vergleich homöopathischer Medikamente mit Placebo auf der Basis
von 89 randomisierten Therapiestudien (Faktoren >1 zeigen Überlegenheit der
Homöopathie an, ein Faktor < 1 spricht für eine Überlegenheit des Placebos, modifiziert
nach [7])

Ähnlich äußerten sich Fachleute der Universität von York in einem Gutachten für
das NHS, das nationale Gesundheitssystem Großbritanniens: „Zur Zeit gibt es
nicht genügend Belege zur Wirksamkeit der Homöopathie, weder um die
Homöopathie für eine spezifische Indikation zu empfehlen noch um wesentliche
Änderungen in der Kostenerstattung vorzunehmen.“ [31]
Zwei neuere Übersichtsarbeiten kommen zu einem für die Homöopathie positi-
vem Ergebnis: R. Mathie bewertete insgesamt 79 Studien [9], von denen 47
(59%) ein positives Ergebnis hatten. Er hält die Wirksamkeit der Homöopathie
bei   kindlicher  Diarrhoe,  Fibromyalgie,    Heuschnupfen,   Influenza, bei
verschiedenen Schmerzzuständen, den Nebenwirkungen einer Radio- oder
Chemotherapie sowie bei Verstauchungen und Erkrankungen der oberen
Atemwege für wahrscheinlich. Unwahrscheinlich sei dagegen, dass Homöopathie
bei Kopfschmerzen, Schlaganfall oder Warzen helfe.
M. Dean untersuchte insgesamt 205 kontrollierte klinische Studien zur
Homöopathie [32]. 95 der 168 placebokontrollierten Studien (=57%) waren
signifikant positiv für die Homöopathie, weitere 36 (=21%) zeigten einen
deutlichen, wenn auch nicht statistisch signifikanten Effekt zugunsten der
Homöopathie. Dieses veranlasste ihn zu der Schlussfolgerung, dass „die in dieser
Übersicht dargestellten Daten die Vermutung nahe legen, dass klassische
Homöopathie augenscheinlich in der Lage ist, allgemeine Gesundheitsparameter
wie subjektives Wohlbefinden und Begleiterkrankungen zu beeinflussen.“

                                          Seite 8 von 20                                                                          © KARL UND VERONICA CARSTENS-STIFTUNG
Diesen Ergebnissen widerspricht A. Shang vehement [11]. Mit Techniken der
Meta-Regression6 untersuchte sie 110 placebokontrollierte Therapiestudien zur
Wirksamkeit der Homöopathie. Rechnet man die verschiedenen Fehlerquellen
(z.B. Publication Bias, zum Teil mangelnde Studienqualität) heraus, die die
Ergebnisse beeinflussen könnten, so bleibt bei den Homöopathiestudien kein
Therapieeffekt übrig, der über einen Placeboeffekt hinausgeht: Die Chancen
eines Patienten, von der homöopathischen Therapie zu profitieren, seien
praktisch identisch mit denen, von einer Placebotherapie zu profitieren. Im
Vergleich dazu sei bei einer ähnlichen Analyse 110 placebokontrollierter
schulmedizinischer     Therapiestudien    ein   entsprechender Therapieeffekt
nachweisbar: Hier sei die Chance, von einer schulmedizinischen Therapie zu
profitieren, etwa 1,5 mal so hoch wie unter Placebo.
Shangs zentrale Behauptung deckt sich daher mit der von J. Sterne [10], dass
verschiedene Effekte (z.B. Publication Bias und teilweise mangelnde
Studienqualität) einen zu positiven Eindruck zugunsten der Homöopathie
vermittelten, während bei tiefergehender Analyse ein signifikanter Vorteil der
Homöopathie nicht mehr nachzuweisen sei. Shangs Analysen werden daher als
Beleg der Wirkungslosigkeit der Homöopathie interpretiert, und das „Ende der
Homöopathie“ wird vorhergesagt bzw. festgestellt [33].
Es sind insbesondere diese weitreichenden Schlussfolgerungen, die derzeit heftig
diskutiert und als haltlos kritisiert werden [34, 35]. Insbesondere wird in Frage
gestellt, ob man von den wenigen bisherigen Studien auf die gesamte
Homöopathie schließen könne oder ob eine solche Verallgemeinerung nicht
grundsätzlich unzulässig sei.
Andere Diskutanden halten Shangs Methodik und Auswertung selbst für
unangemessen und falsch [36, 37].

6   Eine Meta-Regression ist eine moderne statistische Methode, die die Technik der Meta-Analyse erweitert. Mit
    einer Meta-Regression ist es möglich, den Einfluss verschiedener Parameter (z.B. der Studienqualität oder
    der Zahl der in der Studie untersuchten Patienten) zu berücksichtigen, um so zu einem korrigierten
    Gesamtergebnis zu kommen.

                                                Seite 9 von 20                                © KARL UND VERONICA CARSTENS-STIFTUNG
5 Die Wirksamkeit homöopathischer Arzneien bei
  einzelnen Erkrankungen
In der Arbeit von Shang [11] wird, im Gegensatz zu den meisten anderen
Übersichtsarbeiten, die allgemeine Placeboannahme nicht verworfen (d.h. eine
gleichmäßige Überlegenheit homöopathischer Arzneien über Placebo bei allen
Erkrankungen kann nicht nachgewiesen werden). Dennoch stellt sich die Frage,
ob es für einzelne Erkrankungen möglich ist, die Wirksamkeit homöopathischer
Arzneien nachzuweisen. Die folgenden Kapitel sollen einen kurzen Überblick über
Detailergebnisse zu verschiedenen Forschungsfeldern geben. Aufgrund der
großen Zahl an Therapiestudien muss hier eine Auswahl getroffen werden. Diese
Auswahl ist rein subjektiv, orientiert sich aber vor allem daran, zu welchen
Erkrankungen mehrere Studien vorliegen.

5.1                     Heuschnupfen: Galphimia glauca
Galphimia glauca ist eines der am besten untersuchten homöopathischen
Einzelmittel. In insgesamt sieben randomisierten Doppelblindstudien hat M.
Wiesenauer die Wirksamkeit dieser Arznei bei Heuschnupfen untersucht. In sechs
Studien zeigte sich Galphimia glauca Placebo überlegen (Abbildung 2). R. Lüdtke
konnte in einer zusammenfassenden Analyse von über 700 Patienten zeigen,
dass sich die typischen Augen- und Nasensymptome unter einer Galphimia-
Behandlung statistisch signifikant 1,25mal häufiger bessern als unter einer
Placebotherapie [13].

                   80
Erfolgsraten [%]

                   60

                   40

                   20

                    0
                         1980   1982   1985       1986          1987   1988   1989

                                  Placebo          Homöopathie

Abbildung 2: Erfolgsraten bei der Therapie des akuten Heuschnupfens mit
Galphimia glauca oder Placebo (Erfolg definiert als starke Besserung oder
Verschwinden typischer Augensymptome; modifiziert nach [13])

5.2 Postoperativer Ileus: Arnica, Raphanus und Opium
Nach einer Analyse von J. Barnes und E. Ernst können homöopathische
Medikamente die Regenerationszeit nach Bauchoperationen verkürzen [18].
Diese Analyse fasste insgesamt sechs Studien zusammen, in denen Arnica
montana, Raphanus, China und Opium in verschieden Kombinationen nach einer
abdominalen oder gastrointestinalen Operation gegeben wurden [38-43]. Die

                                              Seite 10 von 20                   © KARL UND VERONICA CARSTENS-STIFTUNG
Zeit bis zu den ersten Darmaktivitäten ließ sich gegenüber Placebo um durch-
schnittlich 7,4 Stunden verkürzen (vgl. Abbildung 3). Für die Zeit bis zum ersten
Stuhlgang ergab sich ebenfalls ein signifikanter Vorteil für die homöopathischen
Medikamente. Verschiedene Autoren bezweifeln allerdings, dass Barnes´ Studie
als Beweis für die Wirksamkeit der homöopathischen Arzneimittel angesehen
werden kann, vor allem deshalb, weil die methodisch beste Studie mit den
größten Patientenzahlen kein positives Ergebnis erbrachte [41].

                                                                 N=200

                    80                  N=80                                        N=80
                                                 N=96                     N=300
                    60
     Dauer [Std.]

                             N=20

                    40

                    20

                     0
                         Cast elain   Valero   Chevrel   Aulagnier       GRECHO   Dorfman
                           1979        1981     1984       1985           1989     1992

                                        Hom öopathie               Placebo

Abbildung 3: Zeit bis zu den ersten Darmaktivitäten nach abdominalen oder
gastrointestinalen Operationen unter homöopathischer und Placebobehandlung
(N-Fallzahl in beiden Gruppen)

5.3 Muskelkater: Arnica montana und Rhus tox
Die wissenschaftliche Hypothese, dass Arnica montana oder Rhus toxicodendron
bei einem experimentell erzeugten Muskelkater eine über Placebo hinausgehende
Wirkung haben, ist eng mit dem Namen von G. Hildebrandt verknüpft. Dieser
fand in insgesamt vier Studien, dass die Muskelkraft gesunder Probanden nach
einer definierten Kraftanstrengung unter homöopathischer Medikation weniger
stark geschwächt wird als unter Placebo. Widerlegt wurde diese Hypothese
allerdings in zwei Doppelblindstudien mit weitaus größeren Fallzahlen [44, 45],
wobei die Muskelkatersymptome bei einer der beiden Studien unter Placebo
sogar etwas geringer ausgeprägt waren.
Das Modell des experimentell erzeugten Muskelkaters wurde von D. Tveiten auf
praxisrelevante Situationen erweitert, als er Arnica montana in einer rando-
misierten Doppelblindstudie beim Oslo-Marathon 1990 mit Placebo verglich [46].
Er fand tendenzielle Vorteile für das homöopathische Medikament und konnte
diese fünf Jahre später bestätigen [47]. Diese positiven Ergebnisse decken sich
allerdings nicht mit denen von A. Vickers, der in einer wesentlich größeren Studie
an 400 Marathonläufern keine Vorteile von Arnica entdecken konnte [48], im
Gegenteil, die Ergebnisse zeigten eine klare Tendenz zugunsten von Placebo.
Eine zusammenfassende Analyse von E. Ernst kommt daher auch zu der Schluss-
folgerung, dass es derzeit keine Daten gibt, die belegen, dass homöopathische
Potenzen von Arnica montana oder Rhus toxicodendron zur Prävention oder
Behandlung eines Muskelkaters geeignet sind [20].

                                               Seite 11 von 20                         © KARL UND VERONICA CARSTENS-STIFTUNG
5.4 Kindliche Diarrhoe
In einer Serie von drei nahezu identischen Therapiestudien gelang es J. Jacobs
zu zeigen, dass eine individualisierte homöopathische Behandlung bei der
kindlichen Diarrhoe wirksam ist. Die Studien wurden in Nicaragua [49, 50] und
Nepal [51] durchgeführt. Die Kinder wurden einmalig mit einem von fünf
homöopathischen Einzelmitteln oder Placebo behandelt. In allen drei Studien
konnte die Erkrankungsdauer und die Zahl der Stühle pro Tag deutlich verkürzt
werden (Abbildung 4). Durchschnittlich wurden die Erkrankungsdauer um 0,7
Tage verkürzt und die Schwere der Erkrankung um 0,7 Stühle pro Tag gesenkt.

                             Homöopathie
                5
                             Placebo
                4
 Dauer [Tage]

                3

                2

                1
                    gesamt        Jacobs 1993        Jacobs 1994   Jacobs 2000

Abbildung 4: Dauer der kindlichen Diarrhoe nach homöopathischer und
  Placebobehandlung     in     drei     randomisierten, placebokontrollierten
  Doppelblindstudien (modifiziert nach [14])

5.5 Rheumatische Erkrankungen
In einer ersten Pilotstudie zur Wirksamkeit homöopathischer Arzneimittel bei
Fibromyalgie konnte P. Fisher eine deutliche, statistisch aber nicht signifikante
Schmerzabnahme unter homöopathischen Therapie im Vergleich zu Placebo
belegen [15].
Basierend auf diesen Ergebnissen behandelte er in einer randomisierten
Doppelblindstudie 30 weitere Fibromyalgiepatienten, wobei in diese Studie nach
dem Modell der doppelten Selektion nur Patienten eingeschlossen wurden, deren
Symptomenbild zum Arzneimittelbild von Rhus toxicondendron passte [16]. Die
Anzahl der druckschmerzhaften Fibromyalgiepunkte konnte von etwa 14 auf
unter 11 gesenkt werden; ein Erfolg, der signifikant besser war als unter
Placebo.
Eine weitere Bestätigung der Ergebnisse lieferte kürzlich I. Bell [17]. Ihr gelang
es zu zeigen, dass die Zahl der druckschmerzhaften Fibromyalgiepunkte im
Vergleich mit Placebo signifikant gesenkt wurde, und zwar von etwa 17 auf etwa
15 Punkte. Gleichzeitig verbesserte sich die gesundheitsbezogene Lebensqualität
signifikant stärker als unter Placebo.
Auch bei anderen rheumatischen Erkrankungen liegen Studien zur Wirksamkeit
der Homöopathie vor. In der Studie von L. Andrade profitierten 10 von 17
Patienten (59%) mit rheumatoider Arthritis von einer homöopathischen Einzel-

                                   Seite 12 von 20                         © KARL UND VERONICA CARSTENS-STIFTUNG
mitteltherapie, aber nur 7 von 16 Patienten (44%) von Placebo [52]. Ähnliche
Ergebnisse hatte bereits R. Gibson vorgelegt, in dessen Studie die homöo-
pathischen Arzneien bei 19 von 23 Patienten (83%), Placebo aber nur bei 5 von
23 Patienten (22%) erfolgreich war [53]. Diesen positiven Ergebnissen steht die
Studie von P. Fisher gegenüber [54], in der bei 180 Patienten die Placebobe-
handlung signifikant besser war als eine homöopathische Einzelmittelbehandlung.
Das homöopathische Komplexmittel Zeel comp® hat sich bei der Behandlung der
Gonarthrose verschiedenen Standardbehandlungen als gleichwertig erwiesen,
und zwar oralem Diclofenac [55], Hyaloronsäure [56] und COX-II-Hemmern
[57].

5.6 Migräne und Spannungskopfschmerzen
B. Brigo konnte in einer Studie bei 60 Migränepatienten zeigen, dass unter einer
homöopathischen Behandlung die Kopfschmerzhäufigkeit innerhalb von vier
Monaten von 10 auf weniger als 2 Attacken pro Monat gesenkt werden kann
[58], während unter Placebo lediglich eine Reduktion von 10 auf 8
Attacken/Monat beobachtet wurde (vgl. Abbildung 5).
Brigos Studie galt in den 90er Jahren als das Modell schlechthin zum Nachweis
der    Wirksamkeit    der   Homöopathie.    Drei    voneinander     unabhängige
Replikationsversuche konnten seine Ergebnisse allerdings nicht bestätigen [26,
59, 60]. Die drei Studien waren hinsichtlich der behandelten Patienten, der
verwendeten Arzneimittel und der Länge des Beobachtungszeitraums zwar alle
etwas unterschiedlich, doch konnte in keiner Studie die Größe der Effekte
bestätigt werden. In zwei Studien war Placebo sogar leicht besser als die homöo-
pathische Arznei. E. Ernst kommt daher zu dem Schluss, dass „die vorliegenden
Daten nicht darauf hinweisen, dass Homöopathie in der Prophylaxe von Migräne
oder Kopfschmerzen über den Placeboeffekt hinaus wirksam ist“ [24].

                                                                    Homöopathie
                         5
                                                                    Placebo
 Kopfschmerzhäufigkeit

                         4
   [Attacken/Monat]
   Verringerung der

                         3

                         2

                         1

                         0
                             Brigo 1991   Whithmarsh       Straumsheim   Walach 1997
                                             1997              1997

Abbildung 5: Verringerung der Kopfschmerzhäufigkeit in vier randomisierten
  placebokontrollierten Doppelblindstudien bei Kopfschmerzen oder Migräne
  (modifiziert nach [24])

                                              Seite 13 von 20                   © KARL UND VERONICA CARSTENS-STIFTUNG
5.7 Erkältungskrankheiten: Homöopathische Nosoden
Oscilloccinum® ist der Handelsname der homöopathischen Nosode Anas
barbariae hepar et cordis extractum. Nach A. Vickers „verkürzt Oscillococcinum
wahrscheinlich die Dauer der Krankheit von Patienten mit Grippesymptomen“
[19]. Diese Einschätzung beruht auf der zusammenfassenden Beurteilung von
zwei randomisierten Doppelblindstudien: nach J. Ferley gesundeten 39 von 228
Oscillococcinum-Patienten (17,1%) innerhalb von 48 Stunden [61]. R. Papp
erzielte mit einer Erfolgsquote von 19,2% ähnliche Ergebnisse [62]. A. Vickers
schätzt daher, dass das Risiko eines homöopathisch Behandelten, nach
zweitägiger Behandlung noch krank zu sein, nur 93% des Placeborisikos beträgt.
Zwei weitere Studien, die allerdings nicht als vollständige wissenschaftliche
Artikel vorliegen [63, 64], bestätigen die Wirksamkeit von Oscillococcinum in der
Behandlung von Grippesymptomen.
Demgegenüber kann die Wirksamkeit von Anas barbariae hepar et cordis
extractum als Vorbeugemaßnahme nicht abgesichert werden. Basierend auf drei
klinischen Studien fand A. Vickers zwar einen tendenziellen, statistisch aber nicht
signifikanten Unterschied zwischen homöopathischer und Placebotherapie [19].
Dabei schätzte er das relative Risiko, Grippesymptome zu entwickeln, auf 63%.
Weiterhin gibt es eine Reihe homöopathischer Komplexmittel, die in
randomisierten Studien bessere Ergebnisse als Placebo bei Erkältungskrankheiten
gezeigt haben [65-70] oder Standardmedikationen annähernd gleichwertig waren
[71-75].
Für die klassische Homöopathie ist die Datenlage uneinheitlich: E. de Lange de
Klerk fand zwar deutliche, statistisch aber nicht signifikante Unterschiede zu
Placebo [76]. A. Steinsbekk dagegen erhielt unter Placebo sogar leicht bessere
Ergebnisse, wobei in dieser Studie die homöopathischen Arzneien nicht vom Arzt
verordnet sondern von den Patienten in einer Selbstbehandlung auf Basis
einfacher Beschreibungen der homöopathischen Arzneimittelbilder allein
verantwortlich herausgesucht wurden [77].

5.8 Allergien: Isopathie
Die schottische Arbeitsgruppe um D. Reilly und M. Taylor widmet sich seit fast
zwei Jahrzehnten der Wirksamkeitsforschung isopathischer Behandlungen. In
vier verschiedenen Doppelblindstudien wurden Allergiepatienten einmalig mit
homöopathisch potenzierten Allergenen behandelt und über vier Wochen
beobachtet. Wie auch Abbildung 6 zeigt, berichten zwei Studien bei
Heuschnupfen von deutlichen Unterschieden zwischen Isopathie und Placebo [78,
79], die allerdings in einer dritten Studie nicht bestätigt werden konnten [12].
Bei allergischem Asthma zeigten sich in einer placebokontrollierten Doppelblind-
studie ebenfalls signifikante Effekte zugunsten der Isopathie [80]. Ein Repli-
kationsversuch von G. Lewith dagegen misslang [81].

                                   Seite 14 von 20                    © KARL UND VERONICA CARSTENS-STIFTUNG
Therapie: Pollenmix                          Therapie: Hauptallergen

                                   20
Überlegenheit der hom.

                                   15       N=36
    Therapie [mm]

                                                                                   N=28

                                   10
                                                             N=144

                                    5                                                                   N=51               N=202

                                    0
                                          Re illy 1985      Re illy 1986        Re illy 1994        Ta ylor 2000          Le w ith 2002
                                        (He uschnupfe n) (He uschnupfe n)   (a lle rg. Asthma )   (a lle rg. Rhinitis ) (a lle rg. As thma )

   Abbildung 6: Unterschiede zwischen isopathischer und Placebobehandlung bei
     Heuschnupfen und allergischem Asthma (Überlegenheit gemessen als Differenz
     der auf einer visuellen 100mm Analogskala ermittelten Beschwerdestärke, N-
     Gesamtfallzahl; modifiziert nach [12])

   5.9 Verletzungen und Verstauchungen: Komplexmittel
   Das homöopathische Komplexmittel Traumeel® besteht aus 14 homöopathischen
   Einzelmitteln. Es konnte in mehreren Doppelblindstudien nach Sportverletzungen
   [82], traumatischen Blutergüssen [83] und akuten Sprunggelenksdistorsionen
   [84] seine Überlegenheit über Placebo zeigen (Abbildung 7).

                                                   Placebo
                                                   Homöopathie
                                   100
             Therapieerfolge [%]

                                    80

                                    60

                                    40

                                    20

                                        0
                                                 Zell 1988                  Thiel 1991                     Böhmer 1992

   Abbildung 7: Therapieerfolge unter Traumeel® und Placebo bei verschiedenen
   Indikationen (Therapieerfolge definiert nach den jeweiligen Kriterien der Studie)

                                                                        Seite 15 von 20                                      © KARL UND VERONICA CARSTENS-STIFTUNG
6 Homöopathieforschung im praxisrelevanten
     Kontext
   Mehr als in der konventionellen Medizin wird in der Komplementärmedizin der
   klassischen   Wirksamkeitsforschung      die   sogenannte     Outcome-Forschung
   gegenübergestellt (siehe Kapitel 2.1). In diesen Studien berichten zwischen 55%
   und 71% aller Patienten von starken oder deutlichen Verbesserungen ihres
   Gesundheitszustandes [1-3, 85, 86]. W. Richardson und A. Steinsbekk ergänzen,
   dass etwa die Hälfte der Patienten ihre konventionelle Medikation reduzieren
   oder absetzen konnten [3, 86].
   Die bisher größte Outcome-Studie zur Homöopathie hat C. Witt vorgelegt [5].
   Fast 4000 Patienten (davon über 1000 Kinder), die jeweils bei einem von über
   100 ambulant praktizierenden klassischen Homöopathen behandelt wurden,
   wurden über zwei Jahre lang regelmäßig hinsichtlich ihres Gesundheitszustands
   und ihrer gesundheitsbezogenen Lebensqualität befragt. In allen Aspekten der
   Lebensqualität konnten klinisch relevante und statistisch signifikante
   Verbesserungen nachgewiesen werden. Im körperlichen Bereich erreichten die
   meist chronisch erkrankten Patienten eine Lebensqualität, die der deutschen
   Normbevölkerung entspricht (Abbildung 8).
   Verglichen mit einer üblichen konventionellen Standardbehandlung scheint die
   homöopathische Behandlung (also das „Gesamtpaket“ aus homöopathischer
   Anamnese und homöopathischen Arzneien) zumindest gleich effektiv zu sein. In
   einer vergleichenden Studie von D. Riley verbesserten sich die Beschwerden
   akuter Erkrankungen des Ohrs oder der oberen Atemwege innerhalb von zwei
   Wochen bei 83% aller homöopathischen und 68% aller konventionellen Patienten
   [4]. Die Lebensqualität der Patienten war in beiden Gruppen nahezu identisch.
   Bei chronischen Erkrankungen (vor allem Asthma, allergische Rhinitis,
   Neurodermitis, LWS-Syndrom, Kopfschmerzen, Schlafstörungen, Depression)
   konnte C. Witt zeigen, dass homöopathisch behandelte Kinder und Erwachsene
   von stärkeren Verbesserungen des Gesundheitszustands berichten als
   konventionell behandelte. Die insgesamt anfallenden Kosten waren in beiden
   Behandlungsgruppen statistisch nicht unterschiedlich [87].
                                       stark
                     Überdurchschn.

                                                                      körperliche            psychische Lebensqualität
Lebensqualität

                                       leicht
                                      leicht
                 Eingeschränkt
                                      Stark

                                                Beginn der   3 Mon.                 1 Jahr               2 Jahre
                                                Behandlung
   Abbildung 8: Veränderung der Lebensqualität nach Beginn einer
     homöopathischen Einzelmittelbehandlung bei 2800 Erwachsenen
     (modifiziert nach [5])

                                                                Seite 16 von 20                               © KARL UND VERONICA CARSTENS-STIFTUNG
7 Schlussfolgerungen
Legt man heutige Standards zugrunde, so muss man die methodische Qualität
der Studien zur Wirksamkeit homöopathischer Medikamente in den meisten
Fällen als nicht besonders hoch bewerten. Verschiedene grundlegende Kriterien,
an denen die Zuverlässigkeit einer Studie gemessen wird, sind oft nicht
eingehalten, ein Phänomen, das aber im Übrigen auch auf viele konventionelle
Studien zutrifft.
Dennoch lässt sich unzweideutig behaupten, dass eine homöopathische
Behandlung die Gesundheit von Patienten günstig beeinflussen kann. Ein Großteil
dieser   positiven   Effekte   ist   aber  möglicherweise   nicht  auf    reine
Arzneimitteleffekte zurückzuführen, sondern auf sogenannte Kontexteffekte, also
Effekte,   die    aus    der    speziellen  Behandlungssituation   und     dem
Behandlungsumfeld resultieren. Hierzu zählen auch Effekte der spezifischen
homöopathischen Anamnese.
Welche Rolle die reinen, vom Rest der Behandlung isolierten Arzneimitteleffekte
spielen, kann derzeit nicht abschließend geklärt werden, weder für die allgemeine
noch für spezifische Placeboannahmen bei einzelnen Indikationen. Der Grund für
diese vorsichtige Bewertung der Evidenzlage liegt in dem Phänomen, dass bei
mehreren Indikationen verschiedene Therapiestudien mit kleinen Fallzahlen zu
positiven Aussagen kommen, die dann in großen konfirmativen Studien nicht
bestätigt werden konnten (allergisches Asthma, postoperativer Ileus,
rheumatoide Arthritis, Muskelkater).
Dennoch lassen sich einige Indikationen ausmachen, bei denen man aufgrund
der vorliegenden Daten die spezifische Wirksamkeit der Homöopathie
unterstellen kann: kindlicher Durchfall, Heuschnupfen, Zerrungen und
Verstauchungen, Fibromyalgie und Erkältungskrankheiten, eventuell auch
postoperativer Ileus, Insektenstiche und nicht-allergisches Asthma.
Dagegen muss angenommen werden, dass bei der Behandlung von Muskelkater,
Warzen und Spannungskopfschmerzen oder Migräne der Arzneimitteleffekt nicht
über einen Placeboeffekt hinausgeht.
Völlig ungeklärt ist die Frage, ob die klassische, individualisierende Homöopathie
anderen Formen wie Komplexmitteltherapie, Isopathie oder klinische
Homöopathie überlegen ist.
Das Grundkonzept der Homöopathieforschung, die Wirksamkeit der Homöopathie
an der isolierten Wirksamkeit der homöopathischen Arzneimittel festzumachen,
muss insgesamt als gescheitert angesehen werden, nicht nur weil die Ergebnisse
nicht eindeutig genug sind, sondern auch deswegen, weil auch positive
Ergebnisse von der konventionellen Medizin nicht zur Kenntnis genommen
werden. So konnte noch 2005 ein Schweizer Immunologe über die Homöopathie
behaupten, dass es „keine einzige wissenschaftliche Doppelblindstudie gibt,
welche ihre Wirkung belegen könnte“ [88].
Die Zukunft der Homöopathieforschung liegt daher nicht in der Erforschung der
isolierten  Arzneimittelwirkung,    sondern   muss    andere   Elemente   der
homöopathischen Behandlung stärker berücksichtigen, vor allem die Anamnese.
Hierbei dürften Studien stärker in den Vordergrund rücken, die homöopathische
und schulmedizinische Gesamtkonzepte einander gegenüber stellen. Deren
Aussagekraft hängt allerdings davon ab, ob unterschiedliche Patienten-
präferenzen ausreichend berücksichtigt werden.

                                   Seite 17 von 20                   © KARL UND VERONICA CARSTENS-STIFTUNG
8 Literatur
1.    Clover A: Patient benefit survey: Turnbridge Wells Homoeopathic Hospital. Brit Hom J
      2000;89(2):68-72.
2.    Sevar R: Audit of outcome in 829 consecutive patients treated with homeopathic medicines. Brit Hom
      J 2000;89(4):178-187.
3.    Steinsbekk A, Lüdtke R: Patients’ assessments of the effectiveness of homeopathic care in Norway: A
      prospective observational multicentre outcome study. Homeopathy 2005;94:10-16.
4.    Riley D, Fischer M, Singh B, Haidvogel M, Heger M: Homeopathy and Conventional Medicine - An
      Outcomes Study Comparing Effectiveness in a Primary Care Setting. J Alternat Complement Med
      2001;7(2):149-159.
5.    Witt CM, Lüdtke R, Baur R, Willich SN: Homeopathic medical practice: Long-term results of a cohort
      study with 3981 patients. BMC Public Health 2005;5:115.
6.    Kleijnen J, Knipschild P, ter Riet G: Clinical trials of homeopathy. BMJ 1991;302:316-323.
7.    Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges L, Jonas WB: Are the clinical effects of
      homoeopathy placebo effects? - A meta-analysis of placebo-controlled trials. Lancet 1997;350:834-
      843.
8.    Cucherat M, Haugh MC, Gooch M, Boissel J: Evidence of clinical efficacy of homeopathy - A meta-
      analysis of clinical trials. Eur J Clin Pharmacol 2000;56:27-33.
9.    Mathie RT: The research evidence base for homeopathy - A fresh assessment of the literature.
      Homeopathy 2003;92(2):84-91.
10.   Sterne JAC, Egger M, Smith GD: Systematic reviews in health care: Investigating and dealing with
      publication and other biases in meta-analysis. BMJ 2001;323:101-105.
11.   Shang A, Huwiler-Muntener K, Nartey L, Juni P, Dorig S, Sterne JA, Pewsner D, Egger M: Are the
      clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of
      homoeopathy and allopathy. Lancet 2005;366(9487):726-32.
12.   Taylor MA, Reilly D, Llewellyn-Jones RH, McSharry C, Aitchison TC: Randomised controlled trials of
      homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. BMJ
      2000;321:471-476.
13.   Lüdtke R, Wiesenauer M: A metaanalysis on the pollinosis treatment with homeopathic preparations
      of Galphimia glauca. Wien Med Wochenschr 1997;147:323-327.
14.   Jacobs J, Jonas WB, Jimenez-Perez M, Crothers D: Homeopathy for childhood diarrhea: combined
      results and metaanalysis from three randomized, controlled clinical trials. Pediatr Infect Dis J
      2003;22(3):229-234.
15.   Fisher P: An Experimental Double-blind Clinical Trial Method in Homoeopathy - Use of a Limited
      Range of Remedies to Treat Fibrositis. Brit Hom J 1986;75(3):142-147.
16.   Fisher P, Greenwood A, Huskisson EC, Turner B, Belon P: Effect of Homoeopathic Treatment on
      Fibrositis (Primary Fibromyalgia). BMJ 1989;299:365-366.
17.   Bell IR, Lewis DA, Brooks AJ, Schwartz GE, Lewis SE, Walsh BT, Baldwin CM: Improved clinical status
      in fibromyalgia patients trated with individualized homeopathic remedies versus placebo.
      Rheumatology 2004;43:577-582.
18.   Barnes J, Resch KL, Ernst E: Homeopathy for Postoperative Ileus? - A Meta-Analysis. J Clin
      Gastroenterol 1997;25(4):628-633.
19.   Vickers AJ, Smith C: Homoeopathic Oscillococcinum for preventing and treating influenza and
      influenza-like syndroms. Cochrane Library 2000;1.
20.   Ernst E, Barnes J: Are homoeopathic remedies effective for delayed-onset muscle soreness? - A
      systematic review of Placebo-controlled trials. Perfusion 1998;11(1):4-8.
21.   Khan MT, Rawal RS. Comparative treatments of verruca plantaris. In: Proceedings of 31th Congress
      of LMHI; 1976; Athens, Greece; 1976.
22.   Labrecque M, Audet D, Latulippe L, Drouin J: Homeopathic treatment of plantar warts. Can Med Assoc
      J 1992;146(10):1749-1753.
23.   Kainz JT, Kozel G, Haidvogl M, Smolle J: Homoeopathic versus Placebo Therapy of Children with
      Warts on the Hands - A Randomized, Double-Blind Clinical Trial. J Derm 1996;193:318-320.
24.   Ernst E: Homeopathic prophylaxis of headaches and migraine? A systematic review. J Pain Symptom
      Management 1999;18(5):353-357.
25.   House of Lords Select Committee on Science and Technology. 6th report: complementary and
      alternative medicine. London: Stationery Office; 2000.
26.   Walach H, Haeusler W, Lowes T, Mussbach D, Schamell U, Springer W, Stritzl G, Gaus W, Haag G:
      Classical homeopathic treatment of chronic headaches. Cephalalgia 1997;17:119-126.
27.   Möllinger H: Ein Leserbrief zur Arbeit von M. Wolf, R. Lüdtke, O. Rose. Allgem Homöopath Zeitschr
      2002;247:264-266.
28.   Resch KI, Ernst E, Garrow J: A randomized controlled study of reviewer bias against an
      unconventional therapy. J R Soc Med 2000;93:164-167.
29.   Linde K, Scholz M, Ramirez G, Clausius N, Melchart D, Jonas WB: Impact of study quality on outcome
      in placebo-controlled trials of homeopathy. J Clin Epidemiol 1999;52(7):631-636.
30.   Vandenbroucke JP: Homoeopathy trials: going nowhere. Lancet 1997;350:824.
31.   NHS Centre for Reviews and Dissemination: Homeopathy. Effective Health Care Bull 2002;7(3):1-12.

                                           Seite 18 von 20                          © KARL UND VERONICA CARSTENS-STIFTUNG
32. Dean ME: The Trials of Homeopathy. Essen: KVC-Verlag; 2004.
33. The end of homoeopathy. Lancet 2005;366(9487):690.
34. Linde K, Jonas W: Are the clinical effects of homoeopathy placebo effects? Lancet
    2005;366(9503):2081-2082.
35. Lüdtke R: Das Ende des deutschen Fußballs. Forsch Komplementarmed 2006;13(1).
36. Fisher P, Berman B, Davidson J, Reilly D, Thompson T: Are the clinical effects of homoeopathy
    placebo effects? [letter]. Lancet 2005;366(9503):2082-2083.
37. Aickin M: The End of Biomedical Journals: There Is Madness in Their Methods. J Altern Complement
    Med 2005;11(5):755-757.
38. Aulagnier G: Action d'un traitement homéopathique sur la reprise du transit post opératoire.
    Homéopathie 1985;2(6):42-45.
39. Chevrel JP, Saglier J, Destable MD: Reprise du transit intestinal en chirurgie digestive - Action
    homéopathique de l'opium. Presse Médicale 1984;13(14):883.
40. Dorfman P, Amodéo C, Ricciotti F, Tétau M, Véroux G: Iléus post-opératoire et homéopathie - Bilan
    d'une évaluation clinique. Cahiers de Biotherapie 1992;114:33-39.
41. GRECHO: Evaluation de deux produits homéopathiques sur la reprise du transit après chirurgie
    digestive - Un essai contrôlé multicentrique. Presse Médicale 1989;18(2):59-62.
42. Castelain T: Etude de la action homéopathique de Raphanus sativus niger 5CH et d´Opium 15Ch sur
    la reprise du transit en chirurgie digestive post-opératoire [dissertation]. Bordeaux, France:
    Université de Bordeaux II.; 1979.
43. Valero EM: Etude de l'action préventive de Raphanus sativus 7CH, sur le temps de reprise du transit
    intestinal post-opératoire - Pyrogenium 7CH sur les infections post-opératoires [dissertation].
    Grenoble, France: Université Grenoble; 1981.
44. Jawara N, Lewith GT, Vickers, Aj, Mullee MA, Smith C: Homoeopathic Arnica and Rhus toxicodendron
    for delayed onset muscle soreness - A pilot for a randomized, double-blind, placebo-controlled trial.
    Brit Hom J 1997;86(1):10-15.
45. Vickers AJ, Fisher P, Smith C, Wyllie SE, Lewith GT: Homoeopathy for delayed onset muscle soreness
    - A randomised double blind placebo controlled trial. Brit J Sports Med 1997;31:304-307.
46. Tveiten D, Bruseth S, Borchgrevink CF, Lohne K: Effect of Arnica D30 on hard physical exercise - A
    double-blind controlled trial during the Oslo Marathon. Tidsskr Nor laegeforen 1991;111:3630-3631.
47. Tveiten D, Bruset S, Borchgrevink CF, Norseth J: Effects of the homeopathic remedy Arnica D30 on
    marathon runners: A randomized, double-blind study during the 1995 Oslo Marathon. Complem Ther
    Med 1998;6(2):71-74.
48. Vickers AJ, Fisher P, Wyllie SE, Rees R: Homeopathic Arnica 30X Is Ineffective for Muscle Soreness
    After Long-Distance Running - A randomized, double-blind, Placebo-controlled trial. Clin J Pain
    1998;14(3):227-231.
49. Jacobs J, Jiminez LM, Gloyd S, Carares FE, Gaitan MP, Crothers D: Homoeopathic treatment of acute
    childhood diarrhoea - A randomized clinical trial in Nicaragua. Brit Hom J 1993;82(2):83-86.
50. Jacobs J, Jiménez LM, Gloyd SS, Gale JL, Crothers D: Treatment of Acute Childhood Diarrhea With
    Homoeopathic Medicine: A Randomized Clinical Trial in Nicaragua. Pediatrics 1994;93(5):719-725.
51. Jacobs J, Jiménez LM, Malthouse S, Chapman E, Crothers D, Masuk M, Jonas WB: Homeopathic
    Treatment of Acute Childhood Diarrhea - Results from a Clinical Trial in Nepal. J Alternat Complement
    Med 2000;6(2):131-139.
52. Andrade LEC, Ferraz MB, Atra E, Castro A, Silva MSM: A Randomized Controlled Trial to Evaluate the
    Effectiveness of Homeopathy in Rheumatoid Arthritis. Scand J Rheumatol 1991;20:204-208.
53. Gibson RG, Gibson SLM, MacNeill AD, Buchanan WW: Homoeopathic Therapy in Rheumatoid Arthritis
    - Evaluation by Double-Blind Clinical Therapeutic Trial. Brit J Clin Pharmacol 1980;9:453-459.
54. Fisher P, Scott DL: A randomized controlled trial of homeopathy in rheumatoid arthritis. Rheumatol
    2001;40:1052-1055.
55. Maronna U, Weiser M, Klein P: Orale Behandlung der Gonarthrose mit Zeel comp - Ergebnisse einer
    doppelblinden Äquivalenzstudie versus Diclofenac. Orthopäd Prax 2000;36(5):285-291.
56. Nahler G, Metelmann H, Sperber H: Behandlung der Gonarthrose mit Zeel comp - Ergebnisse einer
    randomisierten, kontrollierten klinischen Prüfung im Vergleich zu Hyaluronsäure. Orthopäd Prax
    1996;32(5):354-359.
57. Birnesser H, Klein P, Weiser M: A Modern Homeopathic Mediation Works as well as COX2 Inhibitors
    for Treating Osteoarthritis of the Knee. Der Allgemeinarzt 2003;25(4):261-264.
58. Brigo B, Serpelloni G: Homoeopathic Treatment of Migraines - A Double-blind Controlled Study of
    Sixty Cases (Homoeopathic Remedy versus Placebo). Berlin J Res Hom 1991;1(2):98-106.
59. Whitmarsh T, Coleston-Shields DM, Steiner TJ: Double-blind randomised Placebo-controlled study of
    homoeopathic prophylaxis of migraine. Cephalalgia 1997;17:600-604.
60. Straumsheim P, Borchgevink C, Mowinckel P, Kierulf H, Hafslund O: Homeopathic treatment of
    migraine: A double blind, placebo controlled trial of 68 patients. Br Hom J 2000;89:4-7.
61. Ferley JP, Zmirou D, d'Adhemar D, Balducci FA: Controlled Evaluation of a Homoeopathic Preparation
    in the Treatment of Influenza-like Syndromes. Brit J. Clin Pharmacol 1989;27:329-335.
62. Papp R, Schuback G, Beck E, Burkard G, Bengel J, Lehrl S, Belon P: Oscillococcinum in patients with
    influenza-like syndroms: A placebo controlled double-blind evaluation. Brit Hom J 1998;87(2):69-76.
63. Casanova P: Homeopathie, syndrome grippal et double insu. Tonus 1984.

                                          Seite 19 von 20                          © KARL UND VERONICA CARSTENS-STIFTUNG
64. Casanova P, Gerard R: Bilan de 3 anées d´études randomisées multicentriques
    oscillocacinum/Placebo. Laboratoires Boiron, ed. Oscillococcinum - rassegna della letteratura
    internazionale. 1992;2:11-16.
65. Heidbreder D, Gerster G, Gracza E: Sinusitis - Klinische Prüfung verschiedener homöopathischer
    Medikamente in unterschiedlichen Potenzen. Therapeutikon 1988;2(12):701-706.
66. Weiser M, Clasen BPE: Randomisierte plazebokontrollierte Doppelblindstudie zur Untersuchung der
    klinischen Wirksamkeit der homöopathischen Euphorbium compositum-Nasentropfen S bei
    chronischer Sinusitis. Forsch Komplementärmed 1994;1:251-259.
67. Lecocq PL: L52. les voies thérapeutiques des syndromes grippaux. Cahiers de Biotherapie
    1985;87:65-73.
68. Bordes LR, Dorfman P: Evaluation de l'activité antitussive du sirop Drosetux - Etude en double
    aveugle versus placébo. Cahiers d'Oto-rhino-laryngologie, de chirurgie cervico faciale et
    d'audiophonologie 1986;21:731-734.
69. Niederle S: Akute, streptokokken-negative Tonsillitis bei Kindern - Eine doppelblinde
    placebokontrollierte Studie belegt die Wirksamkeit und Verträglichkeit der homöopathischen
    Therapie. Kassenarzt 2001;21:33-34.
70. Diefenbach M, Schilken J, Steiner G, Becker HJ: Homöopathische Therapie bei Erkrankungen der
    Atemwege - Auswertung einer klinischen Studie bei 258 Patienten. Z Allg Med 1997;73:308-314.
71. Schmidt W: Zur Therapie der chronischen Bronchitis - Randomisierte Doppelblindstudie mit
    Asthmakhell. Therapiewoche 1987;37(29):2803-2809.
72. Maiwald L, Weinfurtner T, Mau J, Connert WD: Therapie des grippalen Infekts mit einem
    homöopathischen Kombinationspräparat im Vergleich zu Acetylsalicylsäure - Kontrollierte,
    randomisierte Einfachblindstudie. Arzneim Forsch 1988;38,I(4):578-582.
73. Gassinger CA, Wünstel G, Netter P: Klinische Prüfung zum Nachweis der therapeutischen Wirksamkeit
    des homöopathischen Arzneimittels Eupatorium perfoliatum D2 (Wasserhanf composite) bei der
    Diagnose "Grippaler Infekt". Arzneim Forsch 1981;31,I(4):732-736.
74. Torbicka E, Brzozowska-Binda A, Wilczynski J, Uzarowicz A: RSV infections in infants: therapy with a
    homeopathic preparation. Biomedical Therapy 1998;16:256-260.
75. Bordes LR, Soudant J, Dorfman P: Drosetux, un médicament homéopathique à l'épreuve du double
    insu. Médecine & Enfance 1988;8(7)Suppl.
76. de Lange-de-Klerk ESM, Blommers J, Kuik DJ, Bezemer PD, Feenstra L: Effects of homoeopathic
    medicines on daily burden of symptoms in children with recurrent upper respiratory tract infections.
    BMJ 1994;309:1329-1332.
77. Steinsbekk A, Bentzen N, Fonnebo V, Lewith G: Self treatment with one of three self selected,
    ultramolecular homeopathic medicines for the prevention of upper respiratory tract infections in
    children. A double-blind randomized placebo controlled trial. Br J Clin Pharmacol 2005;59(4):447-
    455.
78. Reilly DT, Taylor MA: Potent Placebo or Potency? - A Proposed Study Model with Initial Findings Using
    Homœopathically Prepared Pollens in Hayfever. Brit Hom J 1985;74(2):65-75.
79. Reilly DT, Taylor MA, McSharry C, Aitchison T: Is Homoeopathy a Placebo Response? - Controlled
    Trial of Homoeopathic Potency - With Pollen in Hayfever as Model. Lancet 1986;II,2:881-886.
80. Reilly DT, Taylor MA, Beattie NGM, Campbell JH, McSharry C, Aitchison TC, Carter R, Stevenson R: Is
    evidence for homoeopathy reproducible? Lancet 1994;344:1601-1606.
81. Lewith G, Watkins AD, Hyland MEea: Use of ultramolecular potencies of allergen to treat asthmatic
    peaople allergic to house dust mite duble blind randomized controlled clinical trial. Br Med J
    2002;324:520-523.
82. Böhmer D, Ambrus P: Behandlung von Sportverletzungen mit Traumeel-Salbe - Kontrollierte
    Doppelblindstudie. Biol Medizin 1992;21(4):260-268.
83. Thiel W, Borho B: Die Therapie von frischen, traumatischen Blutergüssen der Kniegelenke
    (Hämarthos) mit Traumeel N Injektionslösung. Biolog Med 1991;2:506-515.
84. Zell J, Connert WD, Mau J, Feuerstake G: Behandlung von akuten Sprunggelenksdistorsionen -
    Doppelblindstudie zum Wirksamkeitsnachweis eines homöopathischen Salbenpräparats. MMW
    Fortschr Med 1988;106(5):96-100.
85. Goldstein MS, Glik D: Use of and satisfaction with homeopathy in a patient population. Altern Ther
    Health Med 1998;4(2):60-65.
86. Richardson WR: Patient benefit survey: Liverpool Regional Department of Homeopathic Medicine. Brit
    Hom J 2001;90(3):158-162.
87. Witt C, Keil T, Selim D, Roll S, Vance W, Wegscheider K, Willich SN: Outcome and costs of
    homoeopathic and conventional treatment strategies: a comparative cohort study in patients with
    chronic disorders. Complement Ther Med 2005;13(2):79-86.
88. Stadler BM: Die geistige Verunreinigung in der Alternativmedizin. Neue Züricher Zeitung 6. März
    2005.

                                          Seite 20 von 20                          © KARL UND VERONICA CARSTENS-STIFTUNG
ÜBER UNS
Wir glauben an die Kraft der globalen Austausches von Ideen und die Macht der Bildung, deshalb arbeiten wir und entwickeln ReadkonG ©, um den Menschen aus der ganzen Welt zu helfen, die Antworten und Ideen, die sie besonders interessieren, zu finden.
[*/quote*]

[pordi]

Am 18. August 2003 hat das Web-Archiv diese Seite archiviert. Sie trägt das Bearbeitungsdatum "13 Aug 2003".

Was zu erwarten war: Markus Wiesenauer im Vorstand. Außerdem der berüchtigte Michael Elies, bekannt durch seine hanebüchenen Aussagen über Homöopathie und seine noch unglaublicheren Aussagen über Hamer und dessen "Gesetze".

[*quote*]
Board
Veronica Carstens MD (Chairperson)
Michael Elies MD
Markus Wiesenauer MD
Horst Niemeyer LLD
 
Director:
Henning Albrecht PhD
h.albrecht@carstens-stiftung.de
[*/quote*]

https://web.archive.org/web/20030818180226/http://carstens-stiftung.de:80/index.html

[*quote*]
[Logo]   
Karl und Veronica Carstens-Stiftung
A Foundation for the Promotion and Support of Complementary Medicine   
    
Site Synopsis
Below: [Contact, Board, Site Languages]

The Foundation

Dates and Deadlines
Symposium 2000
Symposium 2001
Symposium 2002

Research and Results

  Projects List

  Literature by Author: 
  [ A ... Gn ]  [ Go ... K ]  [ L ... S ] [ T ... Z ]

Funding and Promotion

  Getting Funds

  Doctoral Scholarships

Publishing

  KVC Verlag

  Book List

External Links

Search this Site


Nachwuchsförderung
(German Section)
  Promotionsförderung

  Studentisch organisierte Lehre

  Wilseder StudentInnen Forum für
  Homöopathie

  Alt-Wilseder Forum für Homöopathie

Job-Forum


Guestbook


Contact
Karl und Veronica Carstens Foundation
Am Deimelsberg 36
D-45276 Essen
Phone: +49 - 2 01 - 56 305 - 0, Fax: - 30
Mail: kvc@carstens-stiftung.de

Impressum


Board
Veronica Carstens MD (Chairperson)
Michael Elies MD
Markus Wiesenauer MD
Horst Niemeyer LLD
 
Director:
Henning Albrecht PhD
h.albrecht@carstens-stiftung.de



Site Languages
This site was designed in English for international use. The German section ('Nachwuchs - Förderung') adresses mainly students in German-speaking countries.

Webmasters: Feel free to link to this site without individual permission, and please notify us of your site.
 
© Karl und Veronica Carstens - Stiftung im Stifterverband für die die Deutsche Wissenschaft
13 Aug 2003   http://www.carstens-stiftung.de /index.html  Comments & Suggestions
[*/quote*]

[pordi]

Im Januar 2006 das gleiche Bild:


"Vorstand:
Dr. Veronica Carstens (Vorsitzende), Dr. Horst Niemeyer, Dr. Michael K. H. Elies, Dr. Markus Wiesenauer

Geschäftsführung:
Dr. Henning Albrecht"




https://web.archive.org/web/20060102053528/http://www.carstens-stiftung.de:80/fusszeile/impressum.php

[*quote*]
 Zur Startseite   
Impressum                                                           
Anschrift:
Karl und Veronica Carstens-Stiftung
Im Stifterverband für die Deutsche Wissenschaft
Am Deimelsberg 36
45276 Essen
Telefon: +49-201-56305-0
Telefax: +49-201-56305-30
E-Mail: info@carstens-stiftung.de
Internet: www.carstens-stiftung.de

Spendenkonto:
Bank im Bistum Essen
BLZ: 360 602 95
Kontonummer: 10 47 90 10

Die Karl und Veronica Carstens-Stiftung ist eine gemeinnützige Stiftung nach privatem Recht.

Vorstand:
Dr. Veronica Carstens (Vorsitzende), Dr. Horst Niemeyer, Dr. Michael K. H. Elies, Dr. Markus Wiesenauer

Geschäftsführung:
Dr. Henning Albrecht

Zuständige Aufsichtsbehörde:
Bezirksregierung Düsseldorf - Stiftungsaufsicht
Umsatzsteuer-Identifikationsnummer gemäß § 27 a Umsatzsteuergesetz: DE 202506896
Inhaltlich Verantwortlicher gemäß § 6 MDStV: Dr. Henning Albrecht

Redaktion/Webmastering:
Ingo Munz
E-Mail: i.munz@carstens-stiftung.de

Haftungshinweis:
Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links.
Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.
[*/quote*]

[Rhokia]

Die Carstens-Stiftung kennt man ja. Aber wer ist das "European Committee of Homeopathy (ECH)"?

Eine Google-Suche mit diesem Namen und Wörtern wie

study studie studies studien

für den Zeitraum von 1. Jan. 1900 – 1. Jan. 2010 bringt nahezu null Ergebnisse.

Suche mit "European Committee of Homeopathy" study für den Zeitraum  1. Jan. 1900 – 1. Jan. 2010 bringt magere DREI Treffer. Für mich ist da nahezu null.


[*quote*]
History of Homeopathy - Dr. Ganka Kroumovahttps://www.homeopathy-gelian.com › ...· Diese Seite übersetzen
11.10.2007 — Kent focused his whole enormous energy on study and implementation of this method becoming ... which are members of the European committee of Homeopathy.

TAKING THE CASE OF HOMEOPATHY JULIET LOUISE SMITHhttp://eprints.bournemouth.ac.uk › Smith,Juliet_P...
PDF
von JL Smith · 2012 · Zitiert von: 1 — 1.3 Research into the use of homeopathic remedies . ... The European Committee of Homeopathy identifies twelve. 'schools' of 'distinctive doctrines' in ...
264 Seiten

GOA - WIMF 2019http://www.wimforum.org › speakers
Diese Seite übersetzen
15.06.2004 — Christiaan studied pharmacy in Italy (until 1987). ... From 1995 to 2005 he was Research Subcommittee co-ordinator of the European Committee of Homeopathy.
[*/quote*]


Der dritte Treffer:  "From 1995 to 2005 he was Research Subcommittee co-ordinator of the European Committee of Homeopathy."

Wenn der schon 1995 dabei war, muß es das  European Committee of Homeopathy schon 1995 gegeben haben. Und nichts mit Studie? Dabei st der Zeitraum der Ergebnisse doch bis Ende 2009 ausgedehnt. Das ist drei Jahre nach dem internen Papier der Carstens-Stiftung.

Was ist das überhaupt für eine Webseite? Schaun mer mal.

Die Arschkrampe, die die Webseite gemacht hat, hat alle Texte versteckt. Im Browser sieht man bloß die Gipsköpfe. Was da als Beschäftigungstherapie für homöophantastische Blindgänger versteckt ist, kann man aber mit dem Cache von Google sehen: auf "Nur-Text-Version" klicken!


Da sieht man dann das deutsche Elend:

[*quote*]
Dr. Christiane Kirchner
Head of the unit “Homoeopathic and Anthroposophic Medicinal Products” of the division “Complementary and Traditional Medicinal Products”, Federal
Institute for Drugs and Medical Devices (BfArM)
Christiane Kirchner is Head of the unit “Homoeopathic and Anthroposophic Medicinal Products” of the division “Complementary and Traditional Medicinal Products” of the Federal Institute for Drugs and Medical Devices in Germany. She was born in Germany, studied pharmacy and has additional qualifications in “General Pharmacy” and in “Public Health”. She has worked in BfArM for more than 25 years.

Christiane Kirchner has long-standing experience in the assessment of pharmaceutical quality and formal aspects of homoeopathic and anthroposophic medicinal products, in the assessment of safety of preparations of zoological or human origin and stability testing of homoeopathic products.

She works in committees of the German Homoeopathic Pharmacopoeia (“Manufacturing Methods” and “Analytical Methods”) and in working groups on national and European level (e.g. HMPWG and EDQM, “Working Party Homoeopathic Manufacturing Methods”).

She is author and co-author of publications on regulatory aspects of homoeopathic medicinal products.
[*/quote*]



[*quote*]
Dies ist der Cache von Google von http://www.wimforum.org/speakers.html. Es handelt sich dabei um ein Abbild der Seite, wie diese am 14. Juli 2022 15:28:12 GMT angezeigt wurde. Die aktuelle Seite sieht mittlerweile eventuell anders aus. Weitere Informationen.
Vollständige VersionNur-Text-VersionQuelle anzeigen
Tipp: Um deinen Suchbegriff schnell auf dieser Seite zu finden, drücke Strg+F bzw. ⌘-F (Mac) und verwende die Suchleiste.
Toggle navigation logo
Home
Forum 2019
Program
1st Forum 2017
Speakers
Venue & Accommodation
Registration
Contact Us


Speakers
Mr. Ahmed M Hussein Babiker
Profile
×
Mr. Ahmed M Hussein Babiker
BSc, MSc in Clinical Pharmacy
Head, Registration and Pricing Section,
Pharmacy and Drug Control Department Ministry of Public Health, Doha, Qatar
Mr. Babiker has more than 24 years of experience in different fields of pharmacy practice including; hospital pharmacy, community pharmacy, clinical pharmacy, drug information, patient safety, quality and risk management. He has presented many papers in international scientific conferences and published an original research article in reputable Journal.

Mr. Babiker is a pharmacist with initially a degree from Sudan, which he substantiated by doing additional internationally, recognized examinations. He has research experience through a Master program at Queens University Belfast in the United Kingdom. His research interests are in the areas of patient safety and pharmacy practice.

He has worked as drug information pharmacist at Hamad Medical Corporation, the principal health institute in Qatar, which contributed to his clinical knowledge and skills. Through his work for the Ministry of Public Health, especially the Community Pharmacies Steering Group for the National Health Strategy Project 1.6 Community Pharmacies Strategy and as vaccine registration supervisor, he also has experience with the development of policies. Moreover, He is a member of a National Clinical Guideline Development Group in the State of Qatar.

In addition, Mr. Babiker is interested in sport activities; he was volunteering with Qatar Anti-doping Commission as a Doping Control Officer (DCO) since 2005. He participated in many and different sports activities in Qatar as DCO as well as DCO Venue Manager.

Close
Dr. Anil Khurana
Profile
×
Dr. Anil Khurana
MD(Hom)
Deputy Director General, CCRH
Dr. Anil Khurana is presently working as Deputy Director General in Central Council for Research Homoeopathy. He has additional charge as Director General, Central Council for Research in Unani Medicine in August 2017- April 2018. Since May 2018, Dr Khurana is nominated as Member, Board of Governor, Central Council of Homoeopathy which is the regulatory Council for the education and Practice of Homoeopathy in India.

He has experience of over 30 years in the Council and has worked all areas of research i.e. clinical research, basic research, fundamental research, drug standardization, clinical verification and drug proving. He has undertaken Post Doctoral Fellowship in HIV AIDS in University of California, Los Angeles, US. He has also acquired qualification of Bio ethicist from ICMR-IGNOU (joint course). Dr Khurana is recipient of various awards and has more than 70 research publications in various national and international peer-reviewed journals to his credits.
Close
Arvind Kothe
Profile
×
Arvind Kothe
MD (Hom) , PGCR (AIIPM&R, Mumbai)
Director, JIMS Homoeopathic Medical College & Hospital
Sriramnagar, Muchintal, Palmakula,Post, Shamshabad-Hyderabad, Telangana
Dr. Arvind kothe has teaching experience of 40 years and administrative experience of 30 years. He has held position of Chairman, Committee for Excellence in Homoeopathic Education, Central Council of Homoeopathy and member of Special Committee on Homoeopathic Drug Pathogenetic trials.

Currently Director and Prof. Dept. of Homoeopathic Materia Medica, JIMS Homoeopathic Medical College & Hospital, Hyderabad, India. He is also PhD guide in Maharashtra University of Health Sciences, Editor of Indian Journal of Applied Homoeopathy. He is member of several international schools like Glees Academy of Homoeopathic Physician and Committee on Accreditation of Schools, Liga Medicorum Homoeopathica Internationalis ( LMHI).

Close
Ashish Kumar
Profile
×
Ashish Kumar
B. Tech, MBA
Managing Director, Schwabe India
A graduate from MIT Muzaffarpur in B.Tech, Mr. Ashish Kumar did his MBA from UK from Cardiff Business School. He was among few candidates selected for a scholarship to complete Diploma in Innovation Management funded by Welsh Development Authority, Wales. Thereafter, he was selected by ICI, UK. From there he joined ICI India as a Management Trainee in December 1997 and went to become the youngest Country Manager in 2007 for Huntsman. During those years, he was well exposed to projects of Human Resources, Business Turnaround, and Acquisitions in different parts of the world. He excelled himself to become a turn-around expert over the years. He was awarded as the best Strategist for Huntsman in Asia.

In the Schwabe Group, he has been instrumental in the big turnaround of Schwabe India from 2011 and today has positioned Schwabe India as one of the most professionally managed companies in the Industry. In the Schwabe Group, Schwabe India had been awarded as the best company 2 times in a row within 4 years after he had taken over the leadership. He has been in the global strategic team for the Schwabe Group for Homoeopathy business and has been contributing to the development of the homoeopathy within the Group countries. An avid “People’s Person” he has been one of the “Remarkable Change Leaders” who has not only transformed Schwabe India financially and operationally, but he has built a people culture in Schwabe which has been recognized by many reputed organizations like Economic Times.

Close
   
Dr. Catherine Lang
Profile
×
Dr. Catherine Lang
Scientific Programme Manager, European Pharmacopeia (Ph. Eur.)
Department of the European Directorate for the Quality of Medicines & Healthcare (EDQM)
Catherine LANG is Scientific Programme Manager in the European Pharmacopeia Department at the EDQM, Council of Europe. She was born in France and she holds a Master’s in Science (Biochemistry) from the University Louis Pasteur de Strasbourg and a DESS in Applied Microbiology from the Pharmaceutical University of Strasbourg.

After graduation, she worked for one year as a researcher in the R&D laboratory of a large food company.

From 1994-2000, she was Head of the microbiological quality control laboratory responsible for quality control and batch release in a pharmaceutical company.

In 2000, she worked in quality, safety and environment management of a large pharmaceutical industry and in 2001 she obtained a master’s degree in this field.

She has a large experience at the EDQM as a scientific administrator to several groups of experts and working parties such as groups dealing with veterinary vaccines and sera, human vaccines and sera, human blood and blood products, working parties dealing with botulinum toxin, dialysis solutions, gelatines, homoeopathic raw materials and stocks, water for pharmaceutical use.

Close
   
Dr. Chandani Herath
Profile
×
Dr. Chandani Herath
DHMS, Diploma in Counselling, Diploma in Toxicology, Master in Public Administration - SLIDA
Medical Officer In-Charge
Govt. Homeopathic Hospital, Welisara, Sri Lanka
In Welisara, there is a Govt. Homeopathic Hospital under the Ministry of Health and Indigenous Medicine. In Sri Lanka, about 178 Homeopathic registered doctors are there and out of them about 40 are institutionally qualified. They have either diploma or degree which obtained from Pakistan or India. Due to the absence of Homeopathic Teaching Institute, few number of Homeopathic qualified doctors enter to the field of Homeopathy, annually. Presently Ministry of Health and Indigenous Medicine gets 10 scholarships for BHMS (Bachelor of Homeopathic Medicine & Surgery) from Ministry of AYUSH, India.

Dr. Chandani is currently Medical Officer In-Charge, of Govt. Homeopathic Hospital, Welisara, Sri Lanka. She completed her DHMS from Pakistan Homeopathic Medical College, Lahore Dr. Chandani is involved in Clinical practice in OPD & IPD sectors of the hospital, Hospital Administration, Planning and development activities with regard to Homeopathy in Health sector and Policy planning and legal activities with regard to Homeopathy. She also have Diploma in Counselling, Diploma in Toxicology, Master in Public Administration – SLIDA

Close
   
Christiaan Mol
Profile
×
Christiaan Mol
General Secretary, European Coalition on Homeopathic and Anthroposophic Medicinal Products (ECHAMP)
Christiaan studied pharmacy in Italy (until 1987). Then he attended an intensive course homeopathy in Augsburg/ Germany (1988). Studies of philosophy of science in Stuttgart (1999). His focus was on understanding how thinking and empirical knowledge match. The researcher must be aware of what his basic assumptions are. This is very important to allow and understand a pluralistic approach to medicine. In studies on profit management in Heidelberg (2015) he gained insights in the management of associations as well as foundations.

Since 2013 he is the General Secretary of the industry association ECHAMP (European Coalition on Homeopathic and Anthroposophic Medicinal Products); in that role he focuses on aligning processes on technical issues for the sector of potentised medicinal products in general. He is member of the Committee on manufacturing of the German Homeopathic Pharmacopoeia (GHP) and Board member of the International Association of Anthroposophic Pharmacists, IAAP. In these institutions technical aspects of homeopathic and anthroposophic medicinal products are discussed and adequate technical standards are worked out.

Today’s role in industrial company: he is one of the trustees in the board of the Wala foundation, who is the owner of Wala Heilmittel GmbH.

Close
   
Dr. Christiane Kirchner
Profile
×
Dr. Christiane Kirchner
Head of the unit “Homoeopathic and Anthroposophic Medicinal Products” of the division “Complementary and Traditional Medicinal Products”, Federal
Institute for Drugs and Medical Devices (BfArM)
Christiane Kirchner is Head of the unit “Homoeopathic and Anthroposophic Medicinal Products” of the division “Complementary and Traditional Medicinal Products” of the Federal Institute for Drugs and Medical Devices in Germany. She was born in Germany, studied pharmacy and has additional qualifications in “General Pharmacy” and in “Public Health”. She has worked in BfArM for more than 25 years.

Christiane Kirchner has long-standing experience in the assessment of pharmaceutical quality and formal aspects of homoeopathic and anthroposophic medicinal products, in the assessment of safety of preparations of zoological or human origin and stability testing of homoeopathic products.

She works in committees of the German Homoeopathic Pharmacopoeia (“Manufacturing Methods” and “Analytical Methods”) and in working groups on national and European level (e.g. HMPWG and EDQM, “Working Party Homoeopathic Manufacturing Methods”).

She is author and co-author of publications on regulatory aspects of homoeopathic medicinal products.

Close
   
Diadelis Remirez Figueredo
Profile
×
Diadelis Remirez Figueredo
Senior Researcher
Reviewer of Safety and Efficacy of Herbal Medicines and Synthetic products
Dr. D. Figueredo received her B.A. degree (1995, Biochemistry) from Faculty of Biology, Havana University, Cuba, and both her MSc (1995, Biomedicine) and PhD (1999 Pharmaceutical Sciences) degree from National Center for Scientific Research in Havana, and most of the results were done in the Department of Toxicology at the Free University in Amsterdam. Postdoctoral training in Molecular Toxicology and pharmacology was completed at the Faculty of Pharmacy in Toronto, Canada. She has been referee of scientific journals related with natural products. Other previous academic appointments include lecturer in different international meeting. She has been the recipient of National Award of Pharmacology twice from the Cuban Pharmacology Society. She worked as Expert for the evaluation of preclinical platform in South Africa. (CSIR).

She is currently the Vice president of Cuban Pharmacology Society. She is the WHO focal point for traditional medicine in Cuba. At present she works in the Cuba Regulatory Agency, she is one of the reviewers for authorization of clinical trials, and the evaluation of safety and efficacy of drugs for registering. She is the project leader for Pharmacogenetic guideline.

Dr. Remirez research is described in over 35 published research reports.

Close
   
Edward De Beukelaer
Profile
×
Edward De Beukelaer
DVM, MRCVS
Veterinary surgeon in private practice, president of the IAVH
Riverside veterinary Centre
Pelham Court
Marlborough
Sn8 2AG United Kingdom
Edward was born in Belgium where he studied veterinary medicine (graduated Ghent 1986). He subsequently worked as a veterinary surgeon in mixed large and small animal practice in France and then the UK.

Edward started studying homeopathy in France (SHV, Paris) in 1992. He then went to the CLH school of Mark Brunson in Belgium for 5 years to further his homeopathy training.

Through his involvement in homeopathy in the UK he became part of the IAVH to start a veterinary Materia Medica project collecting ‘specific’ veterinary information relating to homeopathic remedies.

Edward was elected president of the IAVH in September 2015 and was re-elected in November 2018 (IAVH = International Association for Veterinary Homeopathy). He attends 4 yearly meetings of Eurocam which is a EU lobby group which promotes CAM to the EU institutions.

He published a book: ‘Homeopathy? What to expect’. It contains 101 veterinary cases by 12 different veterinary surgeons, edited for the public to help achieving an understanding of the homeopathic prescription.

Close
   
Dr. Eric L Foxman
Profile
×
Dr. Eric L Foxman
Senior Scientist
Homeopathic Pharmacopeia Convention of the United States
Eric L. Foxman has a rich history of work in the homeopathic industry. He has been a member of the Homeopathic Pharmacopeia Convention of the United States since its founding in 1980 and is presently in his 12th year on the Board of Trustees. He serves as the Senior Scientist of the Convention and the Chair of the Council on Pharmacy. In these capacities, Eric is very active in the on-going revision and updating of the contents of the HPUS. He is an active member of the Working Group on commonalities between the Homeopathic Pharmacopeia of India and the United States.

Mr. Foxman has been active a member or representative of the American Association of Homeopathic Pharmacists for over 38 years and serves as the Secretary and Board member of that organization. He has presented numerous workshops on legal, regulatory and technical aspects of the manufacturing and marketing of homeopathic drug products. He also presents updates to the HPUS through an annual webinar on behalf of the AAHP.

A licensed pharmacist, Eric is a consultant to the homeopathic industry with a focus on helping companies achieve compliance with the myriad of regulatory requirements for companies’ high-quality, well-formulated homeopathic drug products. He provides formulation, production and labeling consultation and review and other support work for his clients across the homeopathic industry.

Close
   
Frédéric Ducher
Profile
×
Frédéric Ducher
Pharm. D.
Director, Global Regulatory Affairs, Boiron
Deputy Qualified Person
Frédéric Ducher is director of global regulatory affairs at Boiron. He is also Deputy Qualified Person to Boiron and a member of the executive committee.

Born in Périgueux, France, he became a pharmacist at the University of Bordeaux and completed his studies with a Master in Analytical Methods. He moved to Paris to be an intern in pharmacy in Parisian hospitals and completed his training with a Master's degree in quality assurance and a postgraduate degree in biomedical and industrial pharmacy.

After four years in the hospital, he joined GlaxoSmithKline in 1997, holding various positions in regulatory affairs, project team leader and marketing, mainly in the respiratory field. In 2008, he joined Bayer to consider the regulatory team and then the marketing department of Cardiology.

He then joined Boiron in 2015 with the goal of developing regulatory affairs worldwide. The 70-person department includes activities for Redaction with a laboratory for analytical development and stability testing, registration and marketing approvals, pharmaceutical business and pharmacovigilance.

Close
   
Dr. Geetha Krishnan
Profile
×
Dr. Geetha Krishnan
Technical officer in the Traditional,
Complementary and Integrative Medicine Unit of WHO
Dr. Geetha Krishnan Gopalakrishna Pillai is currently the AYUSH expert in the World Health Organization. He is the first person to have been selected by the Govt. of India to this post, where as a Technical officer in the Traditional, Complementary and Integrative Medicine Unit of WHO, he works on policies and guidelines of WHO for AYUSH (Ayurveda, Yoga, Unani, Siddha, and Homeopathy) systems. Dr Geetha is a researcher, and clinician. His broad background expertise is in Ayurveda, with specific skills, training and experience Integrative Medicine and herbal drug development. He has proposed the Axial Model of Integrative medicine, a working model for integrating multiple systems of medicine in 2011. Based on this model, he successfully established the integrative medicine department in India’s largest multispecialty hospital. Here he proved the clinical benefits and economic viability of Integrative medicine through successful application of the model and managed more than 17000 patients in a period of seven years. He has experience and expertise in using clinical interventions of Ayurveda and Yoga in Integrative practice and research.

He has several completed and ongoing clinical research projects, to his credit -as a Principal Investigator- in the areas of Cancer, Diabetes, and Infectious diseases. He also has several peer reviewed publications to his credit, from each completed project and has been awarded patents in US and Germany. His research has been supported by government, private, and institutional grants. He has been successful in initiating and establishing several effective collaborations.

Close
   
Dr. Gunther Herr
Profile
×
Dr. Gunther Herr
M. Jur. (Oxon)
Qualified Lawyer Director Legal & Regulatory Affairs,
Biologische Heilmittel Heel GmbH
Dr. Gunther Herr is Director Legal & Regulatory Affairs for Biologische Heilmittel Heel GmbH ("Heel") in Baden-Baden, Germany.

He was born in Germany, studied law at University of Constance and University of Oxford and qualified in law.

From 2003 until 2006 he worked as Attorney-at-Law in a law firm specialized in healthcare. Since 2006 he has been with Heel, a leading manufacturer and distributor of complex homeopathic medicinal products with subsidiaries and partners in around 50 countries.

Dr. Herr is member of the Executive Board of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and member of EUCOPE's Legal Working Group. He is a guest lecturer for both the "Zusatzqualifikation Pharmarecht" and the "LL.M.- Weiterbildungsstudiengang Pharmarecht" at University of Marburg.

Close
   
G. V. R. JOSEPH
Profile
×
G. V. R. JOSEPH
MSc, Ph.D., M.A., N.D., PG Dip DRA
Comparing the major homeopathic pharmacopoeia
G. V. R. Joseph is Director of Homoeopathic Pharmacopoeia Laboratory. He was born in Andhra Pradesh, India, did his Ph.D. in Botany, studied Naturopathic medicine and also did masters in Sociology besides Post graduate diploma in Drug Regulatory affairs. Dr.Joseph specialized in Drug Standardization and working in the same field per the past 20 years. He worked in various capacities in Government of India at different parts of the Country. He was the Programme Officer for Medico Ethno Botanical Research travelled extensively different parts of India in connection with the folklore study and medicinal plants. He authored eighteen books and published numerous research articles of Inter National and National reputation.

He Represented India for negotiations on Traditional Health Medicinal Plants Directive (THMPD) with European Commission and represented India couple of International forums. During his posting at International Cooperation section he worked extensively on Drug regulatory affairs. Since 2017 Dr.Joseph is working as a Director, Homeopathic Pharmacopoeia Laboratory (HPL) and also performing duties as Government Analyst for entire India on Homeopathic Medicine. HPL is the only Government owned Drug Testing Laboratory which tests the quality and sets the standards for Homeopathic Medicines.

Close
   
Dr. Hélène RENOUX
Profile
×
Dr. Hélène RENOUX
MD
Medical Doctor with an additional qualification in Homeopathy
President of the European Committee for Homeopathy (ECH)
President of the Société Savanted’ Homéopathie (SSH)
Hélène Renoux is a general practitioner working in a Paris suburb and has been qualified in homeopathy in 1995 at INHF-Paris (Institut National Homéopathique Français).

Native of Nantes (Brittany) she completed there her full medical training at the University before moving to Paris for an additional qualification in Tropical diseases and Public health (Université Paris XI, Pierre et Marie Curie) in 1987. She spent several months, as medical student, working in west Africa in dispensaries as volunteer, in Senegal, Togo, and after being graduated she spent half a year in Pakistan with afghan refugees working for the NGO « AICF » (Action Internationale Contre la Faim) in 1988.

She has taught classical homeopathy at INHF-Paris where she has been General Secretary for four years (2008 – 2012). She also conducted nine educational provings with the students and the teaching team in Paris, and she still conducts provings with different working groups in France. She is also editorial board member of " La Revue d'Homéopathie" published by Elsevier.

She joined the ECH Provings Subcommittee in 2009 and became ECH General Secretary in November 2012 and ECH President in November 2016. She also became the General Secretary of the SSH (Société Savante d’Homéopathie) in January 2012 and its President in December 2017.

Close
   
Ilse Muchitsch Mag
Profile
×
Ilse Muchitsch Mag
European Committee for Homeopathy, Subcommittee pharmacy coordinator
Ilse Muchitsch is working as a pharmacist in Austria, Vienna since successfully completing her University degree (Magistra Pharmaciae - Mag.pharm.) in Pharmacy (thesis in Biochemistry). She is currently working in a pharmacy in Vienna.

She leads the Interdisciplinary Homeopathic Working Group since 2000: HomResearch for Pharmacy – Medicine – Biochemistry – Physics – Psychology at the Austrian Chamber of Pharmacy, Department Vienna. In the last 18 years in-service training events, lectures at the University of Vienna (Department of Pharmacy) and working groups have been organized by her, dedicated to the task of exploring scientific models of explanation, teaching and practice of homeopathic pharmacy. She started several international cooperations, such as studies in thermoluminescence with Prof. Louis Rey (France) to learn about different criteria of dilutions and other preparations.

Furthermore, Ilse Muchitsch is an author of the Austrian Journal of Pharmacy. Ilse Muchitsch is co-working with Michael Frass , MD. Professor of Medicine, Internal physician, internal intensivist, homeopath, at the Medical University of Vienna. She wrote the pharmaceutical part in the text book “Homeopathy in Intensive Care and Emergency Medicine“. She is coauthor of several scientific papers. She cooperates with the “Outpatient Unit: Homeopathy in malignant Diseases”, Medical University Vienna, Austria, Dept. Medicine I, Division Oncology.

Since 2014 she is Pharmacy coordinator of the European Committee for Homeopathy headlining following responsibilities: to support the availability of safe and high-quality homeopathic medicines, to review the documents for public consultation of HMPWG (homeopathic medicinal product working group), e.g. concerning First Safe Dilutions (FSD) and homeopathic use and to raise the standards of homeopathic pharmacy practice by encouraging the development of appropriate harmonized training programs for pharmacists and support staff across Europe.

Close
   
Dr. Iracema de A Benevides
Profile
×
Dr. Iracema de Almeida Benevides
MD. Msc.
President, Brazilian Association of Anthroposophic Medicine Associação Brasileira de Medicina Antroposófica, ABMA.
Vice-President, International Federation of Anthroposophic Medical Associations, IVAA.
Iracema Benevides is the President of the Brazilian Association of Anthroposophic Medicine and Vice- President of the International Federation of Anthroposophic Medical Associations. She was born in Brazil and qualified as Medicine Doctor, specialized in general surgery, medical nutrition, public health, anthroposophic medicine and homeopathy. She holds a Master in International Health Care Management Economics and Politics.

She worked as General Surgeon and Family Health doctor in Public Health from 1996 to 2003. She served with the Brazilian Minister of Health as a consultant, technical assistant and project coordinator, dedicated to Monitoring and Evaluation of the Primary Health Care Strategy and collaborated to the development and implementation of the National Policy of Integrative and Complementary Practices from 2004 to 2010.

She has also been a lecturer at the Faculdade da Saúde e Ecologia Humana Medical School and the Medical School of Pontifícia Universidade Católica, both in Belo Horizonte, Brazil from 2010 to 2016 and workes as a general practitioner and Anthroposophic doctor in private practice in Belo Horizonte, Brazil since 2013 to present.

Her current scope of work includes collaboration with the Brazilian Ministry of Health, WHO, PAHO and UNICEF from 2001 to present. Currently she integrates the team responsible for the development and updates of the Virtual Library in Health on Traditional Complementar and Integrative Medicine of the Americas, a project supported by PAHO (http://mtci.bvsalud.org/en/).

Close
   
Prof. Ivan Kosalec
Profile
×
Prof. Ivan Kosalec
PhD
University professor
Ivan Kosalec finished study of pharmacy (1997) and currently holds a position of professor at University of Zagreb (Croatia). He is also expert in the field of (traditional) herbal medicinal products and member of Herbal Medicinal Products Committee at European Medicines Agency.

In the Croatian medicines agency, he is assessor of (traditional) herbal medicinal products and homeopathic medicinal products more than five years. At Faculty of Pharmacy in Biochemistry together with colleagues is involved in course of complementary and traditional medicine where teach students about quality assessments and pharmaceutical side of homeopathic medicinal products.

Main focus of his work in the field of homeopathy is evaluation of homeopathic medicinal products, their quality based on pharmacopoeia’s assessments and methods of products preparation in homeopathic pharmacy. As a microbiologist, critical thinking and rationalization of contamination of homeopathic stocks and herbal products are also topic of his teachings and in professional papers.

Close
   
Prof. Dr. J. D. DARYANI
Profile
×
Prof. Dr. J. D. DARYANI
MD (Hom.)
Former, Principal & Medical Suptd., Professor & Head, Deptt. of Repertory,
Dr MPK Homoeopathic Medical College, Hospital & Research Centre, Jaipur.
Dr. J. D. Daryani is Former, Dean, Faculty of Homoeopathy in Rajasthan University and Rajasthan Ayurved University, Jodhpur. Former, Chairmen, Special Committee for Drug Proving – Central Council for Research in Homoeopathy, Ministry of AYUSH, Govt. of India. Currently he is Member of Academic Council, Homoeopathy University, Jaipur, Advisory Committee of AYUSH, Govt. of Rajasthan and Advisory Committee of Regional Research Institute of Homoeopathy, Jaipur.

He is visiting Professor, Guide / Supervisor for MD & PhD scholars in Homoeopathy in various Universities/ Institutions.

Dr Daryani has attended and presented scientific papers in several National & International Conferences in USA, Belgium, France, Germany, Switzerland, Russia, Singapore, Kuala Lumpur, Bangkok, Dubai, Pakistan, Sri Lanka, Bangladesh etc.

Close
   
Jack Hendrickx
Profile
×
Jack Hendrickx
Industrial Pharmacist, QP
Remedy Bank
Mr. Jack Hendrickx was born in Antwerpen (Belgium) where he also graduated as pharmacist in 1977. After his military training, he went back to university for a graduation in industrial pharmacy. In 1980, he started his profession in the homeopathic laboratory HOMEODEN in Ghent. In 1984 he founded a company for the development and sales of equipment dedicated for homeopathic preparation. Now, LABOTICS has become number 1 in the world when it comes to homeopathic machinery. They have constructed over 700 machines, including more than 100 Korsakov machines; furthermore they lead the market of dynamizing and impregnation equipment, and have clients in more than 30 countries, including India. Their newest development is K-TRONIC ADAMAS, a fully validated Korsakov dilutor allowing dilutions with 0.3% of precision.

In 2012, Mr. Hendrickx, started Remedy Bank, a cooperative company for the making of raw and starting materials for homeopathic use. He is co-founder of co-founder, Phablets. Cli. Biol. Wim De Marez (Hildegard Pharmacy, Brussels (BE), member and former Coordinator (2004-2012) of Pharmacy Subcommittee (homeopathyeurope.org)

He has given keynote presentations on diverse Congresses of Liga Medicorum Homeopathica Internationalis (LMHI), ECH and ABFH (Brazil).

Close
   
Dr. Jayesh R. Bellare
Profile
×
Dr. Jayesh R. Bellare
FNASc FNAE
B-Tech(IIT-B),Ph.D.(U.Minn,USA),PostDoc (MIT,USA)
Professor, Chemical Engineering &
Ex-Head, BioSchool, Indian Institute of Technology
I.I.T. Powai, Mumbai - 400 076 India
Dr. Jayesh Bellare is Institute Chair Professor of Chemical Engineering at IIT Bombay. He is a renowned expert in nanostructured materials for healthcare, biomedical devices, and electron microscopy. His research includes nanomedicines across multiple systems of medicines (particularly Homeopathic medicines, Ayurvedic Bhasma and Allopathich nanoparticles), 3D scaffolds, regenerative medicine, hollow-fiber-membranes, and stem-cell expansion. He is an expert in cryo-electron microscopy of soft nanomaterials. He is an elected Fellow of the National Academy of Science, India, the Indian National Academy of Engineering, the Maharashtra Academy of Sciences, and the Electron Microscopy Society of India.

He is a consultant to several industries, advisor to many Government panels and institutions, and has served on the board of directors of two companies. He has numerous publications, patents and awards. Among the recent ones are the Lifetime Achievement Award from the Government of India, Ministry of Ayush for his Nanotechnology work, and the Excellence in Teaching Award from the Department of Chemical Engineering, IIT Bombay.

Close
   
Dr. João Paulo Silvério Perfeito
Profile
×
Dr. João Paulo Silvério Perfeito
Msc
Manager of Specific, Low Risk,
Herbal and Homeopathic Medicines and Medical Gases of General Office of Drugs - Brazilian Health Regulatory Agency (ANVISA)
João Paulo Silvério Perfeito is Manager of Specific, Low Risk, Herbal and Homeopathic Medicines and Medical Gases of General Office of Drugs at the Brazilian Health Regulatory Agency (ANVISA) since 2016. He is Brazilian, graduated in Pharmaceutical Sciences with qualification in Clinical and Industrial Pharmacy.

He is also qualified in Pharmaceutical Industrial Management and Public Health. From 2010 to 2012, he took a postgraduate course at Universidade de Brasília (Brasilia/Brazil) and obtained a master’s degree in Health Sciences.

He is working as an Expert in Health Regulation at the Brazilian Health Regulatory Agency (ANVISA) since 2007 and since 2010 he is being member of Technical Thematic Committee of the Brazilian Pharmacopoeia. From 2012 to 2014, he worked as Deputy Coordinator of Herbal and Homeopathic Medicines of General Office of Drugs – ANVISA. From 2014 to 2016, he worked as Coordinator of Specific and Low Risk Medicines and Medical Gases of General Office of Drugs - ANVISA.

Close
   
Prof. K.R.C. Reddy
Profile
×
Prof. K.R.C. Reddy
BAMS, MD (Ayurv), Ph.D.
harmacopoeia Commission for Indian Medicine & Homoeopathy
Director In-charge, Pharmacopoeial Laboratory for Indian Medicine
Ministry of AYUSH, Govt. of India Ghaziabad
Dr. Reddy is Director, Pharmacopoeia Commission for Indian Medicine and Director I/c, Pharmacopoeial Laboratory for Indian Medicine. He is former Head , Department of Rasa Shastra, Faculty of Ayurveda, Institute of Medical Sciences, BHU,Varanasi. He was also Superintendent, Ayurvedic Pharmacy, Institute of Medical Sciences (IMS), BHU and Manager-Ayurvedic Pharmacy, National Institute of Ayurveda and other significant positions in government.

He is recipient of several awards like Nagarjuna Award, Acharyaratna Award, Murthy Scientist Award among many others.

He has been appointed in TKDL, CSIR, as expert of Ayurveda for Rare Ayurvedic books and unidentified medicinal plant products letter dated 17th Sept.,2010 and continuing till today. He has around 100 research publications in national and international peer reviewed journals, and owes authorship in 18 books.

Close
   
Dr. (Mrs.)K. S. Sethi
Profile
×
Dr. (Mrs.)K. S. Sethi
DHMS, Dip NIH, PG Hospital management, PG diploma Human Rights
Advisor (Homoeopathy) Ministry of AYUSH, Government of India
Dr. KS Sethi completed DHMS from Nehru Homoeopathic Medical College & Hospital in 1977 and Diploma from National Institute of Homoeopathic in1980.

She has experience of working in CCRH and as Chief Medical Officer (CMO) in CGHS from 1988 till 2006; as CMO (NFSG) from 2006 till 2015; Joint Advisor (H) December,2015 till 15th May, 2017.

Dr Sethi was posted as Director I/C (HPL) Ghaziabad from 11th January 2016 to 21st February,2017.

She is recipient of Life Time Achievement Award 2017 by Board of Homoeopathic System of Medicine Delhi and Special appreciation award 2018 by Board of Homoeopathic System of Medicine Delhi.

Currently she is working as Advisor (Homoeopathy) in Ministry of AYUSH

Close
   
Dr. K.V. Athman
Profile
×
Dr. K.V. Athman
M.V.Sc., Ph D(Animal Reproduction)
Founder Secretary & Patron, Charity Society for Holistic Veterinary Medicine
Dr. K. V. Athman is Former ADR(V&AS) & Professor, Kerala Agricultural University (KAU) Vellanikkara, Thrissur and Faculty, Post Graduate Certificate Course in Veterinary Homeopathy, Kerala Veterinary & Animal Science University (kvasu)Pookode, Wayanad.

He has experience of working as Associate Director Research(V&AS), KAU, Professor & Head, University Veterinary Hospital, Thrissur & CBF, Thumboormuzhy, Professor DAR, UVH , LRS of Veterinary Faculty, KAU, Consultant for various Dairy Farms of Kerala and outside.

In Academic career he has guided 12 M.V.Sc. and 3 PhD students both in Animal Reproduction & Animal Surgery. After retirement in 2009, Dr. Anthman is concentrating mainly on Veterinary Homeopathy.

Close
   
Prof. Laxmikanta Nanda
Profile
×
Prof. Laxmikanta Nanda
M.D (Hom.)
Consultant Homoeopath
Laxmikanta Nanda is the former principal cum superintendent, Dr. A. C. Homoeopathic Medical College, Bhubaneswar, India.and worked in the same college as Head of the department Materia Medica and a teacher for B.H.M.S and Post Graduate Course .

He visited Royal London Homoeopathic Hospital , London and New England School of Homoeopathy sponsored by W.H.O. and Department of AYUSH, Govt. of India. Presented Research paper in International Seminar at Cape Town, Berlin, New Delhi organized by LMHI and also at Dubai.

He is a member of Advisory board, of the journal of “ Indian Journal of Research in Homoeopathy “published by CCRH , former convener of the journal” Indian Journal of Education and Practice “ published by Central Council of Homoeopathy.

He was former member of Central Council of Homoeopathy from 2006 to 2018, Chairman, Committee of Excellency in Education, C.C.H. from 2015 to 2018 and former Member of Scientific Advisory Committee, Central Council for Research in Homoeopathy from 2006 to 2018 . Published four books and contributed Scientific paper in 91 journal including 6 International journals.

Research Studies undertaken by Dr.Nanda; A Study on , Biochemical and molecular basis of evaluation of efficacy of Rauwolfia Serpentina in its (Q,6C,30C) Preparation on hypertension-induced rat models. at Dept. of Biotechnology, Utkal University, funded by Ministry of AYUSH, Govt. of India, under extra mural project.A clinical study on effect of potentised Commiphora Mukul (Guggul) in Osteo arthritis. ( 2003 to 2005).A clinical Trial of Fennugreek (Triogonella Fornum Graceum.L.) Mother Tincture on type- II Diabetis Mellitus

Close
   
Ms. Monica Yeoh Siu Cheng
Profile
×
Ms. Monica Yeoh Siu Cheng
Mpharm
Principal Assistant Director, Natural Products Unit, Complementary and Alternative Medicine Section, Product Registration Centre, National Pharmaceutical Regulatory Agency, Malaysia
Monica Yeoh is a regulatory officer in the Natural Products Unit, Complementary and Alternative Medicine Section, Product Registration Centre, National Pharmaceutical Regulatory Agency, Malaysia. She was born in Kuala Lumpur, qualified in Pharmacy and has worked with the Malaysian government for twelve years.

She worked as a pharmacist in University Malaya Medical Centre from 2006 to 2007 and then in Ampang Hospital from 2008 to 2015. She has worked as a regulatory officer in Natural Products Unit, NPRA, since 2016. Her current focus is on evaluation of new products for registration.

Close
   
Dr. Mudita Arora
Profile
×
Dr. Mudita Arora
GM, R&D and Quality Assurance
Bakson Drugs & Pharmaceuticals Pvt. Ltd.
Dr. Mudita completed her B.H.M.S. from Nehru Homoeopathic Medical College, Delhi University in 1996, and then did Diploma in management from AIMA, New Delhi. She also has undergone Clinical Training in Maternal and Child Health, Radiotherapy and Ultrasonology under conventional medicine in reputed hospitals of Delhi.

In June 2004 she joined reputed Pharmaceutical and now has 15 years of experience in Research & Development. In her current role as GM, R&D and Quality Assurance, Bakson Drugs & Pharmaceuticals Pvt. Ltd which is an ISO 9001: 2015 and G.M.P. certified company, she is responsible for product management and clinical research. The products are produced in compliance with the pharmacopoeial and other international standards including GMP. They are extensively put to trials before launch and their marketing as well as after sale review are carefully monitored to deliver the best to the consumers in terms of efficacy and cost effectiveness.

Close
   
Dr. Neil Gower
Profile
×
Dr. Neil Gower
M-Tech Hom (UJ) CML (UNISA)
Chairperson: Complementary Medicines Committee (CMC)
South African Health Products Regulatory Authority (SAHPRA)
Senior Lecturer: Department of Complementary Medicines University of Johannesburg
Dr Neil Gower is a Senior Lecturer in the Department of Complementary Medicine (formerly Homoeopathy), at the University of Johannesburg. He completed a Masters Degree in homoeopathy (MTech Hom) in 2004 and registering as a homoeopathic practitioner with the Allied Health Professions Council of South Africa (AHPCSA). He began lecturing part-time for the University of Johannesburg in 2005 and was Head Clinician from 2007-2011 and appointed a fulltime lecturer in 2008 in the Department of Homoeopathy. Dr Gower was the National Secretary of the Homoeopathic Association of South Africa (HSA) (2005-2015). He was a Council member of the Medicines Control Council of South Africa (MCC) (2015-2018) until transition to SAHPRA. He continues to be member of expert advisory committee members to the SAHPRA including: Chairperson of the Complementary Medicines Committee (CMC), member of the Legal Committee (LC), Good Practices Committees (GXPCC) and Regulatory Advisory Committee (RAC).

Dr Gower has completed a Certificate in Medicine and Law (CML) (with distinction) from UNISA/UP, Certificate in Legislative Drafting from UJ (cum laude) as well as Certificates in Project Management (UJ) (cum laude) and Dispensing and Compounding (UP). This is in addition to various courses in the field of health, ethics and regulatory standard. He is currently registered for and undertaking a Doctoral degree in Health Studies with the University of South Africa investigating the role of Complementary Medicine and Universal Health Coverage.

Neil has a significant interest and knowledge in regulatory affairs of medicine in general and has provided numerous presentations on associated subject matter both nationally and internationally. He is passionate about the field of Traditional and Complementary Medicine, which underlies his involvement in lecturing, research supervision as well as system development.

Close
   
Mr. Nishant Jain
Profile
×
Mr. Nishant Jain
CEO at B. Jain Pharmaceuticals Pvt. Ltd
Nishant Jain, CEO at B. Jain Pharmaceuticals Pvt. Ltd, is a third generation of the family which has been associated with the homeopathic field. Nishant Jain is an MBA from S. P. Jain Institute of Business Studies, Mumbai, India. He has played a key role in introducing RADAR (a Belgium based homeopathic software) to the grass root level practice in India and added a huge number of doctors to the RADAR family of users. He is very passionate about homeopathy and works for promotion of homeopathy at different levels.

He has travelled worldwide to represent India at an international platform for homeopathic manufacturing. B. Jain Pharmaceuticals has been Mr.Nishant’s dream with the idea to take Indian homeopathic manufacturing to greater heights at a world level. B. Jain Pharmaceuticals inspite of being a new company achieved exports to more than 20 countries within a span on 7 yrs. of its launch. B. Jain Pharmaceuticals has made a mark in the Homeopathic industry and is known for its various accreditation like GMP, Health Canada License, ISO , NSF etc. along with maintenance of high Quality standards in terms of Production and Quality Control. B. Jain aims to make standardized manufacturing as a norm in Homeopathic industry.

Close
   
Dr. P. K. Naveen
Profile
×
Dr. P. K. Naveen
BVSc, MVSc
Dr. Naveen was born in Kerala, qualified as Graduate in Veterinary Science in 1959. He completed his Post Graduation in Animal Reproduction in 1981.

He has worked in Kerala Government Service as Veterinary Surgeon, Deputy Director and Joint Director. He has rich 32 years of experience in Veterinary medicine.

Dr. Naveen is practicing veterinary Homoeopathic Medicine for over 50 years. He is founder president of Charitable Society for Holistic Veterinary Medicine. Presently, he is Faculty Member of Post Graduate Certificate course in veterinary homoeopathy of Kerala veterinary and Animal Sciences University.

Close
   
Dr. Petra Weiermayer
Profile
×
Dr. Petra Weiermayer
DVM (Doctor of Veterinary Medicine)
President of the Austrian Association for Veterinary Homeopathy (OEGVH), Coordinator of the Political Subcommittee of the International Association for Veterinary
Homeopathy (IAVH), Member of the Research Subcommittee of the European Committee for Homeopathy (ECH), Homeopathic horse practitioner
Petra Weiermayer was born in Vienna, Austria, qualified in Veterinary Medicine and works as a homeopathic horse practitioner in Vienna, Austria since 2011. She worked as a clinical assessor at the Austrian Agency for Food and Health Safety from 2009 to 2014. She received the Diploma of the European Academy for Veterinary Homeopathy in 2009.

Since 2013, she is a board member of the OEGVH. From 2015 to 2018, she was General Secretary of the IAVH. Since 2018, she is the President of the OEGVH and IAVH National Representative of Austria. Since 2017, she is coordinator of the Political Subcommittee of the IAVH and since 2014, she is member of the Research Subcommittee of the ECH.

Her main political tasks in the last 3 years were lobbying for veterinary homeopathy within the developing process of the EU Regulation on Veterinary Medicine and within the renewal of the EU Regulation on Organic Farming. Her main current political tasks are promotion of veterinary homeopathy all over the world. Her recent research task was the organisation of the Research Workshop at the ECH / IAVH Symposium in November 2018 were she presented her main current research project being a randomized controlled trial (RCT) in veterinary homeopathy.

She gives lectures to students of veterinary homeopathy and in March 2018 she published a homeopathic case report in the Equine Veterinary Science Journal, which was also presented at the World Veterinary Association (WVA) Congress in Barcelona, in May 2018.

Close
   
Dr. Rachna Paliwal
Profile
×
Dr. Rachna Paliwal
Research Officer (Homoeopathy)
Ministry of AYUSH
Dr. Rachna Paliwal is a Homoeopathy Post graduate from National Institute of Homoeopathy, Kolkata. She joined as Research Officer in the Drug Control Cell of Ministry of AYUSH in 2016 after selection through UPSC. In the Ministry she is dealing with all technical and regulatory matters of Homoeopathy drugs and Industry. She is a notified and only Central Drug Inspector for Homoeopathy (Additional Charge) in India. Prior to joining the Central Government service she was working as Homoeopathic Medical Officer in the State of West Bengal and as an Assistant Professor (on deputation) in The Calcutta Homoeopathic Medical College and Hospital.

In short span of her service in the Ministry, she has made herself conversant with the regulatory matters pertaining to Homoeopathy drugs and has the zeal to work for the development of AYUSH drugs as a whole by addressing the quality and safety issues with innovative ideas.

Close
   
Dr. Raj. K. Manchanda
Profile
×
Dr. Raj. K. Manchanda
M.D. (Homoeopathy), M.B.A. (Health Care Administration)
Director General, Central Council for Research in Homoeopathy, Ministry of AYUSH, Govt. of India
Co- chairman, sub-committee of Drug Technical Advisory Board (Homoeopathy)
Secretary for Research, Liga Medicorum Homoeopathica Internationalis (LMHI)
Dr. Raj. K. Manchanda born in India, graduated as a homoeopathic physician from Nehru Homoeopathic Medical College, Delhi University and gained further insight into the science during his post-graduation in Homoeopathy from Dr. MPK Homoeopathic Medical College, Jaipur, Rajasthan, India. His interest in healthcare further inspired him to pursue a M.B.A degree in Health care administration from Faculty of Management of Sciences, Delhi University.

Currently, he is holding post of Director General of Central Council for Research in Homoeopathy, Ministry of AYUSH, Govt. of India. He has professional experience of 35 years as an able clinician, teacher, researcher, and administrator. He has rare insight into policy matters related to Homoeopathic Education, Research, Medicinal products and Global Affairs. He was awarded - “Award of Recognition” by Robert Bosch Foundation, Germany in 2011 for Indo-German collaborations.

Dr. Manchanda has over 120 research papers published in National & International peer-review journals on various research topics like Basic & Fundamental, clinical, drug standardization and clinical verification. He also owes authorship of Textbook of Dermatology for Homoeopaths in English and Spanish. He has presented more than 50 research papers aiming to spread the spirit of evidence based medicine and encourage research in Homoeopathic science globally.

Close
   
Dr. Rajesh Shah
Profile
×
Dr. Rajesh Shah
MD (Hom)
Founder and Director, Life Force Homoeopathy
Dr. Rajesh Shah, MD (Hom) is a global homeopath, researcher and an academician. He is in the book of world records for treating patients from highest number of countries, the count is 180 countries.

He has been seriously working on New Drug Discovery since about two decades. He has developed over 150 new homeopathic medicines, including those from biological sources such as HIV nosode, Hepatitis C nosode, Mycobacterium Tuberculosis nosode, Cancer nosode, Malaria nosode, and more. He has also conducted double-blind, placebo controlled Drug Provings, Clinical trials, experiments in animal models, plant models, as well as in-vitro studies, in collaboration with reputed institutions such as Haffkin Institute, ICT (UDCT), IIT-Bombay, Tata Memorial, Nair hospital, Mumbai University, etc. He has introduced 17 step scientific method of development of new nosodes. He is working on revamping all major homeopathic nosodes. He is a recipient of Best Research paper award from AYUSH’s CCRH, by the hands of the Vice President of India.

He has also defined Force parameters for Standardization of Potentization.

His research papers on New Drug Discovery are published in peer-reviewed, international journals. He is an author of several books. He has conducted seminars and workshops for homeopathic and allopathic doctors in India, USA, England, Belgium, Holland, Greece, Sweden, Norway, Japan, Croatia, and other countries. He is an author of several books including My Experiences with Ferrum Metallicum, Phenomena and Facets, etc.

He is former member of CCRH’s Drug Standardization Committee under the Ministry of AYUSH.

Close
   
Dr. Ramankutty P
Profile
×
Dr. Ramankutty P
Joint Director(AH) retd. Kerala Animal Husbandry Services
B.V.Sc (Kerala veterinary College)
Trained in vet clinical medicine, Kerala veterinary college
DMMH, DOMH from Premier Homeopathic medical college, Chandigarh and Health and medical institute, Calcutta respectively.
Dr. Kutty served as veterinary surgeon and various capacities in Kerala, Animal Husbandry department. He retired as Joint Director on 31 March 2017. He developed interest to study Homoeopathy and acquired distant education on principles of homeopathy from Premier Homeopathy Medical College, Chandigarh. He acquired membership certificate and diploma of Biochemic Medicine and diploma in Materia medica in homeopathy (DMMH and DOMH) during 1988. With this basic knowledge, guidance and support from homeopath friends, he started using Homeopathy in veterinary practices and since then found it to be very encouraging.

Since 2005, he is putting efforts to train veterinarians in homeopathy. He has also formed an organization, The Charitable Society for Holistic Veterinary Medicine with the active support of fellow veterinarians having experience and faith in veterinary Homeopathy. With active involvement of his organisation, the Post Graduate Certificate Course in Veterinary Homeopathy has been initiated by the Kerala Veterinary and Animal Science University, Kerala. Dr. Kutty is technical committee member of Kerala Veterinary and animal science university.

He is also Member Patron and President of Charitable society for Holistic Veterinary medicine and Member of Institute of homeopathy Research and development, Trichur, Kerala.

Close
   
Dr. Robbert van Haselen
Profile
×
Dr. Robbert van Haselen
Msc
Director, World Integrated Medicine Forum, International Institute for Integrated Medicine, Research Consultant
Robbert van Haselen is Director of the International Institute for Integrated Medicine and the World Integrated Medicine Forum. He was born in the Netherlands, qualified in Health Sciences and Naturopathic medicine and worked in private practice for eight years.

He worked as Head of Research for VSM, (a Dutch homeopathic company) from1990 to 1995 and in the same role for Heel (a German homeopathic company) from 2006 to 2011.

From 1995 to 2005, he worked at the Royal London Homoeopathic Hospital as Deputy Director of Research and as an independent research consultant.

He took over as Editor-in-Chief of the journal ‘Complementary Therapies in Medicine’ in 2004 and turned it into one of the world's leading peer reviewed Traditional and Integrated Medicine journals. By handover in 2015, it received more than 600 submissions per year from over 50 countries (2015 Impact Factor 1.94). From 1995 to 2005 he was Research Subcommittee co-ordinator of the European Committee of Homeopathy. He currently runs a project that aims to foster 'critical thinking' in both research and education and link this to improving the quality of clinical case reports. He is a member of the HPCUS since 2009 and is involved in the development of guidelines for the clinical review in the monograph review process.

He works as an independent research consultant, and is involved in various activities under the header of the “International Institute for Integrated Medicine” (INTMEDI), which he founded in 2004. This includes founding the World Integrated Medicine Forum (www.WIMForum.org).

Close
   
Ronko Itamura
Profile
×
Ronko Itamura
M.D., Ph.D. MFHom
Senior Director and Dean of the Japanese Physicians Society for Homeopathy (JPSH).
National Vice-President for Japan of the Liga Medicorum Homoeopathica Internationalis (LMHI).
Executive Director of The Society for Integrative Medicine Japan (IMJ).
Senior Research Fellow of Institute for Future Engineering.
She graduated from Kansai Medical University with a medical doctor degree and finished her doctorate in Kyoto University with a Ph.D. Worked at the Department of Microbiology in Mount Sinai School of Medicine (U.S.A.) as a post-doctor (1992 –1994). She has been a Registered Dermatologist since 1995 and Board Certified member of Japanese Psychosomatic Medicine in 2004. She got the MFHom of the Faculty of Homeopathy (UK) as a first Japanese doctor in 2003. She completed the Koiné Three-Year International Postgraduate Course(2004-2007). Fellowship in Integrative Medicine of Arizona Center for Integrative Medicine (AzCIM) ( 2012-2014). She organizes and teaches the training course of JPSH accredited by the Faculty of Homeopathy from 2001. The JPSH is distinctive and significant for the only society that consists exclusively of professional medical practitioners who hold a state qualification in japan.

Her good papers are “Effect of homeopathic treatment of sixty Japanese patients with chronic skin disease. ”Complement Ther Med (2007) and “Intergenerational transmission for Carcinosinum” AmJHomMed (2012).

She translated ”Prisma”, “Homeopathic practice” and “Homeopathy in Primary care”, and co-translated “International Dictionary of Homeopathy” ,‘‘Homeopathy for Women‘ and “Be fruitful : The Essential Guide to Maximizing fertility and Giving Birth to a Healthy Child”.

Close
   
Shri Roshan Jaggi
Profile
×
Shri Roshan Jaggi
Joint Secretary
NI-III, RD-III, General Administration, Parliament,
Coordination, Planning and Evaluation, Establishment - I, Establishment - II,
Receipt & Issue, RTI, NAM, Budget, Cash, Legal, NMPB
Shri Roshan Jaggi, is an officer from Indian Forest Service (Jammu & Kashmir cadre: 1988 batch) and is presently working as Joint Secretary to the Government of India, Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy (AYUSH) for last more than one and a half year. He served in the cadre state at different senior positions in Government departments, PSUs including the Pollution Control Board and Forest Development Corporation and State-Wildlife Department and thus carry a varied experience of administration and public life spanning over more than thirty years.

He has remained associated with the Medicinal Plant Sector as well & contributed substantially for lively hood avenue generation for Nomadic tribals through the development of Medicinal Plant sector in the State of Jammu & Kashmir. He has the experience of working in Eco-Tourism sector of Jammu & Kashmir. In the Ministry, he has been, apart from other assignments, has been dealing with flagship scheme of National AYUSH Mission - which aims at development and growth of AYUSH sector in partnership with States & Union Territories.

Close
   
Dr. S. Venkatesh
Profile
×
Dr. S. Venkatesh
Director General of Health Services, Government of India
Dr Srinivasaraghavan Venkatesh, Director General of Health Services, Government of India is also an ex-officio Member of the Board of Governors of the Medical Council of India. A distinguished alumnus of JIPMER, Puducherry and the Harvard School of Public Health, Dr Venkatesh also holds Diplomate of the National Board.

In his public health career spanning over three and half decades, he has held several key positions in the Ministry of Health & Family Welfare, Government of India. Dr Venkatesh led Strategic Information and Targeted Intervention programmes at the National AIDS Control Organization. He was Director of the National Centre for Disease Control and Project Director of the Integrated Disease Surveillance Programme. He started MPH (Field Epidemiology) course and strengthened Epidemic Intelligence Service programme at NCDC.

He planned and conducted the Integrated Biological & Behavioural Surveillance in 2014. He spearheaded the development and launch of the National Action Plan to combat Antimicrobial Resistance in 2017. He led the curriculum development & training for Population Based Screening for selected Non-Communicable Diseases in 2017. He contributed to launch of the National Programme for Prevention & Control of Viral Hepatitis in July, 2018. He has been a strong proponent of the Programme-Academia interface for strengthening health systems.

Close
   
Dr. S. P. Shani
Profile
×
Dr. S. P. Shani
Deputy Drugs Controller (India), CDSCO(HQ), FDA Bhawan
Dr. S. P. Shani Deputy Drugs Controller (India) having obtained the Doctorate in 2016 in Pharmaceutical Sciences, M.Pharmacy in 1990. He joined the CDSCO in the year 1994 and was the in charge of Biological division and conducted many GMP, GCP and GLP inspections of various Biological Units with or without International regulators.

He has been played a key role in qualifying the WHO NRA Assessment for CDSCO in 2012. He has also worked as ADC Port Office, Delhi for scrutinising the various consignments of Pharmaceuticals and Cosmetics for import and export. He also worked as Deputy Drugs Controller (India) at CDSCO East Zone, Kolkata where in coordination with various State Licensing Authorities for enforcing the Drugs & Cosmetics Act, 1940 and Rules made thereunder.

He has also conducted WHO-GMP inspections for Pharmaceuticals and Ayurvedic drugs. He has participated in various national & international trainings & workshops of Pharmaceutical Sciences. He is the Member secretary of Screening Committee for launching the prosecution against firms and member secretary of Drugs and Magic Remedies (Objectionable Advertisements) Act Sub Committee and Coordinator with the BIS for clarifications & Suggestions in respect of Cosmetics. Presently, he is also the member/representative from CDSCO in various committees related to ASU&H Drugs likes Sub-committee of DTAB on Homoeopathy, Empowered committee for control of misleading advertisements of AYUSH Drugs, Committee for Procurement of ASU Medicines by State Govt./Hospitals/Dispensaries/CGHS Store- formulation of guidelines, Expert committee for the purpose of developing a Standard template for the labelling of licensed ASU Medicines and for amendment in license form

Close
   
Dr. Srinivas Rao Chinta
Profile
×
Dr. Srinivas Rao Chinta
M.D(Hom) Repertory
Assistant Adviser(H), Ministry of AYUSH, Government of India
Member Secretary-Sub Committee of DTAB on Homoeopathy.
Working in the Ministry of AYUSH as Assistant Adviser(Homoeopathy) since 2007.

Dealing with matters connected with the education and practice of Homoeopathy including the drug related issues of Homoeopathy under the Drugs and Cosmetics Act, 1940 and Rules made thereunder.

Dealing with policy issues and drafting/amendment of key legislations of Ministry of AYUSH.

Member-Secretary to the Sub-Committee of Drug Technical Advisory Board on Homoeopathy constituted under the Drugs and Cosmetics Act, 1940 to address the issues relating to Homoeopathy Drugs.

Close
   
Prof. Dr. Shriram Sheshgir Savrikar
Profile
×
Prof. Dr. Shriram Sheshgir Savrikar
Chairman, Scientific Body, Pharmacopeia Commission of Indian Medicine and Homeopathy (PCIM &H), Govt of India (New Delhi)
Prof. Savrikar is Chairman of Scientific body, Pharmacopeia commission of Indian medicine and Homoeopathy (PCIM & H). He also Advisor, to Hon’ble Shri Shripadji Naik, Minister of AYUSH, Govt of India, New Delhi and Adivsor to Hon’ble Shri Girish Mahajan, Minister of Medical Education, Maharashtra

Prof. Savrikar is former Professor, R. A. Podar Medical College (Ayu), Mumbai and has total teaching experience of 40 yrs. He is expert and member of Governing Body, Central Council of Research in Ayurvedic Sciences (CCRAS), Court, Banaras Hindu University, Varanashi, Management Council, Maharashtra University of Health Sciences, Nashik, Maharashtra and Scientific Advisory Committee, IPGT&RA, Gujarat Ayurved Univeristy, Jamnagar

Prof Savrikar has experience as Vice Chancellor, Gujarat Ayurved University, Jamnagar, Gujarat, Committee, IPGT&RA, Gujarat Ayurved Univeristy, Jamnagar. He is recipient of various awrds and recognitions like Waradekar award for Social work and Research in Medicine, Sunderalal Joshi award for outstanding performance in administration in field of Ayurved, Recipient of Excellence in Ayurveda National Award 2013 by MedScape India, Recipient of ' Vd. D. V. Shende Rasaushadhi award-1997’, Honoured with ' Pranacharya ' degree by Shri Indraprasthiya Vaidya Sabha' Delhi , ‘Ayurved Martand’ by All India Ayurvedic Specialist (P.G.) Association, New Delhi, ‘Sanman patra’ by Ayurved Vyaspeeth, Maharashtra at Ahemadnagar, Maharashtra, Late Hirendranath Duttt Gupta Memorial Oration – 2007 by East India Pharmaceutical Works Ltd. Kolakata, India. He is nominee for IASTAM Naginadas Shah Award 2019 by Indian Association of Traditional Asian Medicine, India.

Close
   
Sandra F. Chico
Profile
×
Sandra F. Chico
ANMAT
Professional, Inspector senior in National Administration of Food, Drugs and Medical Technology (ANMAT),
Coordinator of the commission of legislation update for herbal medicines.
Sandra F. Chico is a Pharmacist, Specialist in Clinical Pharmacy and Sterilization, a professional in ANMAT (National Administration of Food, Drugs and Medical Technology). She was born in San Miguel de Tucuman in the north of Argentina. From 1996 to 2005, she worked at the Eva Peron Hospital (ex resident), as pharmacy's clinical at the Rivadavia Hospital, as Head of Sterilization of Ushuaia Hospital.

She works in INAME (National Institute of Drugs) as senior Inspector of medicines for operating authorizations (qualification), structure modification, good manufacturing practices and control in the area of medicines, herbal medicines and active pharmaceutical ingredients of plant origin since 2006. It is also:

She is coordinator of planning and strategies for herbal medicines. She is coordinator and member of the commission for updating legislation on herbal medicines (ex-phytotherapics).

She is coordinator of the Herbal Medicines Subcommittee (ex Fitoterapia) of Farmacopea Argentina (FA). She is a member of the Thematic Technical Committee on Plant Drugs (CTT Vegetal Drugs) in the MERCOSUR Pharmacopoeia Cooperation Project.

She is a Focal Point of ANMAT / Argentina for "International Regulatory Cooperation for Herbal Medicines (IRCH)", WHO (WORLD HEALTH ORGANIZATION) from 2013 to date. She is member of the Working Group of the Ibero-American Form of the EAMI Network (Meeting of Competent Authorities in Medicines of Ibero-American Countries).

Close
   
Prof. Shailendra K Saxena
Profile
×
Prof. Shailendra K Saxena
PhD, FRSC (London), FRSB (UK), FAcadTM (Austria), MASM (USA), MASV (USA)
Vice Dean & Professor, Centre for Advance Research, King George's Medical University (KGMU), Lucknow, India.
Dr. Shailendra K. Saxena is Vice Dean and Professor at King George's Medical University, Lucknow, India. He distinguished himself in biomedical profession and has gained worldwide recognition for his immense contributions in eradication of various infectious diseases with an excellent track record working overseas including USA, United Nations and World Health Organization (WHO) for several years. His research interests are to understand the molecular mechanisms of host defense during human viral infections and to develop new predictive, preventive, and therapeutic strategies for them using JEV, HIV and emerging viruses as a model, via stem cell and cell culture technologies. He has authored several Books and Book Chapters, which are taught in several countries worldwide, and published several prestigious papers in quality peer-reviewed international journals with high impact factor (Science, PNAS, Nature Medicine) with high citation. His work has been highly cited by numerous investigators globally in various peer-reviewed journals and prestigious books of Microbiology/Virology and monographs. He has been invited to present his research work in various conferences abroad. He has received many awards and honors in India and abroad including various Young Scientist Awards; BBSRC India Partnering Award, UK; Fogarty International Center, National Institutes of Health, USA, funded HIV/AIDS prevention research MERIT Fellowship; Dr. JC Bose National Award of Department of Biotechnology, Min. of Science and Technology, Govt. of India; KGMU-Academic Excellence Award, Springer Nature Award 2018 and Fellow of various national and international prestigious societies/academies including The Royal Society of Chemistry London (FRSC), The Royal Society of Biology UK (FRSB), Academy of Translational Medicine Professionals, Austria, The Academy of Environmental Biology, India (FAEB), Indian Virological Society (FIVS), The Biotech Research Society, India (FBRS), Elected Full Member of Sigma Xi, The Scientific Research Society (USA), and is named as the “Global Leader in Science” by The Scientist magazine (USA) and “International Opinion Leader/Expert involved in the vaccination for JE” by IPIC (UK).

Close
   
Shivang Swaminarayan
Profile
×
Prof. Shailendra K Saxena
Dr. Shivang Swaminarayan is member of Central Council for Research in Homoeopathy, Govt of India. He is on editorial board of': 4 dvancement in Homeopathic Research"& "Journal of Case Studies in Homoeopathy" as well National Secretary of Pharmacist Wing, of Homoeopathic Medical Association of India. Dr. Swaminarayan is cofounder of "Homoeopathy Knowledge Centre" and founder of "Friends 4 Homoeopathy". He was Chairman of Committee for Homoeopathy at IDMA (GSB) & was member of various Task Force of AYUSH & Government of India. He was Scientific Committee Member & Co-ordinator of Allied Life Sciences of 661 World Homoeopathy Congress LIGA 2011.

Dr. Swaminarayan, a trained Homoeopathic Physician, headed healthcare division of Healwell International Ltd (SINTEX group of Companies) for 17 years with experience of market entry, business development,regulatory & policy interventions, research etc. He pursued MBA apart from PG studies in Health & Family Welfare Management from National Institute of Health & Family Welfare (NIHFW) & PG studies in ONE HEALTH.

He brings with him rich & diverse professional, clinical & research experience of two & half decades. Dr Swaminarayan is among very few & the first Indian homoeopath to initiate large scale scientific research in Veterinary homoeopathy, an unexplored and unattended area till date. His other research interests are in the field of Mother and Child health,School Health,Public Health,m health, capacity building for rural healthcare, application of homoeopathy in organic farming, & health economics.

He hails from family of Doctors & married to Sangita,a vivid Architect & Interior Designer who has International projects to her credit.

Close
   
Dr. Sukhbir Kaur
Profile
×
Dr. Sukhbir Kaur
MSc PhD
Professor, Department of Zoology, Panjab University Chandigarh
Born on 14th May, 1961, she did her doctorate from the prestigious Post Graduate Institute of Medical Education and Research, Chandigarh in 1991. After working as a CSIR-Research Associate and Senior Research Officer in the Indo-US project at PGIMER, she joined the present Department as a Reader in 1998 and became Professor in 2006. Her field of specialization is Parasite Immunology and Therapeutics with special emphasis on visceral leishmaniasis.

She has mentored more than 60 post-graduate, doctoral (PhD) and post-doctoral students. She is also a fellow of the prestigious Indian Society for Parasitology and Zoological Society of India. She has held many administrative positions such as Coordinator of the Central Animal house and NSS and was Chairperson of the Department from 2015-2018. She is the Coordinator of the UGC Centre for Advanced Studies (2015-2020) with a grant of ~180 lacs.

Presently she is the President of the Indian Society for Parasitology. Dr. Kaur has received number of extramural grants from ICMR, UGC, DST-SERB-EMR. She is on the panel of many National and State Bodies and Organisations as an Expert Member.

She has published 70-75 research papers in journals of international repute. Currently she is handling 3 national projects and working into the molecular mechanisms of plants products and their active components.

Based on her experience in the field of Therapeutics and Vaccinology she was sanctioned a project from CCRH and presently is working in collaboration with them for generating experimental data on the efficacy of homeopathic drugs against life threatening parasitic diseases.

Close
   
Dr. Surjit Singh Makker
Profile
×
Dr. Surjit Singh Makker
BVSc & AH, MSc (IT), MCA, M.F.Hom. (Member Faculty of Homeopathy Malaysia)
DTS (Direct Trainer Skills)
Joint Director, Animal Husbandry Department, Govt. of Punjab, India. ,
Veterinary Homoeopath in Small, Large, Birds and Zoo Animals
Developed Veterinary Hospital Management Software’s and various types of Veterinary Diagnostic Software’s.

Giving Free On-line Treatment to all type of Animals in Universe, Since the year 2000 through website www.vethomopath.com.

Developed one Mobile App. on Veterinary Homoeopathy.

Read more than 26 papers in various National and International Conferences in India and Abroad (Malaysia, Singapore, Riga Latvia, Paris and Brazil, Germany) on Veterinary Homoeopathy.

Life Member of Liga Medicorum Homoeopathica Internationalis (LMHI) - The international homeopathic medical society Liga Medicorum Homoeopathica Internationalis (LMHI),

Member Faculty of KVASU, MANNUTHY, Kerala for the preparation of Course materials for Post Graduate Certificate Course in Veterinary Homeopathy in KVASU for the topic “ Introduction to Clinical Repertory in Veterinary Practice.”

Conferred India`s most coveted “Rashtriya Gaurav Award” and CERTIFICATE OF EXCELLENCE by India International Friendship Society New Delhi on March 26th, 2018 for outstanding Achievements in Veterinary Homoeopathy.

Close
   
Dr. Theodoros LILAS
Profile
×
Dr. Theodoros LILAS
Phd.
Assistant Professor at University of the Aegean
Dr. Theodore Lilas is Assistant Professor at Aegean University in the field of Computer Science. He is an Electrical and Computer Engineer from National Technical University of Athens. He holds MSc in Computer Science from Columbia University, New York, where he received graduate research assistantship from Center for Telecommunications Research for Student Electronic Notebook, a predecessor of tablets from IBM. His PhD thesis at NTUA was supported with research assistantship from General Secretary for Research and Technology in the field of artificial intelligence enhancing robotics with computer vision. Has participated in several National and European research projects including expert systems, telemedicine and robotics rehabilitation projects.

Has also worked as consultant in industry and participated in intelligent automation projects. Since 2005 is teaching Computer Science and Telematics at Aegean University and in 2012 has been elected Assistant Professor in the same University. Research focuses on intelligent autonomous systems. Since 2011 he is coordinating R&D for VithoulkasCompass decision support system algorithms and research in data mining clinical cases.

Close
   
Dr. Thomas Breitkreuz
Profile
×
Dr. Thomas Breitkreuz
Dr. med.
Internal Medicine, Anthroposophic Medicine, Intensive Care, Palliative Care
Medical Director, Die Filderklinik, Stuttgart, Germany
Chairman of Commission C, BfArM, Bonn, Germany
President of IVAA (International Federation of Anthroposophic Medial Associations) Speaker of the Board, Hufelandgesellschaft, Berlin, Germany
Dr. Thomas Breitkreuz is Medical Director of the Filderklinik, an anthroposophic Hospital for Integrative Medicine in Stuttgart, Germany. He is a specialist in Internal Medicine and Palliative Care, combining in his clinical practice conventional western and anthroposophic medicine. He is Chairman of Commission C (Anthroposophic Medicine) at the BfArM, the Federal Institute for Drugs and Medical Devices, Germany (www.bfarm.de). He is the President of IVAA, the umbrella organisation of all anthroposophic medical associations across the world (www.ivaa.info). He is the speaker and board member of Hufelandgesellschaft, the national German umbrella organization of the medical associations representing the different traditions in the field of Integrative Medicine.

His international activities include research in integrative oncology and antimicrobial resistance, organization of international conferences and workshops in the field of Integrative Medicine and collaboration on the expert level with TCIM stakeholders, ministries and public health services in the area of integrative medicine within the hospital sector.

Close
   
Dr. Todd A. Hoover
Profile
×
Dr. Todd A. Hoover
MD, Dht
Consultant/ Trustee, Homeopathic Pharmacopeia Convention of the United States
Todd A. Hoover, MD, DHt is a Trustee on the Board of the Homeopathic Pharmacopeia of the United States and the past Delegate from the U.S. to the Liga Medicorum Homeopathica Internationalis and past president of the American Institute of Homeopathy. He is Board Certified in Family Medicine and Homeopathic Medicine. He has been widely published and has lectured extensively, both in the U.S. and in international conferences over the past 30 years.

For the past ten years, Dr. Hoover led the development of the HPCUS Proving Guidelines and the recently published Clinical Data Guidelines. He has focused his work with the HPCUS on compliance strategies for pharmacopeia evaluation of new homeopathic drugs. And his recent work in researching the validity of provings will be of considerable value in helping to confirm the foundations of our homeopathic medicine.

In addition to his homeopathic experience, Dr. Hoover has pursued yoga training in a university here in India for the past six years and graduated with his BA in yoga last week. He hopes to carry on the work of improving health through both of these profound healing tools in the years to come.

Please welcome Dr. Todd Hoover for this round table discussion on Market approval for New Homeopathic Medicines.

Close
   
Dr. Vadim Merkulov
Profile
×
Dr. Vadim Merkulov
Doctor of medical sciences, professor, specialty – molecular biology,
Deputy Director General for expert evaluation of medicinal products of Federal State Budgetary Institution
“Scientific Centre for Expert Evaluation of Medicinal Products”
Dr. Vadim was born in Briansk in the year 1970. He completed his graduation from State Medical Institute of Smolensk in 1994. After graduation passed military service in scientific positions in the Armed Forces of the Russian Federation.

He was holding position of First Deputy Director General of the Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of Russia from 2010-2015. Further he was Deputy Director General of the Federal State Budgetary Institution “NS EEMP” of the Ministry of Health of Russia for the Expertise of Medicines in 2015.

From 2008 to 2016 he was having the post of professor of chair medical nanobiotechnology Russian National Research Medical University. N.I. Pirogov. Currently he is working at the post of professor of Pharmacology, Institute of Pharmacy FGAOU First MGMU now named Sechenov.

Dr. Vadim's scientific interests are in development and examination of drugs and biomedical cell products; molecular biology; molecular diagnosis of viral infections; development of antiviral and anticancer drugs. He is author of more than 150 scientific papers and is having 9 patents to his credit.

Close
© WHD 2018. All Rights Reserved.
CENTRAL COUNCIL FOR RESEARCH IN HOMEOPATHY
61-65, Institutional Area, Opp. 'D' Block, Janak Puri,
New Delhi – 110058, INDIA
Managed by - Connextions Orbis
[*/quote*]

[Rhokia]

Ein Newsletter des ECH vom 7. Jänner  2017:

https://www.assh-asso.fr/images/ECH_Newsletter_n7_January_2017.pdf

Hier haben wir endlich etwas Kontretes:
[*quote*]
ECH INTERNAL NEWS  n   January 2017  n   Pictures: Archives and Franz Johann Morgenbesser, Vienna  n   Editor: Edit Katona  n 
Editorial Support: Chris Connolly n   ECH Administrative Office: Noorwegenstraat 499940 Evergem (Ghent)  n Phone +32 9 218 85 85  n 
Fax: +32 9 344 40 10  n   Email: info@homeopathyeurope.org  n   Internet: www.homeopathyeurope.org
[*/quote*]


Was die Leute betrifft: "Bagot, M. Frass, S. Kruse, P. Lechleitner, E. Pichler, E. Rossi, J. Wurster" Ist das European Committee for Homeopathy (ECH) so etwas wie der AfD der Medizin?


https://www.assh-asso.fr/images/ECH_Newsletter_n7_January_2017.pdf

[*quote*]
1
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
INTERNAL NEWS
NO. 7
n 
European Committee for Homeopathy
JANUARY 2017
THE TOPICS
n     OUR VERY BEST WISHES FOR 2017
n     INTERVIEW WITH HELENE RENOUX, NEW PRESIDENT OF ECH
n     FIRST EUROPEAN CONGRESS FOR HOMEOPATHY: A HUGE SUCCESS
n     JAUME COSTA, ECH GENERAL SECRETARY – INTRODUCTION
n     MESSAGE OF MR. ALOJZ PETERLE (MEP) TO THE ECH CONGRESS
n     PANEL DISCUSSION PHARMACY IN VIENNA
n     ONCOLOGY PANEL DISCUSSION ON ECH CONGRESS 2016
n     INTERVIEW WITH DORA PACHOVA, NEW COORDINATOR OF EDUCATION SUBCOMMITTEE IN ECH
n     CRISTAL SUMNER, THE NEW COORDINATOR OF THE PATIENT/USER SUBCOMMITTEE
n     WORKING TOGETHER FOR HOMEOPATHY
n     ECHOING: NEWLY FORMED COMMUNICATION WORKING GROUP IN ECH
n     MANAGEMENT OF THE ECH WEBSITE AND SOCIAL MEDIA ACCOUNTS – INTERVIEW WITH CHRIS CONNOLLY
n     FOR YOUR DIARY
OUR VERY BEST WISHES FOR 2017
By Hélène Renoux, ECH president
The start of this year, which coincides with the beginning of a
new mandate for a new council is a fitting moment to wish you,
and all of us, a fantastic 2017.
rent economic restrictions and ecological evolutions. This certain-
ly explains why the sceptics are more aggressive than ever. It is
vital that we use our energy, not only against our opponents, but
mostly to emphasise the value of homeopathy to the wider public
and the reliable alternative it offers.
Thomas Peinbauer’s presidency reached its conclusion at the end
of 2016 with a very successful congress in Vienna – he left us a
rich legacy and an array of promising ongoing projects. This renewed presentation of our biannual newsletter will reflect
the drive with which we want to approach our common work and
projects: both looking to the future and addressing the outside
world, while focusing on our common interest and passion for
Homeopathy.
Medical Homeopathy faces a unique opportunity in today’s cli-
mate, with changes in people’s mentalities compounded by cur- Let’s make 2017, and all the years thereafter, the years of Ho-
meopathy.2
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
INTERVIEW WITH HÉLÈNE RENOUX process, I would just remind the person that solutions are already
available around us, in nature and that we shouldn’t despise it.
By Tomasz Kokoszczynski If you were a magician, what would you change in the world
to make homeopathy more appreciated?
We are on the way to be more and more appreciated, the public is
in need of the relation to the environment Homeopathy proposes.
The governments will follow, they usually follow the evolutions,
and rarely precede it. If I was a magician I would make our decision
makers wiser...
You are living in Paris,
aren’t you? Do you feel
that the city has any
deeper influence on you?
This is a good way to intro-
duce myself isn’t it? Like all
of us many influences are un-
derneath, I come from Brit-
tany, the seashore, where I
completed my medical stud-
ies in Nantes. I then moved
to Paris to study Tropical Diseases and Public Health before using
this knowledge with Afghan refugees in Pakistan in 1988. After-
ward I came back to Paris for personal reasons and to study Ho-
meopathy. It was certainly my own path to access this awareness
of how I could be helpful for my fellow human beings, and how I
could give some meaning to my life.
What is your goal of life?
As medical doctors we are very lucky because we don’t have to
wonder if our work is helpful, people tell us it is every day. I think
my main goal is to find some serenity, it comes through personal
expression, discovering the others around me, being surrounded by
some love and enjoying the beauty of my environment. It sounds
so simple when it is not at all.
What was your personal way to homeopathy? Any inspira-
tion to choose this field?
When finishing my medical studies I felt we were on the wrong way
to address people and their sickness, as if we were trying to force
opening doors instead of looking for the key. Homeopathy is a key.
How could you describe the main idea of homeopathy if
you would have to explain it to a layperson?
After explaining the principle of similarity and the potentization
Could you tell what you do to relax? Do you have any hob-
by?
I like writing, in French, I like the French language and poetry, it
certainly influences a lot my thoughts.
Is there something more you would like to tell about your-
self our readers?
Don’t forget that The European Committee for Homeopathy is a
great achievement, both strong and fragile, we owe it to our prede-
cessors I would like to thank, Jacques Imberecht who is the inven-
tor, the father of all this, Ton Nicolai who gave ten years of his life
to ECH, Thomas Peinbauer I had the pleasure to work with for four
year as General Secretary, and Patricia Le Roux who was bound to
be before her dramatic accident. We also owe it to our successors,
they will need more and more such associations to express their
ideas and needs. We are torchbearers.
Well what do you intend to do now inside ECH?
Actually even if I am French I don’t plan the revolution! I would like
to continue the successful projects ECH has initiated, make them
go further and deeper for the sake of Homeopathy: enhancing the
recognition of our practice as the European Standardisation process
CEN has started to do, supporting the cases collections projects
which are of great help to assess the efficiency and relevance of
Homeopathy, and remaining watchful about homeopathic medici-
nal products availability. I would be proud to have laid my stone to
the common edifice.
Thank you for the interview.
FIRST EUROPEAN CONGRESS FOR
HOMEOPATHY A HUGE SUCCESS
Around 500 people from 50 countries, including medical doctors,
veterinarians, pharmacists, researchers, patients and policymakers
attended the first European Congress for Homeopathy in Vienna
from 17-19 November 2016.
The Congress highlighted the dramatic progress in basic and clinical
homeopathic research and the important contribution of homeopa-
thy to the health care systems of numerous countries. Important
challenges such as availability of homeopathic remedies and restric-
tive changes in legislation were also identified.
The main topics presented and discussed were anti-microbial resis-
tance, oncological treatments, Attention Deficit Hyperactive Disor-
der (ADHD) and homeopathy as nanomedicine.
The Congress was jointly organised by the European Committee
for Homeopathy (ECH), the European Federation of Homeopathic
Patients’ Associations (EFHPA) and the International Association for
Veterinary Homeopathy (IAVH).
The audience of the Opening ceremony of the congress in Vienna.
ECH members can login in the ECH website to gain access to
the abstracts of the Congress.
Dr Jaume Costa, ECH General Secretary3
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
JAUME COSTA, ECH GENERAL
SECRETARY – INTRODUCTION
By Tomasz Kokoszczynszki
What is actually your nationality?
Where do you live now? I have heard
you are active on homeopathy in Ire-
land, is that true?
I was born in Barcelona, so I am Catalan,
and my nationality is Spanish. I live in Trim,
County Meath, in the Republic of Ireland.
Other medical homeopaths, practising in
the Republic of Ireland and registered with the Faculty of Home-
opathy, and myself have set up a group that meets around four
times a year to discuss cases, materia medica and homeopathic
methodologies. I consider very important continuous professional
development and peer support. A group is ideal for both.
You are practicing homeopathy only, or working as a regu-
lar doctor? What is your specialty?
I studied medicine in Barcelona and public health at the University
of Texas. Most of my career has been in public health as European
Union official. At present, I am registered with Barcelona Medi-
cal Council and I am in the Board of Barcelona Medical Council
Homeopathic Doctors’ Section. Once a month I go to Barcelona
and I see patients, attend the meetings of my study group and the
Academia Medico Homeopatica de Barcelona and visit my mother.
I have also my homeopathic practice in Trim, Ireland.
Royal London Hospital for Integrated Medicine, whose Director of
Education was and is Sara Eames. There I was also very fortunate to
have inspiring teachers such as Brian Kaplan and Russell Malcolm.
Homeopathy is a win-win situation for both patient and physi-
cian. Patients, many times, can have the opportunity to recover
full health or to become a healthy patient, this is to accept disease
and its constraints in a positive way. Doctors using homeopathy
can achieve much greater job satisfaction from seeing their patients
become empowered and back to health.
Tell us about your hobbies? What do you do in your free
time? Do you have any free time at all?
I enjoy hill walking and swimming very much. I practise yoga and
meditation either in a group or in my own. I also like reading a
good novel. Last but not least, I try to be available as much as pos-
sible for my two sons.
You have very positive attitude toward life. There is a lot of
positive energy talking to you. This is your nature, or you
have done in your life something to be more positive?
Life is a great teacher and so is homeopathy. Homeopathy teaches
us to be humble, grateful and accepting. Humble because we never
know enough. Grateful because homeopathy brings small miracles.
Accepting because homeopathy helps us understand that most
people do their best. Dr Malcolm told me once that the best qual-
ity in a homeopath is persistence. I completely agree with him not
only in relation to homeopathy but also regarding life in general.
On another note, Dr Servais said to the students in Paris that ho-
meopathy helps people accept life as it comes. I feel this is a recipe
for contentment and happiness.
What was your way to homeopathy? What and who in-
spired you to be a homeopath? Why you are still in it?
I got into homeopathy because a family member was diagnosed
with psoriatic arthritis and had good results with homeopathic
treatment. This prompted me to go to the Institute Homeopathique
Francais in Paris to study – I was living in Luxembourg at the time. I
was very privileged to meet excellent teachers such as Philippe Ser-
vais, Yves Maillé and Dominique Poulin. In Paris I met also Hélène
Renoux, we were both members of the students’ association of the
homeopathic school. Later I had the opportunity to study at the What is your main goal about homeopathy? What do you
want to achieve for homeopathy? What main idea drives
you and how homeopathy helps you to carry it out?
Homeopathy should be part of the European health care systems.
A strong coalition of patients, health professionals, industry, policy-
makers and researchers is paramount to succeed in our endeavour.
We have a great advantage: homeopathy empowers patients and
is really a patient-centred medicine.
MR. ALOJZ PETERLE (MEP)
ADDRESSES THE ECH CONGRESS This address is a strong statement that European citizens “increas-
ingly recognise the benefits of Homeopathy” while Member States
lack coherence in regulating it. He also states that homeopathy has
an innovative place in healthcare with regards to cost efficiency and
health inequalities.
Thank you for the interview.
All the participants of the congress, and the homeopathic commu-
nity as a whole, are hugely grateful for this wise, enlightened and
supportive declaration.
The Slovenian member of the European Parliament, Mr Alojz Pe-
terle, who was the first Prime Minister of his country in 1990, had
initially accepted the invitation from ECH, IAVH and EFHPA to at-
tend the political conference of the European congress in Vienna to
show his support to Homeopathy.
Unfortunately other commitments prevented him from attending
but he submitted an inspired and supportive address (see the video
on ECH website) whose content is transcribed below.
“Honourable speakers, doctors, practitioners,
dear guests, ladies and gentlemen,
Thank you very much for inviting me to the first European Home-
opathy Congress, which aims to increase the recognition of home-
opathy across the European Union and its Member States.
To me homeopathy stands for a holistic, complete, cost-effective
and safe approach to promote health, prevent and treat disease. In
particular, I am its strong supporter due to its patient-centeredness.
We are obviously facing a growing number of health related chal-
lenges: an aging population, rising levels of diseases such as cancer,
diabetes and heart disease, mental ill-health and antimicrobial re-4
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
sistance. The situation begs the question as to whether there are
better ways to approach healthcare for humans and animals alike.
You have gathered here, because you know that the answer is posi-
tive. Yet you are not alone: European citizens increasingly recognise
the benefits of a homeopathy and its inherent holistic approach
to care. expect that the on-going legislative procedure for Veterinary Me-
dicinal Products will integrate the spirit of the WHO traditional
medicine strategy and respect homeopathic specific nature as well.
My firm belief is that homeopathy can play an innovative role in
the context of the enormous personal, social and economic cost of
chronic disease and health inequalities.
Therefore, I regret, that there is still little coherence in the way
Member States regulate medical doctors and other health profes-
sionals practicing homeopathy in the EU. Furthermore, member
states’ variable implementation of EU directives for homeopathic
medicinal products is negatively affecting access by citizens and
providers. For these reasons and given its widespread demand among Euro-
pean citizens, we need to incorporate ways in which homeopathy
can contribute to sustainable healthcare systems in Europe includ-
ing its role in health maintenance, reduction of use of antibiotics,
less invasive and more cost-effective treatment of illness, which
are also some of objectives of the EU Health Strategy 2014-2020.
Finally, evidence for effectiveness and cost-saving and of good prac-
tice can be observed in different Member States, in particular by
the pioneering health service in the Tuscany Region in Italy. The
time is ripe to seriously consider homeopathy as both innovation
and added value for European citizens.
As Co-Chair of the Parliamentary Health Working group, I have
been calling for homeopathy to be taken more determinedly by
the Commission and Member states. Together with my colleagues
from the Parliamentary Interest group on CAM we have been re-
iterating that Commission should take action to resolve the highly
confused and inhibiting regulatory situation that currently exists. I
Thank you for your attention and I wish you a successful session.”
PANEL DISCUSSION PHARMACY
IN VIENNA
On 19 November, during the first ECH congress in Vienna, the ECH
co-ordinator for Pharmacy, Ilse Muchitsch hosted a panel of impor-
tant figures to discuss the future of homeopathic pharmacy.
The invitees were:
•   Agnes M. Dadak, PhD, DVetPharm – Assistant Professor at the
Division of Clinical Pharmacology, Veterinary University Vienna,
Vienna, Austria
•   Jack Hendrickx – pharmacist, Remedy Bank, Homeopathic Start-
ing Materials, Belgium – Labotics Technology & Equipment,
Hoboken, Belgium
•   Dr. Ulrich Herzog – Ministry of Health and Women Head of the
directorate “Consumer Health and Veterinary affairs”
•   Dr. Reinhard Laenger – Head of Dept. for herbal, homeopathic &
veterinary medicinal products – Austrian Medicines and Medical
Devices Agency (AGES MEA), Vienna, Austria
•   Christiaan Mol – pharmacist, is General Secretary of ECHAMP,
member of the Committee on Manufacturing Methods of the
German Homoeopathic Pharmacopoeia.
•   Martin Peithner – pharmacist, General Manager of Dr. Peithner
KG, Vienna, Austria, – Member of PHARMIG, member of the
herbal committee of AESGP, member of the national pharma-
copeia commission and from 2006–2011 he was on the ex-
pert group HOM of the European pharmacopeia commission
(EDQM).
•   Dr. Robbert van Haselen – Director of the International Institute
for Integrated Medicine (INTMEDI) and the World Integrated
Medicine Forum (WIMForum), member of the Homoepathic
Pharmacapoeia Convention of the United States (HPCUS) since
2009.
•   Michel van Wassenhoven, MD – Delegate for UNIO (Belgian
Homeopaths MDs Association) for Research questions; initiator
of DYNHOM research WG, President of the Belgian homeo-
pathic medicine registration commission at the Belgian Medicine
Agency (FAMHP), member of the WG homeopathic use of the
HMPWG (HMA).
Dr Sara Eames, ECH vice-president, chaired the debate.
The purpose of the panel was to address specific issues associated
with the availability of homeopathic medicines and regulatory affairs,
as well as how to guarantee the best quality and the availability of
homeopathic medical products in future with members of Pharmacy,
Industry, Authorities, Politics, Universities and Research.
In summarising the main points addressed during the discussion, the
most prominent themes were:
1.    More dialogue needed
The only dialogue taking place currently is between industry and
regulators; patients, prescribers and individual pharmacists are not
involved. Even the dialogue between industry and regulators is con-
sidered insufficient.
2.    Lack of relevant quality standards
We lack studies assessing the safety and efficacy of the homeopathic
medicinal products (HMPs). We have no standards to assess inno-
vative substances or new manufacturing processes. The available
standards do not comply with individualised homeopathy, and the
definitions of quality for HMPs are based on the pharmaceutical in-
gredients but don’t take into account the succussion process.
3.    How to deal with new remedies, innovative manufacturing
There should be tolerance towards new HMPs in order to give them
the opportunity to demonstrate their effectiveness. For this reason
the harmonisation of Common Technical Documents (CTDs) among5
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
the different European countries is a necessity. The guidelines used
by the Homeopathic Medicinal Products Working Group (HMPWG)
always state “when available” for required controls, which is intended
to leave the door open to new HMPs.
There are two “legs” in preparation of homeopathic remedies, which
have to be considered: the pharmaceutical preparation in pharmacy
and the industrial production. Each of them has presents different
challenges and should be considered in different ways. Both are
necessary and should be seen as complementary to the other! The
importance of “magistral preparation of homeopathic remedies” in
pharmacies was pointed out as a pressing requirement to guarantee
the availability of remedies in Europe.
As for pharmacists, it is a medical scientific fact that evidence
based homeopathic medicine (human as well as veterinarian) starts
with evidence based homeopathic remedies. Evidence based ho-
meopathic remedies derive from evidence based starting materi-
als. This congress forged the essential link between homeopathic
medicine and homeopathic pharmacy, both based on science and
technology as well as tradition. The Congress emphasised where
responsibilities lie when dealing with new remedies, which is a
major step forward.
ONCOLOGY PANEL DISCUSSION
(ECH CONGRESS,
18TH NOVEMBER 2016)
ROLE OF HOMEOPATHY FOR
LIFE QUALITY IN CANCER PATIENTS
J. L. Bagot, M. Frass, S. Kruse, P. Lechleitner, E. Pichler,
E. Rossi, J. Wurster
Treatment of patients living with cancerous diseases is a great chal-
lenge both in conventional and complementary therapies. It poses
a challenge for the medical team, for the patients and for their
relatives. The objective of this panel discussion was to discuss the
most efficient homeopathic solutions, as part of an entire day’s
programme of fascinating oncological lectures. The main focus was
on treating side effects of oncotherapy, together with finding or-
ganotropic and constitutional remedies, which help to improve the
quality of life of patients.
Jean-Lionel BAGOT from Strasbourg is
experienced in homeopathic treatment for
side effects of the new targeted therapies
(TT) in oncology. Side effects produce
largely identical symptoms in all TT: fatigue,
muco-cutaneous problems and diarrhoea,
with the patient experiencing a poor qual-
ity of life. These circumstances can force
the oncologist to reduce or even cease treatment prematurely. Ap-
plying homeopathy – including a homeopathic dilution of TT called
hetero-isotherapy – could be a suitable response for improving the
tolerance of and the adherence to cancer treatment. It involves
taking a daily dose of a C7 dilution of the TT and the patient also
receives a symptomatic remedy as a long term treatment. When
4.    More transparency needed
HMPWG aims to be as transparent as possible, but according to
ECHAMP, more robust processes are required whereby there is a
platform for exchange of expertise. It is also apparent that we are
missing references of the literature on which the FSD (First Safe Dilu-
tion) calculation is based.
The Head of Medical Agencies (HMA) aims for transparency when
dealing with European Pharmacopeia, but in reality when their docu-
ments are published there is no way to know if and how the com-
ments sent have been taken into account.
5.    Lack of interest from the authorities
It is interesting to notice that within the HMA only one committee
is dedicated to the whole sector of Homeopathy. Additionally, this
committee clearly lacks funding and some of its members lack ap-
propriate homeopathic knowledge.
The outcome of the constructive discussion in this official setting
was that close and transparent cooperation is needed between all
stakeholders to keep all homeopathic medicinal products available
for humans and animals in future!
Ilse Muchitsch and Hélène Renoux
it is necessary to prescribe another homeopathic medicine, the
combination with hetero-isotherapy improved its effectiveness. In
treating more than 300 patients with hetero-isotherapy Dr. Bagot
observed a significant decrease in side effects, allergic risk and late
consequences, while no disturbance of the activity of chemothera-
py was observed.
The better tolerance to targeted therapy and an improvement
in quality of life help to increase treatment adherence.
Jean-Lionel Bagot, MD: Saint Vincent Hospital Group,
Integrative Medicine Dept, Ste Anne Clinic, 182 route de la
Wantzenau 67000, Strasbourg, France, jlbagot@orange.fr.
Michael FRASS has a great deal of expe-
rience in using homeopathy for patients
with cancer at Vienna University Clinic. He
pointed out that the use of classical home-
opathy as an add-on treatment in cancer
patients has increased worldwide over the
past decade. Advantages are cost-effective-
ness, ability to be used alongside conven-
tional medicine and the lack of negative effects on metabolism.
Studies suggest that homeopathy is able to increase global health
status and subjective wellbeing as well as improvement of several
functioning parameters – pain, insomnia, dyspnoea, and appetite
loss. Retrospective observation shows a possible positive influence
on survival rate of patients with advanced stages of cancer. There-
fore Dr. Frass strongly recommends implementing classical ho-
meopathy as an add-on to conventional cancer therapy.
Michael Frass, MD: Medical University of Vienna, Department
of Medicine I, Clinical Division of Oncology, 18-20 Waehringer
Guertel 1090 Vienna, Austria; and WissHom (Scientific
Society for Homeopathy), Köthen, Germany, michael.frass@
meduniwien.ac.at6
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017

Sigrid KRUSE, MD works with young pa-
tients together with paediatric oncologists
in university children’s hospital in Munich,
experiencing that paediatric oncology is
very different to oncology in adults. She
emphasised that add-on homeopathy
in paediatric oncology is of great ad-
vantage for parents, medical staff and
above all for the children .
80% of oncologic diseases in children concern acute lymphatic leu-
kaemia (ALL) with a healing rate of greater than 80% using conven-
tional therapy. Dr. Kruse reiterated the opinion of Drs. Bagot and
Frass about the advantages of add-on homeopathy to reduce the
side effects of oncotherapy. There is often an additional benefit
in terms of controlling fears, rage, jealousy and other behavioural
disorders, and support in rejuvenation and avoiding relapse.
Parents seek the best treatment for their child, whether comple-
mentary or conventional medicine. They realise that their child
needs conventional treatment in order to survive but naturally have
concerns due to their harsh side effects. They use a range of sourc-
es to find out more information, particularly the internet, and are
often prepared to give complementary medicine secretly, without
informing medical staff. Parents are encouraged to speak openly
if the oncological team is open to add-on therapy. This offers a
chance to advise parents on the effectiveness and the risks of differ-
ent methods available. It is very important and a useful way to gain
the confidence of all players in the team: parents, the ill child and
staff. More than 2000 studies of various homeopathic treatments
and cured cases of cancer supports this.

Peter LECHLEITNER, from Lienz, reports
on the feasibility of add-on cancer treat-
ment in the setting of a modern oncology
department. As homeopathy faces chal-
lenges in the Evidence Based Medicine
environment, especially when treating can-
cer patients, he suggests performing more
RCTs with clear end-points (relief of symptoms, quality of life, pro-
gression free survival, overall survival). There are several challenges
when it comes to finding the correct homeopathic remedy, one
of which is a lack of homeopathic standard treatment guidelines.
Additionally, there are different remedies for the constitution and
the tumour itself (organotropics), and miasmatic symptoms could
superimpose tumour symptoms. Finally, side effects and blockades
by conventional cancer medication result in a symptom mix with
different layers. Dr. Lechleitner insists that one of the best ways to
overcome these obstacles is to first treat the side effects, then
the tumour, then the constitution.
Homeopathy (provided along with other CAM treatments) could
be a powerful example of bringing conventional and complemen-
tary approaches together in a coordinated way.
Peter Lechleitner, MD: Department of Internal Medicine,
Teaching Hospital of Lienz, 5 E.v. Hiblerstraße 9900 Lienz,
Austria, p.lechleitner@kh-lienz.at

Erfried PICHLER has been treating children
suffering from cancer at the paediatric hos-
pital in Klagenfurt for nearly two decades. In
his private clinic he also treats adult cancer
patients. The difference in treatment of in
and out-patients is the ability to react quick-
ly, when necessary, to physical and psycho-
logical side effects during oncotherapy.
Outpatients use CAM more frequently after conventional
therapy. The aim is to stabilise and balance the immune system,
and to improve mental condition – homeopathy works very well
in this situation. The first step to help cancer patients is to find
the appropriate remedy, the constitutional remedy. Dr Pichler often
finds that constitutional remedies reduce side effects caused by
chemotherapy. In case of adverse effects the proper acute remedy
is needed. A complete cure from cancer is possible but these are
exceptional cases. For supplementary therapy he prefers mistletoe
injections for adults but not for children.
Erfried Pichler, MD: general practitioner, homeopath and
chiropractor in private practice in Klagenfurt, Austria; Head
of the homeopathic clinic of paediatric oncology at Klinikum
Klagenfurt; President of the Austrian Homeopathic Society,
erfried.pichler@tmo.at

Elio ROSSI has the opportunity to treat pa-
tients suffering from cancer and side effects
of oncotherapy at an Integrative Oncology
Outpatient Clinic in the public hospital of
Lucca. A Complementary Medicine (CM)
expert and an oncologist provide nutri-
tional advice, qualified information and
evidence-based indications about CM and
their potential interactions with anti-cancer drugs.
Prescription of complementary treatment is based on a sufficient
level of evidence. Nearly 270 patients were visited consecutively
between 2013 and 2016, mainly referred by their medical oncolo-
gists. Typical cancer localisation was breast cancer (58%), and a
third of patients had metastasis. Nearly all the patients had used or
were using chemotherapy and/or radio and/or hormonal therapy.
Homeopathy is the main prescribed therapy, exclusively (53%) or
integrated with other CTs, mainly botanicals and acupuncture. The
Banerji protocol was applied in 15% of patients. Symptoms most fre-
quently treated were adverse effects of anti-cancer therapies (55%),
besides the symptoms caused by the disease and the concomitant
symptoms. Following the treatment Dr. Rossi observed significant
improvement in nausea, insomnia, depression, anxiety, asthe-
nia and hot flashes, proving that a clinic of integrative oncol-
ogy is an opportunity to reduce adverse effects of anti-cancer
therapy and enhance the quality of life of cancer patients.
The homeopathic therapy seems to be less effective than an inte-
grated one, but not statistically significant.
Elio Rossi, MD: Homeopathic Clinic, Campo di Marte Hospital,
Local Health Tuscany, North West Lucca, Italy.7
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017

Jens WURSTER represented the well-
known St. Croce Clinic. In his experience
side effects have to be dealt with first, since
most cancer patients have already been in
conservative therapy. Therefore all levels of
past and ongoing cancer treatment have to
be considered (radiation, chemotherapy).
Besides the local manifestations of tumours
and specific experience of pain, the emotional disposition of the
patient is an important indicator to find an effective remedy. With
the help of Q-potencies and the use of organotropic remedies the
patient can be stabilised. Impressive results with observation pe-
riods of partly more than 10-15 years in different cases of cancer
were presented.
Those who have experienced the power of homeopathy in can-
cer treatment will never want to do without it again.

INTERVIEW OF DORA PACHOVA,
THE NEW COORDINATOR OF THE
EDUCATION SUBCOMMITTEE
OF THE ECH
During the last ECH Council Meeting in
Vienna, our colleague Dora Patchova, was
unanimously elected to take over as coordi-
nator of the Education Subcommittee, re-
placing Leopold Drexler. I, Athos Othonos,
an Education Subcommittee member, had
the pleasure to interview Dora.
Athos: Dear Dora, as you well know,
when it comes to Homeopathy, we always focus on the per-
sonality of the individual as being the most important fac-
tor of all. Therefore, before discussing about your plans as
the new coordinator of the Education Subcommittee, could
you please tell us a few things about yourself?
Dora: I have been a medical doctor since 1987 and a homeopath
since 1993. I have 2 grown up children. My husband and whole
family are very supporting. I’m a passionate traveller and I’m very
grateful that I have been given the chance to explore the world and
to share my homeopathic knowledge. I believe nature is our teacher
in all possible ways. I like to spend my free time, whenever I have
it, with my family and with friends, I like books, music and arts.
Dr. Wurster was confronted with cancer from his early youth and
aimed to explore possibilities to cure it. Triggered through aston-
ishing experiences with homeopathy he specialised in the field
of homeopathic cancer therapy (homeopathic education with Dr.
Barthel, in supervision by Dr. Dario Spinedi). He is the author
of several books, teaches and supervises homeopaths. He has a
strong interest in performing clinical studies in the field of can-
cer as well as on the efficacy of homeopathic high potencies in
tumour cell lines, to discover whether cancer cure is possible by
activating the immune system, together with the appropriate nu-
trients.
Jens Wurster, MD: Clinica St. Croce, Orselina, Switzerland
Edited by Claudia Garn, Edit Katona and Erfried Pichler
Athos: Why did you choose to become a medical doctor?
Dora: I decided I wanted to become a doctor when I was 16. My
mother is a very good paediatrician and I wanted to be like her. At
the same time I wanted to have business trips abroad as my father
who was an engineer. Finally, I became aware that one has not to
be an engineer in order to travel. At that point, I didn’t have any
idea about Homeopathy, I just wanted to help people to improve
their health.
Athos: What are your medical studies and assets?
Dora: I have graduated in 1987 from the Medical University in Plo-
vdiv, Bulgaria. In 1990 I started working in the Bulgarian Academy
of Sciences in the field of Molecular genetic of oncogenic viruses.
I left only after a year because there was no financing for science
at that time and applied for a position as a teacher in the School
of Complementary Medicine in Plovdiv. In 1993 I attended my
first course in Homeopathy and since than I have been studying
it ever since.
Athos: What made you turn to Homeopathy?
Dora: Since my 3rd year at the University I was not satisfied with
the statement: “This disease is incurable and nothing can be done.”
Homeopathy came to me at a time when I was studying and prac-
ticing acupuncture and naturopathy. I was also seeking solutions
for medical problems of my family members. It was a love from
the first sight – from the first lecture I listened. I found what I was
looking for, for so many years.
Athos: Could you, please, tell us a few things about your
homeopathic career up until now, regarding clinical prac-
tice and teaching activities?
Dora: I have 23 years full time homeopathic practice and 21 years
of experience in teaching homeopathy. I am one of the people who
organised the first homeopathic course in Bulgaria in 1993. We had
no teachers in the country, no books and no remedies. So, because
of homeopathy I learned English, I learned how to translate, edit
and publish books, I understood what it is to teach, to organize
seminars and to motivate people, etc. Because of homeopathy I
graduated in two additional master programs – homeopathy and
psychology. I teach homeopathy in Bulgaria, Macedonia and Turkey.
In 2001 we (Maria Djongova and I) founded the Center for Health
and Education “Edicta”. We started organiSing homeopathic cours-
es and international seminars. Edicta is one of the first ten ECH
accredited schools. One of the topics we work on and I give lec-
tures internationally is the importance of family dynamics for the
homeopathic case taking and management.8
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
Athos: When did you start serving ECH? What have you
done, up until the present time?
Dora: My first introduction to the ECH was in 2000. I started going
to the meetings as a chairperson of the Association of Homeopath-
ic Physicians in Bulgaria. The last 16 years I participate in the ECH
meetings and I am member of the Accreditation/Reaccreditation
and E-learning teams of the Education Subcommittee.
For me it was very important to connect with the homeopaths from
Europe and establish professional relations with the fellow organisa-
tions. I have been participating on behalf of Bulgaria in the ECH meet-
ings and worked on various projects in the country and in the EU.
Athos: From your teaching experience, what do you think
ECH should do in the field of Education in order to attract
more medical professionals to Homeopathy?
Dora: In my opinion it’s very important that there are meetings
between homeopaths and other medical specialists. This is a way
to present the possibilities that homeopathy gives to medicine in
general. The more medical specialists know about the options they
have for themselves and for the patients, the better help they can
provide. To achieve this it’s very important we present the results
of our practice to the medical community. We need to attract not
only the young doctors, but also attract new people to homeopa-
thy, experienced conventional doctors, who need a change in their
professional life, the clinical homeopathic doctors, who need to
deepen their knowledge.
A very important task is to communicate to our colleagues that we
need to change the way we present homeopathy to the world. We
have to stop proving that homeopathy works and that we have a
place in the medical system. We have to know our place, to inform
confidently about our results and present the scientific basis how
homeopathy works.
Athos: What are your main goals as a new coordinator of
the Education Subcommittee for the next four years?
Dora: A lot of work has been done so far in the area, which enables
us to think for the future projects with clarity. I have set several
goals for my time as a coordinator of the Educational subcommit-
tee. The main one will be to provide help for the teaching organiza-
tions in the EU: to educate the teachers in better presentation skills,
to help their members to record and present their cases on medical
congresses and science magazines, to work on the e-learning part
of the education, etc.
Athos: What is the present status regarding the Accredita-
tion of Teaching Centres by the ECH? Are there any changes
ahead us?
Dora: I cannot comment on the topic at the moment. You may ask
me again in a year.
Athos: You are, at the same time, an individual, a family
member, a professional, a scientist, a teacher and, recent-
ly, a coordinator! How do you plan to keep up with all these
different, demanding roles?
Dora: To be completely honest with you – I have to figure this
out in the first weeks of January 2017. I realise I’ll have to redirect
some of my tasks to other colleagues and to family members so I
can embrace fully the responsibilities of a coordinator. I do believe
that there is exactly enough time for everything one wants to do in
a day, just it has to be properly distributed.
Athos: On behalf of the members of ECH, thank you for this inter-
view, and, most of all, thank you for volunteering to serve the goals
of the ECH and Homeopathy for the next four years! We wish you
a creative and fruitful service!
LETTER TO SCHOOLS
Dear Colleagues!
In November 2016 Vienna became host to European homeopathy.
There were a variety of interesting presentations and panel discus-
sions during this European Homeopathic Congress, and a merging
of new knowledge and the old spirit of classical homeopathy. A
range of ideas about educational projects were mooted during ECH
subcommittee’s working sessions.
•   The Education Subcommittee drafted the idea to start a series
of educational activities for ECH accredited schools under the
motto “Teach the teachers”. We believe this will raise the
standard of homeopathic practice in Europe to a higher level.
One of our projects relates to critical thinking and clinical case
report skills.
•   The Provings subcommittee is willing to give essential informa-
tion about provings as part of basic education.
•   The Pharmacy subcommittee proposes the development of a 3-4
stage educational programme for pharmacists
•   The Research subcommittee has plenty of exciting news to share
with the homeopathic community in Europe
In order to elevate homeopathy to its deserved position within Eu-
ropean healthcare we need to effectively communicate, first and
foremost to the homeopathic teachers, the expert knowledge that
ECH has gained in the 25 years since its formation. For this reason
we would like to invite teachers from ECH accredited schools to
get in contact with us in order to become part of ECH educational
projects.
We also ask that members of ECH affiliated associations invite ho-
meopathic schools in their countries to learn more about the ECH
accreditation procedure. Thanks to the diligent work of Sub-
committee of Education the procedure is clear and easy to follow.
The members of the subcommittee will be more than happy to
provide information and support.
A major step forward in the last year was the
creation of a new European Standard (EN
16872:2016). You can find out more about this
on the ECH website http://homeopathyeurope.
org/european-standard-medical-homeopathy-
will-become-national-standard/. We encourage homeopathic teach-
ing centres to implement the standard, for which we are currently
working on measures to uphold and promote the standard, which
will become official in Europe by April 2017 at the latest.
Please forward this information to homeopathic teachers and teach-
ing centres. There are already 3000 medical doctors with ECH diplo-
mas. We very much look forward to having more accredited teaching
centres, more ECH diplomas and more doctors, working according
to the new European standard. This is the perfect time to unite at a
European level and share our knowledge and achievements.
Sincerely, Dr. Dora Pachova
ECH Education coordinator9
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
CRISTAL SUMNER, THE NEW
COORDINATOR OF THE PATIENTS/
USER SUBCOMMITTEE
Cristal is known to most people. First she
has attended ECH Education meetings on
behalf of the Faculty of Homeopathy in
the UK since about 2002 and only stepped
away from that responsibility in 2015. She
is currently the Vice President of EFHPA
(European Federation of Homeopathic Pa-
tients Associations) and is the Chief Execu-
tive of the BHA (British Homeopathic Association) which represents
patients in the UK. Cristal shared useful standpoints on why and
who to address and motivate patients for a common work with
homeopaths.
How were you introduced to homeopathy? Being a patient
or as a healer?
I was first introduced to homeopathy through my job at the Faculty
of Homeopathy. In the year 2000, I was recruited to become the
Education and Training Manager and through my work I began to
understand the concepts behind homeopathy and its usefulness.
Naturally working with a large number of homeopathic doctors it
was not long before I was provided with homeopathic medicine for
aches and pains and general first aid.
What motivated you to participate in the self-organizing
activity of patients?
My work now is centred around the rights of patients to access ho-
meopathic care. Patients are powerful in persuading governments
and decision makers, since they can advocate for homeopathy
freely without being accused of having a financial interest. Patients
however are not always healthy and well, and may need assistance
to help get involved or make their views known. I feel we can help
other patient groups around Europe and the World advocate for
greater use of homeopathy.
Cristal, you encouraged those that are from countries with-
out a patient group to consider approaching a patient to
make a start. Why is it important? What is the secret? How
can you address patients successfully?
It is critical to have patients involved to maintain, build and defend
homeopathic services and medicines. In lobbying governments pa-
tients are a very powerful voice. Every country should have a pa-
tient group ready to be proactive. Better to have one formed before
a crisis arises. In Spain a patient is trying to develop a group and
the committee is assisting as much as possible. The committee is
there supporting patients in Europe and in turn hopefully ensuring
homeopathic doctors can easily practice homeopathic medicine.
I don’t feel I know the secret to addressing patients at all;
as they are all different and unique individuals. However,
there are some general rules:
1) listen
2) empathise
3) show respect
4) share information
5) find commonality
6) use that commonality to get people motivated
7) remember small things that mean a lot to keep people involved
and interested – sending a thank-you card, having a phone call,
putting focus on people who work hard, etc.
What was your best experience with patient organizations?
Best experience is hard to identify off the top of my head. I would
say that our work in the UK to ensure access to homeopathic medi-
cines in 2012-13 was very rewarding as patients, and practitioners
worked hand in hand to ensure MPs and other decision makers
were aware of the issues and we were, for a change, listened to and
access remained intact.
Why did you decide to switch from the Education to the
Patients/User team?
I am now only Chief Executive of the BHA (not both the BHA and
Faculty of Homeopathy as before), a charity established in 1902,
which works to increase patient access to homeopathy in the UK.
The BHA is a patient-based organisation and over the past five
years I have also been sitting at the Patient/User SC. For the last 3,
as the Vice President/Vice Chair.
You are very active in various positions in many homeo-
pathic organizations, and you have little children at the
same time. How do you have so much energy?
I don’t really have that much energy. You should see me on a Friday
night! Far from partying it up, I am more likely falling asleep next
to my 2 year old at 19.30. Thanks for the compliment though!
I think life in homeopathy is always interesting, challenging and
rewarding which keeps me going and working toward a better to-
morrow where homeopathy is recognised as an important part of
medicine.
Some years ago you ran the London (?) Marathon to raise
money for a homeopathic charity. Are you still running
regularly?
Ha! You have a good memory. I ran a very hilly marathon in Sussex
(a county in England) several years ago and raised close to £3000
for the British Homeopathic Association. I still run but only do 3-4
miles when I go out due to my knee which tells me when I go too
far. Even with the knee I want to try a long run again as I felt I could
have done better last time round. Or maybe I will do some other
challenge that interests me and could also raise money for the Brit-
ish Homeopathic Association. What about you?
Well, I did not attempt that distance yet, only the half,
which was more than enough for me. But similar to you
I always look for challenges. Cristal, my last question to
you: what do you need for the Patient Subcommittee to be
successful?
Information sharing and working together with doctors to both
promote and defend homeopathy in the EU is what is needed. It is
important patients know where to look to find others in their coun-
try and also important the doctors know where to point their pa-
tients who are interested in promoting and defending homeopathy.
The Patient/User SC is launching a new website to hopefully help
increase cross language and country information sharing. It will be
a hub of information for patients around Europe, accessible in 6
languages (English, French, German, Spanish, Italian and Dutch).
EFHPA will also be active on Social media to enhance engagement
across Europe. ECHAMP has helped facilitate this process through
a special grant.
Thank you for the interview. In the name of my colleagues
I wish you much joy, success and good health in your new
position!
Edit Katona10
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
WORKING TOGETHER
FOR HOMEOPATHY
The recent European Congress for Homeopathy in Vienna repre-
sents an excellent example of the power of collaboration, as the
European Committee for Homeopathy (ECH), the International
Association for Veterinary Homeopathy (IAVH) and the European
Federation of Homeopathic Patients’ Associations (EFHPA) came
together to produce a hugely successful event.
This was not the first such occasion – our organisations jointly ad-
dressed the subject of Antimicrobial Resistance (AMR) as part of
an AMR campaign. ECH’s Dr Lex Rutten drafted a very comprehen-
sive and since highly referenced report, and Dr Liesbeth Ellinger, of
IAVH, presented her study on successful homeopathic prevention
of diarrhoea on piglets without the use of antibiotics.
The co-operation with EFHPA is even more evident – EFHPA hosts
ECH’s patients’ subcommittee and as such is very closely linked to
all ECH projects and achievements.
We will continue to work in this manner and aim to maximise the
opportunities to build upon this cooperation.
Building a strong coalition to promote and defend homeopathy
in Europe is a priority. This means involving industry, policymak-
ers, health professionals, researchers, patients, social networks and
mass media. Cooperation should also be fostered with partners
from non-European countries and organisations involved with agro-
homeopathy.
From left to right: Dr Edward De Beukelaer IAVH President,
Mrs Enid Segall EFHPA President and Dr Thomas Peinbauer
former ECH President during the welcome reception of the
congress in Vienna.
insurance, such is the case in Switzerland, to homeopathic hospitals
with increased quality of care as seen in Tuscany, Italy.
Clearly the situation is not easy when homeopathy is faced with
fierce criticism. However, in many ways this can help us to become
stronger, more committed and able to convey our messages in a
clearer way to patients, citizens and policymakers.
The coalition could have some common goals such as:
•   Increasing research funding for homeopathy   
•   Promoting the integration of homeopathy in the national health
care systems
•   Fostering good quality training
•   Availability of homeopathic medicinal products We are confident that we will succeed in our efforts to put medical
homeopathy higher in the political agenda and to advance in the
integration of homeopathy in the European health care systems.
A strong coalition of industry, policymakers, researchers, patients
and health professionals is paramount if we are to succeed in our
endeavour. We have a great advantage: homeopathy empowers
patients and is really a patient-centred medicine.
We can learn from each other. There are countless success stories,
ranging from full integration of homeopathy in the national health Dr Hélène Renoux, ECH President
and Dr Jaume Costa, ECH General Secretary.
ECHOING:
NEWLY FORMED COMMUNICATION
WORKING GROUP IN ECH ECHOING.
Due to growing interest towards communication challenges
in ECH, we proposed the need to develop more professional com-
munication in homeopathy at a plenary session in Vilnius last April.
Following meetings in November at the ECH Congress in Vienna,
the decision was taken to form a communication working group
within ECH!
Once the decision was made, newly-elected President Hélène Re-
noux personally addressed some members who had expressed
an interest in communications. Members from various subcom-
mittees, from different countries and with varied skills and in-
terests joined the group with one aim: internal and external
communication and networking for ECH to achieve better
awareness and recognition of medical homeopathy. The
group was shortly named after its function: ECHOING (credit to
Tomasz).
ECHOING for awareness of Homeopathy
(Pixabay, CCO Creative Commons)
The first contributors are Helene Renoux, Jaume Costa, Dora
Pachova, Cristal Sumner – from the Council. From the subcommit-
tees: Claudia Garn, Tomasz Kokoszczynski, Athos Othonos and Edit
Katona. Chris Connolly from UK is of great help in implementing
the plans; he is responsible for the technical background and the
final layout of content. The composition of the group may vary in
time, and will depend on circumstances, inspiration and the free
time of its creative members.11
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
ECHOING makes use of modern communication tools, intent
on developing the most efficient and instantaneous communi-
cation channels to satisfy the needs of ECH members in the 21st
century. Other young homeopaths also skilled in new communica-
tion will help to bring more energy to the group.
ECHOING welcomes everybody who:
•   offers her/his help in sharing thoughts and news, special knowl-
edge
•   has ability to write articles, interviews and posts
•   enjoys collecting photos, pictures, illustrations, draws, quotes,
videos, films
Communication channels of ECH (current)
•   Council and Subcommittee meetings, General Assembly
•   E-mail groups on ECH, Council, Subcommittee level
•   Newsletter – two editions per year
ECH WEB AND SOCIAL MEDIA
MANAGEMENT
INTERVIEW WITH CHRIS CONNOLLY
Chris Connolly has a special role in ECH:
after completing his BA (Hons) degree in
Business and Marketing from Sheffield Hal-
lam University in 2014, he started working
full-time with the British Homeopathic As-
sociation and Faculty of Homeopathy. Here
he came to be involved with ECH. One of
his responsibilities is to manage its digital
platforms. That means day-to-day running
of the ECH website, ensuring content is updated and as user-friend-
ly as possible. Additionally, Chris publishes content to the ECH so-
cial media accounts (Facebook/ Twitter/ LinkedIn/ YouTube) based
on activities and developments in homeopathy across Europe and
globally.
Chris, what do you like the most in your ECH activities?
How do you gauge success in this field?
I have a passion for all things digital and language so enjoy all ele-
ments of my work! It has been rewarding to see the progress made
on social media, with the reach and engagement of ECH posts con-
tinually improving, as well as building a strong follower base across
all platforms. ECH now has a combined following of over 3000, so
social media has now become a very useful communication tool.
What can you help to the newly formed communication
working group?
I proofread all communications and provide English editing where
necessary. Any news, reports or events which should be shared can
be sent to me to be prepared for publishing across digital channels.
•   Website renewed with valuable content
•   Social media/Facebook for quick updates
Information for creating the higher order
Homeopathy is information medicine. Our remedies “broadcast”
the necessary information to living organisms. The source of in-
formation surrounds us, but requires energising to fulfil its role,
to trigger the processes in the organism which result in improved
functioning. Even a minute amount of the right information in
the right form is sufficient for the change. More efficient opera-
tion helps the organism to perform higher order mission more ef-
fectively. Many of us believe there is a higher order mission of
not only creatures in our world but also the European Committee
for Homeopathy.
Information from YOUR part is a drop in the ocean!
Edit Katona, present coordinator (katona.edit7@chello.hu)
Do you have common work with Cristal Sumner and Sara
Eames at the Faculty of Homeopathy in UK?
Cristal introduced me to ECH during her tenure as Chief Executive
of the Faculty of Homeopathy. Although she is now solely Chief
Executive of the British Homeopathic Association and I only work
for the Faculty of Homeopathy, we are still based in the same office
in London and our core aims and objectives are very much aligned.
Sara and I are in frequent contact regarding Faculty of Homeopathy
Council activities and for academic purposes concerning the Royal
London Hospital for Integrated Medicine, which is one of the Fac-
ulty of Homeopathy’s accredited teaching centres.
We as ECH members and member states would like to
work together more and more efficiently and successfully
in communicating ourselves for the awareness and accep-
tance of homeopathy. What is your message, what is your
advice for ECH members?
Digital media offers a great opportunity for instant networking and
communication across the globe. Whilst we have continued to uti-
lise its power, there is still potential to be more effective. LinkedIn
and Facebook groups offer the chance to network internally so all
stakeholders can keep up-to-date. Consistency in external messages
is imperative in order to improve the standing of homeopathy in Eu-
ropean health care and internal awareness is necessary if this is to
be achieved. We plan to make use of further tools to make internal
communication easier and more effective, which will harness the
knowledge and enthusiasm of the homeopathic community. Mem-
bers are encouraged to play as active a role as possible, as the more
engaged our members are the more powerful our messages will be.
Thank you for the interview. And thank you very much for
your youthful contribution for the awareness of ECH and
homeopathy globally.
Edit Katona12
European Committee for Homeopathy
INTERNAL NEWS JANUARY 2017
FOR YOUR DIARY
n
    ECH Spring Meeting, Alkmaar, 21–22 April 2017
    Meetings of the ECH Council and Subcomittees.
Visits to the Remedy Bank Laboratory and Botanical Garden.
More information: info@homeopathyeurope.org
n
   
n
    Colloquium organised by the UNIO HOMEOPATHICA BELGICA (UHB)
13 May 2017
Brussels: from basic research to homeopathic practice,
addressing the DYNHOM project.
More information: www.homeopathie-unio.be/fr/general
    3rd HRI International Homeopathy Research Conference,
Cutting Edge Research in Homeopathy, Malta, 9–11 June 2017
    The programme includes topics such as clinical research (quantitative,
qualitative and mixed methods), disease prevention, fundamental research,
laboratory-based research, pathogenetic trials and veterinary research.
The Congress will take place at the Radisson Blue Resort in St. Julians Malta
from 9–11 June 2017.
Early registration fee is available until 3 March 2017.
    More information: www.hrimalta2017.org/
n
    LMHI Congress 2017, Networking in Medical Care
– Collaboration for the Benefit of the Patient,
Leipzig, 14–17 June 2017
    The central theme of the Congress is the open dialogue between homeopathy
and other medical systems. Main topics of the Congress are pain management,
neurological and psychiatric disorders, intensive and palliative care, epidemics
and cystitis. Veterinary, pharmacy, dentistry and research on homeopathy are
also in the programme. The Congress will take place in the “Leipzig Congress
Hall” (Kongress-Halle Leipzig) from 14–17 June 2017.
Early registration fee is available until 28 February 2017.
More information: www.lmhi-congress-2017.de/
n
    ECH Autumn Symposium, Prague, 17–19 November 2017
    Meetings of the ECH Council and Subcommittees.
    More information: info@homeopathyeurope.org
IMPRINT
ECH INTERNAL NEWS  n   January 2017  n   Pictures: Archives and Franz Johann Morgenbesser, Vienna  n   Editor: Edit Katona  n 
Editorial Support: Chris Connolly n   ECH Administrative Office: Noorwegenstraat 499940 Evergem (Ghent)  n Phone +32 9 218 85 85  n 
Fax: +32 9 344 40 10  n   Email: info@homeopathyeurope.org  n   Internet: www.homeopathyeurope.org
[*/quote*]

[Rhokia]

Vielleicht hätte man beim Beginn der Suche besser aufpassen müssen?

Es ist nämlich nicht "The European Committee of Homeopathy", sondern "The European Committee for Homeopathy"


https://www.zoominfo.com/c/european-committee-for-homeopathy/346635647

[*quote*]
logo for The European Committee for Homeopathy
The European Committee for Homeopathy
Hospitals & Physicians Clinics · Belgium · <25 Employees

Get Full Access

Who is The European Committee for Homeopathy
Our aim is to achieve integration of homeopathy within the European healthcare system, meeting growing demand for homeopathic care in a safe medical contextRead More

Phone Number
Phone Number:

+32 9 218 85 85
Website
Website:

www.homeopathyeurope.org

The European Committee for Homeopathy's Social Media

Is this data correct?

View contact profiles from The European Committee for Homeopathy
SIC Code
80,809
NAICS Code
621,62199
Show More
Popular Searches:
The European Committee for Homeopathy

European Committee for Homeopathy

Homeopathic Academy

European Committee of Homeopathy

ECH Council

Hospitals & Physicians Clinics
Medical Specialists
The European Committee for Homeopathy's Org Chart

Phone
Phone
Email
Email
Fathima AyyoobFathima Ayyoob
Medical Doctor

Phone
Phone
Email
Email
Sumon RahimSumon Rahim
Doctor

Phone
Phone
Email
Email

Phone
Phone
Email
Email
See Full Org Chart

Illustration of an envelope
View Email Formats for The European Committee for Homeopathy

The European Committee for Homeopathy's Tech Stack
PHP
PHP

By

PHP
Sectigo
Sectigo

By

Sectigo
GTranslate
GTranslate

By

2GLux
YouTube
YouTube

By

Google
See more technologies
Frequently Asked Questions regarding The European Committee for Homeopathy
Where are The European Committee for Homeopathy’s headquarters?
The European Committee for Homeopathy’s headquarters are in Haven 8008X, Evergem, Flanders, 9940, Belgium

What is The European Committee for Homeopathy’s phone number?
The European Committee for Homeopathy’s phone number is +32 9 218 85 85

What is The European Committee for Homeopathy’s official website?
The European Committee for Homeopathy’s official website is www.homeopathyeurope.org

What is The European Committee for Homeopathy’s SIC code?
The European Committee for Homeopathy’s SIC: 80,809

What is The European Committee for Homeopathy’s NAICS code?
The European Committee for Homeopathy’s NAICS: 621,62199

How many employees are working in The European Committee for Homeopathy?
The European Committee for Homeopathy has <25 employees

What is The European Committee for Homeopathy’s industry?
The European Committee for Homeopathy is in the industry of: Hospitals & Physicians Clinics, Medical Specialists

What is The European Committee for Homeopathy's tech stack?
The technologies that are used by The European Committee for Homeopathy are: PHP, Sectigo, GTranslate, YouTube

See more information about The European Committee for Homeopathy
View Employees
Pratik Dey
Pratik Dey
Homeopathic Physician

Phone
Phone
Email
Email
Drsudha Nambisan
Drsudha Nambisan
Phone
Phone
Email
Email
Ankush Thakral
Ankush Thakral
Phone
Phone
Email
Email

[...]
© 2022 ZoomInfo Technologies LLC
[*/quote*]

[Rhokia]

Es wird immer besser:

https://web.archive.org/web/20091007235500/http://www.homeopathyeurope.org:80/about-homeopathy/clinical-research/experimental-studies

In dieser Webseite des "European committee for homeopathy", deren frühestes Datum im Web Archiv der 7. October 2009 ist, das ist drei Jahre nach dem Erscheinen des internen Papiers der Carstens-Stiftung, ist von "mehr als 300 Studien" keine Rede. Von der WHO erst recht nicht.

Wenn es mehr als 300 Studien gäbe, die xyz belegen, würden die Homöopathen das mit tausenden von Pressemitteilungen verbreiten. Wenn die WHO mit im Spiel wäre, würden die Homöopathen das mit tausenden von Pressemitteilungen verbreiten.

Aber da ist nichts!


Das "European committee for homeopathy" schreibt drei Jahre nach dem Lüdtke-Papier der Carstens-Stiftung:

https://web.archive.org/web/20091007235500/http://www.homeopathyeurope.org:80/about-homeopathy/clinical-research/experimental-studies

[*quote*]
Sections
Home
About ECH
About homeopathy
Regulatory status
Policies
Publications
News and press
Links
Personal tools
Log in
You are here: Home > About homeopathy > Clinical research > Experimental studies
About homeopathy
FAQ
Practice
Indications for use
Medicines
Provings
Clinical research
Observational studies
Experimental studies
Basic research
Resources
History
 
Experimental studies
Rigorous research projects of the highest scientific standards have been conducted and published in leading international medical journals over the last few decades. In many controlled clinical trials homeopathic treatment has proven its effectiveness.
 A number of reviews have evaluated the homeopathy research literature, the most important of them are described below.

Systematic reviews and meta-analyses of the whole homeopathic literature
The first systematic review of homeopathic research was published in the British Medical Journal in 1991. Of the 105 trials with interpretable results, 81 indicated positive results, which included RCTs that received high quality ratings for randomization, blinding, sample size, and other methodological criteria. The authors, three orthodox epidemiologists, came to the following conclusion: "The amount of positive evidence even among the best studies came as a surprise to us. Based on this evidence we would readily accept that homeopathy can be efficacious, if only the mechanism of action were more plausible". And "The evidence presented in his review would probably be sufficient for establishing homeopathy as a regular treatment for certain indications".
[Kleijnen J, Knipschild P, ter Riet G (1991). Clinical trials of homeopathy, British Medical Journal, 302: 316-323]


In 1996, a review by the European Commission Homeopathic Medicine Research Group, later published in a scientific journal (Cucherat), identified 184 controlled clinical trials. They selected the highest quality randomized placebo controlled trials, which included a total of 2,001 patients. Boissel used a rather unusual technique of combining p-values of the selected trials to answer the question: 'Does homeopathy have an effect?' and concluded that homeopathy was more effective than placebo (P < 0.001) though "the strength of this evidence is low because of the low methodological quality of the trials" (P = 0.082 for the highest quality sub-group of just 5 trials).

[Boissel JP, Cucherat M, Haugh M, Gauthier E (1996). Critical literature review on the effectiveness of homeopathy: overview of data from homeopathic medicine trials. In: Homeopathic Medicine Research Group, Report of the, Commission of the European Communities, Directorate-General XII – Science, Research and Development, Directorate E – RTD Actions: Life Sciences and Technologies – Medical Research, Brussels 1996; Chap.11: 195-210]

[Cucherat M, Haugh MC, Gooch M, Boissel JP (2000). Evidence of clinical efficacy of homeopathy – A meta-analysis of clinical trials. European Journal of Clinical Pharmacology, 56:27–33]



A meta-analysis published in The Lancet in 1997 included 186 placebo controlled studies of homeopathy, from which data for analysis could be extracted from 89. The overall mean odds ratio for these 89 clinical trials was 2.45 (95% confidence interval 2.05–2.93) in favour of homeopathy, which means that the chances of homeopathy giving benefit were 2 to 3 times greater than those of placebo. Even when considering a "worst-case" scenario in which only high-quality studies, of high or medium dilutions, published in MEDLINE-listed journals, and with predefined measures of primary outcome were analysed, the pooled odds ratio was 1.97 and remained statistically significant. The main conclusion was that the results "were not compatible with the hypothesis that the effects of homoeopathy are completely due to placebo". In further analysis, the authors clarified that higher quality trials were less likely to be positive than those of lower quality – which is comparable to the conclusion from similar analyses in conventional medicine –, though the difference from placebo remained statistically significant until analysis was restricted to just five trials. There was insufficient volume of evidence to enable conclusions to be drawn about what homeopathic treatment is effective in which diagnosis.
[Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB (1997) Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet, 350: 834-843]

In 2005 an other review was published in The Lancet comparing 110 placebo controlled trials of homeopathy and 110 matched trials of conventional medicine. Homeopathy and conventional medicine showed a similar positive treatment effect overall. Twenty-one homeopathy trials and 9 in conventional medicine were judged of higher methodological quality. From these, the results of 14 unspecified "larger trials of higher quality" (8 homeopathy, 6 conventional medicine) were analysed. The mean odds ratio was 0.88 (95% CI, 0.65-1.19) for the 8 homeopathy trials, and 0.58 (95% CI, 0.39-0.85) for the 6 conventional medicine trials. In this study, in contrast with the 1997 review, an odds ratio less than 1.0 indicated an effect greater than placebo. The authors concluded there was "weak evidence for a specific effect of homoeopathic remedies, but strong evidence for specific effects of conventional interventions. This finding is compatible with the notion that the clinical effects of homoeopathy are placebo effects."
The authors' analysis has been criticised to be prone to selection bias, especially when the set of 21 high-quality trials was reduced to 8 trials with large patient numbers. Obviously, the results depend on how the threshold for "large" studies was defined from these 21 studies. The overall results – and the conclusions drawn from them – change depending on which subset of homeopathic trials is analysed. The choice of other meaningful subsets could lead to the opposite conclusion. For example, four of the 21 trials dealt with preventing or treating muscle soreness and an earlier systematic review already showed that homeopathic medicines are probably not helpful in this condition. When restricting the analysis to the remaining 17 trials an overall statistically significant effect can be found. In addition, there is no external criterion why a "large" trial should have N=98 or more patients as defined by the authors (apart from being able to include a statistically non-significant trial with a sample size of exactly 98). For example, if the data set was split at a threshold of N=66, the median sample size of all 110 homeopathic trials, there had been a significant effect in favour of homeopathy. Surprisingly, the authors themselves highlight – but dismiss – the fact that 8 trials of homeopathy in upper respiratory tract infections have strongly positive findings overall. Clearly, the conclusions by this group of scientists under the direction of Professor Matthias Egger, well known for his anti-homeopathy standpoint, are not so definite as they have been reported and discussed.
[Shang A, Huwiler-Muntener K, Nartey L, Juni P, Dorig S, Sterne JA, Pewsner D, Egger M (2005). Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet, 366:726–32].
[Lüdtke R, Rutten AL (2008) .The conclusions on the effectiveness of homeopathy highly depend on the set of analyzed trials. Journal of Clinical Epidemiology, 61:1197-1204]

[Rutten AL, Stolper CF (2008) The 2005 meta-analysis of homeopathy: the importance of post-publication data. Homeopathy, 97:169-177].

The fact that some meta-analyses showed some positive evidence for homeopathy is remarkable because meta-analyses are far from appropriate when trials are extremely heterogeneous (as in homeopathy) not only in results but also in the interventions and health conditions under study and when a therapeutic system works in some but not all indications. The Cochrane Handbook for Systematic Reviews recommends "Meta-analysis should only be considered when a group of trials is sufficiently homogeneous in terms of participants, interventions and outcomes to provide a meaningful summary".

Systematic reviews and meta-analyses focused on specific medical conditions
The problem of heterogeneity of medical condition has been avoided in 17 systematic reviews focused on RCTs of homeopathy in 15 specific areas. The positive evidence for homeopathy is here more obvious: seven of 17 such reports to date have been positive for homeopathy:

- childhood diarrhoea
[Jacobs J, Jonas WB, Jimenez-Perez M, Crothers D (2003). Homeopathy for childhood diarrhea: combined results and metaanalysis from three randomized, controlled clinical trials. Pediatric Infectious Disease Journal, 22:229–234]

- influenza
[Vickers A, Smith C (2006). Homoeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes (Cochrane Review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd. CD001957]


- post-operative ileus
[Barnes J, Resch K-L, Ernst E (1997). Homeopathy for postoperative ileus? A meta-analysis. Journal of Clinical Gastroenterology, 25:628–633]


- seasonal allergic rhinitis
[Wiesenauer M, Lüdtke R (1996). A meta-analysis of the homeopathic treatment of pollinosis with Galphimia glauca. Forschende Komplementärmedizin und Klassische Naturheilkunde, 3:230–236]

[Taylor MA, Reilly D, Llewellyn-Jones RH, McSharry C, Aitchison TC (2000). Randomised controlled trials of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. British Medical Journal, 321:471–476]

[Bellavite P, Ortolani R, Pontarollo F, Piasere V, Benato G, Conforti A (2006). Immunology and homeopathy. 4. Clinical studies – Part 2. Evidence-based Complementary and Alternative Medicine: eCAM, 3:397–409]


- vertigo
[Schneider B, Klein P, Weiser M (2005). Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials. Arzneimittelforschung, 55:23–29]

Eight of the other 10 reviews were non-conclusive.
[Ernst E, Barnes J (1998). Are homoeopathic remedies effective for delayed-onset muscle soreness? – A systematic review of placebo-controlled trials. Perfusion (Nürnberg), 11:4–8]

[Ullman D (2003). Controlled clinical trials evaluating the homeopathic treatment of people with human immunodeficiency virus or acquired immune deficiency syndrome. Journal of Alternative and Complementary Medicine, 9:133–141]

[McCarney RW, Linde K, Lasserson TJ (2004). Homeopathy for chronic asthma (Cochrane Review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd. CD000353]
[McCarney R, Warner J, Fisher P, van Haselen R (2004). Homeopathy for dementia (Cochrane Review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd. CD003803]
[Owen JM, Green BN (2004). Homeopathic treatment of headaches: A systematic review of the literature. Journal of Chiropractic Medicine, 3:45–52]

[Smith CA (2003). Homoeopathy for induction of labour (Cochrane Review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd. CD003399]

[Pilkington K, Kirkwood G, Rampes H, Fisher P, Richardson J (2005). Homeopathy for depression: a systematic review of the research evidence. Homeopathy, 94:153–163]

[Pilkington K, Kirkwood G, Rampes H, Fisher P, Richardson J (2006). Homeopathy for anxiety and anxiety disorders: A systematic review of the research. Homeopathy, 95: 151–162]

Two reviews were negative.
[Long L, Ernst E (2001). Homeopathic remedies for the treatment of osteoarthritis – A systematic review. British Homeopathic Journal, 90:37–43]

[Ernst E (1999). Homeopathic prophylaxis of headaches and migraine? A systematic review. Journal of Pain and Symptom Management, 18:353–357]

Some non-replicated RCTs positive for homeopathy
For other medical conditions, the published evidence is fragmentary: there are some non-replicated RCTs showing positive effects for homeopathy, e.g. in acute otitis media, attention deficit hyperactivity disorder (ADHD), fybromyalgia, stomatitis, chronic fatigue syndrome, sepsis, and post-partum bleeding.
[Jacobs J, Springer DA, Crothers D (2001). Homeopathic treatment of acute otitis media in children: a preliminary randomized placebo-controlled trial. Pediatric Infectious Disease Journal, 20:177–183]

[Frei H, Everts R, von Ammon K, Kaufmann F, Walther D, Hsu-Schmitz SF, Collenberg M, Fuhrer K, Hassink R, Steinlin M, Thurneysen A (2005). Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomized, double blind, placebo controlled crossover trial. European Journal of Pediatrics, 164:758–767]

[Bell IR, Lewis DA 2nd, Brooks AJ, Schwartz GE, Lewis SE, Walsh BT, Baldwin CM (2004). Improved clinical status in fibromyalgia patients treated with individualized homeopathic remedies versus placebo. Rheumatology (Oxford), 43:577-582]

[Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS, Branski D (2001). A randomized, controlled clinical trial of the homeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Cancer, 92:684–690]

[Weatherley-Jones E, Nicholl JP, Thomas KJ, Parry GJ, McKendrick MW, Green ST, Stanley PJ, Lynch SP (2004). A randomized, controlled, triple-blind trial of the efficacy of homeopathic treatment for chronic fatigue syndrome. Journal of Psychosomatic Research, 56:189–197]

[Frass M, Linkesch M, Banyai S, Resch G, Dielacher C, Lobl T, Endler C, Haidvogl M, Muchitsch I, Schuster E (2005). Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit. Homeopathy, 94:75–80]

[Oberbaum M, Galoyan N, Lerner-Geva L, Singer SR, Grisaru S, Shashar D, Samueloff A (2005). The effect of the homeopathic remedies Arnica and Bellis perennis on mild postpartum bleeding – a randomized, double-blind, placebo-controlled study –preliminary results. Complementary Therapies in Medicine, 13:87–90]


On the other hand, there are some conditions for which trial evidence has been non-conclusive or negative.

Document Actions
Send this
Print this
Search
 
Advanced Search…
News
News Item Sep 24, 2009 Proving shows significant distinction between Aconitum C30 and placebo
News Item Sep 19, 2009 Nobel Prize winner reports effects of homeopathic dilutions
News Item Aug 16, 2009 Individualised homeopathy as effective as Prozac
News Item Jun 10, 2009 EU awards € 1.5 million grant for CAM research
News Item Jun 02, 2009 Homeopathy works in eczema and psoriasis
News Item Jun 01, 2009 European Information Centre on CAM launched
News Item May 18, 2009 Switzerland embeds CAM in constitution
News Item May 01, 2009 Stunning Cuban experiences on leptospirosis
News Item Apr 10, 2009 Second EU Homeopathy Day
 
Site Map
Accessibility
Contact
[*/quote*]

[Rhokia]

Diese Aussage der Carstens-Stiftung dürfte ihr jetzt zum Verhängnis werden:

[*quote*]
Eine von der CARSTENS-STIFTUNG im Auftrag der World Health Organsiation (WHO)
und des European Committee of Homeopathy (ECH) erstellte Übersicht identi-
fizierte über 300 klinische Studien zur Wirksamkeit der Homöopathie, von denen
weniger als ein Drittel in Zeitschriften mit einem Gutachtersystem publiziert
wurden. Von diesen wurde nur der kleinere Anteil in konventionellen Zeitschriften
veröffentlicht, der größere erschien in Journalen, die auf komplementär-
medizinische Themen spezialisiert sind.
[*/quote*]


Diese Aussage ist in diesem Papier der Carstens-Stiftung:

https://de.readkong.com/page/homoopathie-zum-stand-der-klinischen-forschung-eine-5124077

[*quote*]
Homöopathie - Zum Stand der klinischen Forschung - Eine Stellungnahme der Karl und Veronica Carstens-Stiftung

Eine Stellungnahme
der Karl und Veronica Carstens-Stiftung
Stand: März 2006
Herausgeber:        Der Vorstand der KARL UND VERONICA CARSTENS-STIFTUNG
                    Am Deimelsberg 36
                    45276 Essen
                    Tel.: (0201) 56305 – 0
                    Fax: (0201) 56305 – 0
                    www.carstens-stiftung.de
Redaktion: Dipl.-Stat. Rainer Lüdtke

                  © KARL UND VERONICA CARSTENS-STIFTUNG, Essen 2006
[*quote*]


Vorstand und Geschäftsführer:

[*quote*]
Vorstand:
Dr. Veronica Carstens (Vorsitzende), Dr. Horst Niemeyer, Dr. Michael K. H. Elies, Dr. Markus Wiesenauer

Geschäftsführung:
Dr. Henning Albrecht
[*/quote*]


Rainer Lütdke,  Veronica Carstens, Horst Niemeyer, Michael K. H. Elies,  Markus Wiesenauer, Henning Albrecht? Wer von denen ist für diese mutmaßliche Fälschung verantwortlich? Jeder einzelne von ihnen? Oder alle zusammen?


Noch einmal der Kern der Aussage:

[*quote*]
Eine von der CARSTENS-STIFTUNG im Auftrag der World Health Organsiation (WHO)
und des European Committee of Homeopathy (ECH) erstellte Übersicht
[*/quote*]


Das bezieht sich nicht auf EXTERNE Arbeiten (und eventuell Hören-Sagen), sondern auf eine VON DER CARSTENS-STIFTUNG ERSTELLTE ÜBERSICHT, also eine aktive Tätigkeit der Carstens-Stiftung selbst.

Das ist kein Versehen, das ist kein Mißverständnis, sondern eine klare, eindeutige und unmißverständliche Behauptung, die Carstens-Stiftung SELBER hätte diese Übersicht erstellt.

Diese Übersicht, wenn sie existiert, muß in irgendeiner Form vorliegen, als Tabelle, als gedrucktes Papier, Einer muß sie gemacht haben, Andere haben sie gelesen. Also: WO IST SIE? Wer hat sie gesehen? Wenn sie je gemacht wurde, ist sie viel zu wertvoll, als daß man sie wegwerfen würde. Sie MUSS also existieren. Oder eben nicht...

Das "European Committee for Homeopathy" wird von Rainer Lüdtke als Auftraggeber genannt, ebenso die WHO. Aber die WHO würde so etwas nicht tun, und das "European Committee for Homeopathy" hat es augenscheinlich nicht getan.

Wer ist für diese Fälschung, begangen durch die Carstens-Stiftung, verantwortlich?


Das bringt mich auf die Frage, wer davon wußte, bzw. weiß, daß es eine Fälschung ist? Sollen wir einmal fragen...?

POPCORN!